



Connective Tissue Oncology Society

2019 CTOS Annual Meeting

November 13-16, 2019
Tokyo, Japan



Wednesday, 13 November, 2019

12:00 pm - 6:00 pm	Registration	<i>Kiku Lobby, 4th Floor</i>
12:00 pm - 6:00 pm	Poster Set Up	<i>3rd Floor</i>
2:00 pm - 6:00 pm	TARPSWG Semiannual Meeting	<i>Ran Room, 3rd Floor</i>
5:30 pm - 7:30 pm	Welcome Reception	<i>Kiku Ballroom</i>

Thursday, 14 November, 2019

6:00 am - 5:30 pm	Registration	<i>Kiku Lobby, 4th Floor</i>
6:15 am - 7:30 am	Sunrise in Tokyo	<i>Kiku Ballroom</i>
8:00 am - 4:30 pm	5th Annual International Sarcoma Nurse and Allied Professionals Meeting (iSNAP) "Strides in Sarcoma Care"	<i>Hinoki Room</i>
8:30 am - 9:00 am	Opening Remarks	<i>Kiku Ballroom</i>

9:00 am - 10:00 am	– SESSION 1 –	<i>Kiku Ballroom</i>
	New WHO Classification	

WHO Classification of Bone Tumors
Judith Bovee

WHO Classification of Soft Tissue Sarcomas
Paolo Dei Tos

Clinical Implications of the New WHO Classification
Jean-Yves Blay

10:00 am - 10:30 am	Morning Break & Poster Viewing	<i>3rd Floor</i>
---------------------	--------------------------------	------------------

Molecular Biology

TARGET: OSTEOSARCOMA

THE GENOMIC LANDSCAPE OF OSTEOSARCOMA: A TARGET REPORT

Ching C. Lau^{1,2,3}; Aaron Taylor^{1,3}; Monika J.Y. Sun³; Alex Yu³; Jianhe Shen³; Lisa Teot⁴; Don Barkauskus⁵; Mark Krailo⁵; Richard Gorlick⁶; Timothy Triche⁷; Shintaro Iwata^{8,9}; Miki Ohira^{8,10}; Jay Wunder¹¹; Irene Andrulis¹¹; Silvia Regina Caminada de Toledo¹²; Antonio Sergio Petrilli¹²; Lisa Mirabello¹³; Sharon Savage¹³; Robert L. Walker¹³; Marbin Pineda¹³; Yuan Jiang¹³; Sven Bilke¹³; Jack Zhu¹³; Yonghong Wang¹³; Joshua Waterfall¹³; Chris T.K. Man³; Sean Davis³; Jaime M. Guidry Auvil¹³; Daniela S. Gerhard¹³; Paul Meltzer¹³

¹The Jackson Laboratory for Genomic Medicine; ²Connecticut Children's Medical Center;

³Texas Children's Hospital/Baylor College of Medicine; ⁴Boston Children's Hospital/Harvard Medical School; ⁵Children's Oncology Group; ⁶M.D. Anderson Cancer Center; ⁷Children's Hospital Los Angeles/University of Southern California; ⁸Chiba University; ⁹National Cancer Center of Japan;

¹⁰Saitama University; ¹¹Princess Margaret Hospital/University of Toronto; ¹²Universidade Federal de Sao Paulo; ¹³National Cancer Institute

3251212

GRACEFUL PROJECT: A GLOBAL COLLABORATION ON CIC-DUX4, BCOR-CCNB3, HIGH GRADE UNDIFFERENTIATED ROUND CELL SARCOMA (URCS)

Emanuela Palmerini¹; Marco Gambarotti¹; Ravin Ratan⁷; Steven DuBois⁸; Michael J. Nathenson⁸; Antoine Italiano⁹; Enrique de Alava¹²; Robin Jones¹³; Salvatore Provenzano²; Giovanni Grignani³; Virginia Ferraresi⁴; Rossella Bertulli²; Giacomo G. Baldi¹¹; Antonella Brunello⁶; Elisa Carretta¹; Elisabetta Setola¹; Angelo Paolo Dei Tos⁵; Alessandra Longhi¹; Anna Paioli¹; Marilena Cesari¹; Michela Pierini¹; Uta Dirksen¹⁴; Christian Rothermundt¹⁴; Javier Martin-Broto¹²; **Bruno Vincenzi**¹⁰

¹Istituto Ortopedico Rizzoli, Bologna, BO, Italy; ²Istituto Nazionale dei Tumori, Milano, MI, Italy; ³Istituto di Candiolo, Candiolo, TO, Italy; ⁴Istituto Nazionale Tumori "Regina Elena", Roma, RM, Italy; ⁵Azienda ULSS2, Treviso, TV, Italy; ⁶Istituto Oncologico Veneto, Padova, PD, Italy; ⁷MD Anderson Cancer Center, Houston, TX, USA; ⁸Dana-Faber Cancer Institute, Boston, MA, USA; ⁹Institut Bergonié, Bordeaux, France; ¹⁰Policlinico Universitario Campus Biomedico, Roma, RM, Italy; ¹¹AUSL4 Toscana, Prato, PO, Italy; ¹²IBIS Instituto de Biomedicina de Sevilla, Sevilla, Spain; ¹³The Royal Marsden, London, United Kingdom; ¹⁴Kantonsspital St.Gallen, St. Gallen, Switzerland

3244146

TRANSCRIPTOMIC LANDSCAPE OF 79 HOMOGENOUSLY TREATED OSTEOSARCOMA TUMORS AT DIAGNOSIS REVEALS TUMOR CLONES AND MICROENVIRONMENT INTERPLAY ASSOCIATED WITH OSTEOSARCOMA PROGNOSIS

Antonin Marchais, PhD¹; Maria Eugenia Marques da Costa¹; Bastien Job³; Robin Droit¹; Rachid Abbas²; Anne G. Brouchet⁴; Françoise Redini⁵; Olivia Fromigué¹; Cyril Lervat⁶; Hélène Pacquement⁷; Catherine Devoldere⁴; Claudine Schmitt⁴; Damien Bodet⁴; Sophie Piperno-Neumann⁷; Natacha Entz-Werle⁴; Perrine Marec-Berard⁸; Martha Jimenez⁹; Gilles Vassal¹; Birgit Georger¹; Laurence Brugieres¹; Nathalie Gaspar¹

¹Pediatrics, Gustave Roussy Cancer Campus, Villejuif, France; ²SBE, Gustave Roussy, Villejuif, France;

³INSERM, Villejuif, France; ⁴CHU, Toulouse, France; ⁵University, Nantes, France; ⁶Centre Oscar Lambret, Lille, France; ⁷Institut Curie, Paris, France; ⁸IHOP, Lyon, France; ⁹UNICANCER, Paris, France

3255224

IMPACT OF NEXT GENERATION SEQUENCING (NGS) ON DIAGNOSTIC AND THERAPEUTIC OPTIONS IN SOFT-TISSUE AND BONE SARCOMA (STSB)

Mrinal M. Gounder¹; Sally Trabucco²; Dexter X. Jin²; Narasimham Agaram¹; Sandra P. D'angelo¹; Mark Dickson¹; Mary Louise Keohan¹; Ciara Kelly¹; William D. Tap¹; Siraj Ali²

¹Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Foundation Medicine, Boston, MA, USA

3255373

TRACING SARCOMA EVOLUTION REVEALS CLONAL ORIGIN OF ADVANCED METASTASIS

Yuning Tang; Jianguo Huang; Hongyuan Zhang; Hidetoshi Tsushima; David Kirsch; Benjamin Alman
Duke University, Durham, NC, USA

12:00 pm - 1:00 pm

Lunch

Second Floor

1:00 pm - 3:00 pm

– SESSION 3 –

Kiku Ballroom

Clinical Trials + Precision Medicine

3255423

MULTI-INSTITUTIONAL EUROPEAN SINGLE-ARM PHASE II TRIAL OF PAZOPANIB IN ADVANCED TYPICAL SOLITARY FIBROUS TUMORS: A COLLABORATIVE SPANISH (GEIS), ITALIAN (ISG), AND FRENCH (FSG) SARCOMA GROUPS STUDY

Josefina Cruz²; Nadia Hindi¹; Sarah Dumont³; Nicolas Penel⁴; Pablo Luna⁵; Enrique de Alava⁶; Jean-Yves Blay⁷; Silvia Stacchiotti⁸; Paola Collini⁸; Andres Redondo⁹; Daniel Bernabeu¹⁰; Antonio López Pousa¹¹; Giovanni Grignani¹²; David d. Moura¹³; Javier Martinez-Trufero¹⁴; Philippe Terrier¹⁵; Marie Karanian⁷; Axel Le Cesne³; Paolo Casali⁸; Javier Martin-Broto¹

¹Medical Oncology, Hospital Universitario Virgen del Rocío/Instituto de Biomedicina de Sevilla (IBIS), Seville, Spain; ²Medical Oncology, Hospital Universitario de Canarias, Tenerife, Spain; ³Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France; ⁴Oscar Lambret Cancer Center, Lille, France; ⁵Medical Oncology, Hospital Universitario Son Espases, Palma de Mallorca, Spain; ⁶Pathology, Hospital Universitario Virgen del Rocío, Seville, Spain; ⁷Centre Léon Bérard, Lyon, France; ⁸Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ⁹Medical Oncology, Hospital Universitario La Paz (IdiPAZ), Madrid, Spain; ¹⁰Radiology, Hospital Universitario La Paz, Madrid, Spain; ¹¹Medical Oncology, Hospital Sant Pau, Barcelona, Spain; ¹²Medical Oncology, Istituto di Candiolo-Fondazione del Piemonte per l'Oncologia IRCCS Candiolo, Turin, Italy; ¹³Group of Advanced Therapies and Biomarkers in Oncology, Institute of Biomedicine of Seville, Ibis/Hospital Universitario Virgen Del Rocío/Csic/Universidad De Sevilla, Seville, Spain; ¹⁴Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain; ¹⁵Pathology, Gustave Roussy Cancer Campus, Villejuif, France

3253244

DEVELOPMENT AND VALIDATION OF A MOLECULAR SIGNATURE PREDICTIVE OF DURABLE CLINICAL BENEFIT FOLLOWING PAZOPANIB THERAPY IN ADVANCED SOFT TISSUE SARCOMA

Paul Huang¹; Alex Lee¹; Chris Wilding¹; Frank McCarthy¹; Nafia Guljar¹; Khin Thway²; Ben Fulton³; Sara Walker³; Alexandra Bell⁴; Fiona Graham⁴; Elaine MacDuff⁵; Wei Lin Goh⁶; Timothy Kwang Yong Tay⁷; Christina Messiou²; Richard Buus¹; Cyril Fisher⁸; Mohamad Farid⁶; Jeff White³; Ian Judson²; Maggie Cheang¹; Robin Jones²

¹Institute of Cancer Research, London, United Kingdom; ²Royal Marsden Hospital, London, United Kingdom; ³Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; ⁴NHS Greater Glasgow & Clyde Biorepository, Glasgow, United Kingdom; ⁵Pathology, NHS Greater Glasgow & Clyde, Glasgow, United Kingdom; ⁶National Cancer Centre Singapore, Singapore, Singapore; ⁷Singapore General Hospital, Singapore, Singapore; ⁸University Hospitals Birmingham, Birmingham, United Kingdom

3255734

VALIDATION OF GEISTRA SCORE: A PREDICTIVE TOOL OF TRABECTEDIN (TB) BENEFIT IN ADVANCED SOFT TISSUE SARCOMAS (ASTS), BASED ON GROWTH MODULATION INDEX (GMI). A RETROSPECTIVE REGISTRY-BASED ANALYSIS FROM SPANISH GROUP OF SARCOMA RESEARCH (GEIS)

Javier Martinez-Trufero, PhD MD¹; Luis Miguel De Sande Gonzalez²; Pablo Luna¹⁹; Javier Martin-Broto³; Rosa Alvarez⁴; Antonio Casado⁵; Roberto Diaz Beveridge⁶; Andres Poveda⁷; Juana Maria Cano⁸; Josefina Cruz⁹; Antonio López Pousa¹⁰; Maria Angeles Vaz Salgado¹¹; Claudia M. Valverde Morales¹²; Isabel Sevilla¹³; Jeronimo Martinez¹⁴; Jordi Rubio Casadevall¹⁵; Ana De Juan¹⁶; Juan Antonio Carrasco¹⁷; Antonio Gutierrez¹⁸

¹Medical Oncology , Hospital Universitario Miguel Servet, Zaragoza, Zaragoza, Spain; ²Medical oncology, Complejo Asistencial Universitario de Leon, Leon, Leon, Spain; ³Medical Oncology, Hospital Virgen del Rocio, Sevilla, Sevilla, Spain; ⁴Medical Oncology, Hospital Gregorio Marañon, Madrid, Madrid, Spain; ⁵Medical Oncology, Hospital Clinico San Carlos, Madrid, Madrid, Spain; ⁶Medical Oncology, Hospital La Fe, Valencia, Spain; ⁷Instituto Valenciano de Oncologia, Valencia, Spain; ⁸Medical oncology, Hospital General de Ciudad Real, Ciudad Real, Spain; ⁹Hospital Universitario Canarias, Santa Cruz de Tenerife, Spain; ¹⁰Hospital Sant Pau, Barcelona, Spain; ¹¹Hospital Ramon y Cajal, Madrid, Spain; ¹²Medical Oncology, Hospital Vall D'Hebron, Barcelona, Spain; ¹³Hospital Virgen de la Victoria, Malaga, Spain; ¹⁴Hospital Virgen de la Arrixaca, Murcia, Spain; ¹⁵Instituto Catalan Oncologia, Girona, Spain; ¹⁶Hospital Marques de Valdecilla, Santander, Spain; ¹⁷Hospital Alvaro Cunqueiro, Vigo, Spain; ¹⁸Hospital Son Espases, Palma de Mallorca, Spain; ¹⁹Hospital son Espases, Palma de Mallorca, Spain

3255286

NANOTECHNOLOGIES FOR CAPTURE AND RELEASE OF EWING SARCOMA-DERIVED CIRCULATING TUMOR CELLS

Jiantong Dong²; Yazhen Zhu²; Noah C. Federman⁴; Hsian-Rong Tseng²; Paul S. Weiss¹; **Steven J. Jonas, MD, PhD³**

¹Chemistry & Biochemistry, Materials Science & Engineering, Bioengineering, and the California NanoSystems Institute, University of California, Los Angeles, Los Angeles, CA, USA; ²Molecular and Medical Pharmacology & the California NanoSystems Institute, University of California, Los Angeles, Los Angeles, CA, USA; ³Pediatrics, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, University of California, Los Angeles, Los Angeles, CA, USA; ⁴Pediatrics, University of California, Los Angeles, Los Angeles, CA, USA

3254588

LAROTRECTINIB EFFICACY AND SAFETY IN PATIENTS WITH TRK FUSION SARCOMAS

George D. Demetri¹; Catherine M. Albert²; Daniel S. Tan³; Stefan Bielack⁴; Daniel Orbach⁵; Steven DuBois⁶; Noah C. Federman⁷; Birgit Georger⁸; Shivaani Kummar⁹; Theodore W. Laetsch¹⁰; Ramamoorthy Nagasubramanian¹¹; Alexander Drilon¹²; David S. Hong¹³; David M. Hyman¹²; Ulrik Lassen¹⁴; Ray McDermott¹⁵; Alberto Pappo¹⁶; Neerav Shukla¹²; Shivani Nanda¹⁷; Barrett H. Childs¹⁷; Leo Mascarenhas¹⁸; Cornelis M. van Tilburg¹⁹

¹Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; ²Seattle Children's Hospital, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ³National Cancer Center, 11 Hospital Drive, Singapore 169610, Singapore; ⁴Pediatrics 5 (Oncology, Hematology, Immunology), Klinikum Stuttgart-Olgahospital, Stuttgart, Germany; ⁵SIREDO Oncology Center (Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer), Institut Curie, PSL University, Paris, France; ⁶Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA; ⁷University of California, Los Angeles, CA, USA; ⁸Gustave Roussy, Department of Pediatric and Adolescent Oncology, Université Paris-Sud, Université Paris-Saclay, Villejuif, France; ⁹Stanford Cancer Center, Stanford University, Palo Alto, CA, USA; ¹⁰University of Texas, Southwestern Medical Center/Children's Health, Dallas, TX, USA; ¹¹Nemours Children's Hospital, Orlando, FL, USA; ¹²Memorial Sloan Kettering Cancer Center, New York, NY, USA; ¹³University of Texas MD Anderson Cancer Center, Houston, TX, USA; ¹⁴Department of Oncology, Rigshospitalet, Copenhagen, Denmark; ¹⁵St Vincent's University Hospital and Cancer Trials Ireland, Dublin, Ireland; ¹⁶Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA; ¹⁷Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA; ¹⁸Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA; ¹⁹Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, Germany

3255999

ENTRECTINIB IN NTRK FUSION-POSITIVE SARCOMA: INTEGRATED ANALYSIS OF PATIENTS ENROLLED IN STARTRK-2, STARTRK-1 AND ALKA-372-001

Stephen V. Liu¹; Luis Paz-Ares²; James Hu³; Jürgen Wolf⁴; Byung Chul Cho⁵; Maciej Krzakowski⁶; Christine H. Chung⁷; Manish Patel⁸; Matthew Taylor⁹; Harald Zeuner¹⁰; Amine Aziez¹⁰; Xinhui Huang¹¹; Stuart Osborne¹⁰; Anna Farago¹²

¹Georgetown University, Washington, , USA; ²Hospital Universitario 12 de Octubre, Madrid, Spain; ³University of Southern California/Norris Cancer Center, Los Angeles, CA, USA; ⁴Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany; ⁵Yonsei Cancer Center, Seoul, Korea (the Republic of); ⁶Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland; ⁷Moffitt Cancer Center, Tampa, FL, USA; ⁸University of Minnesota, Department of Medicine, Minneapolis, MN, USA; ⁹Oregon Health & Science University, Portland, OR, USA; ¹⁰F. Hoffmann-La Roche, Basel, Switzerland; ¹¹Genentech, San Francisco, CA, USA; ¹²Massachusetts General Hospital, Boston, MD, USA

3206452

WEEKLY NAB-SIROLIMUS IN PATIENTS WITH ADVANCED MALIGNANT PERIVASCULAR EPITHELIOID CELL TUMORS (PECOMA): RESULTS FROM AMPECT, AN OPEN-LABEL PHASE 2 REGISTRATION TRIAL WITH INDEPENDENT RADIOLOGY REVIEW

Mark Dickson¹; Vinod Ravi¹¹; Richard F. Riedel²; Kristen Ganjoo³; Brian A. Van Tine⁴; Rashmi Chugh⁵; Lee Cranmer⁶; Erlinda Gordon⁷; Jason Hornick⁸; David Kwiatkowski⁸; Heng Du⁸; Berta Grigorian⁹; Anita N. Schmid⁹; Shihe Hou⁹; Katherine Harris⁹; Neil Desai⁹; Andrew Wagner¹⁰

¹Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Duke Cancer Institute, Durham, NC, USA; ³Stanford University, Stanford, CA, USA; ⁴Washington University in Saint Louis, St. Louis, MO, USA; ⁵University of Michigan, Ann Arbor, MI, USA; ⁶Univ Washington/Fred Hutchinson Cancer Res Ctr, Seattle, WA, USA; ⁷Sarcoma Oncology Center, Santa Monica, CA, USA; ⁸Brigham and Women's Hospital, Boston, MA, USA; ⁹Aadi Bioscience, Pacific Palisades, CA, USA; ¹⁰Dana-Farber Cancer Institute, Boston, MA, USA; ¹¹MD Anderson Cancer Center, Houston, TX, USA

3256267

A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, CROSS-OVER, STUDY OF SELINEXOR VERSUS PLACEBO IN ADVANCED, UNRESECTABLE, DE-DIFFERENTIATED LIPOSARCOMA (DDLPS)

Mrinal M. Gounder²; Steven Attia⁴; Neeta Somaiah¹; Bartosz Chmielowski³; Sant P Chawla M. Inc⁵; Javier Martin-Broto⁶; Scott Schuetze⁷; Giovanni Grignani⁸; Bruno Vincenzi⁹; Kristen Ganjoo¹⁰; Robin L. Jones¹¹; Richard F. Riedel¹²; Melissa Burgess¹³; Silvia Stacchiotti¹⁴; Christopher Ryan¹⁵; Andrew Wagner¹⁶; Xiwen Ma¹⁷; Jatin Shah¹⁸; Sharon Shacham¹⁹; Michael Kauffman²⁰; Albiruni Razak²¹
¹MD Anderson Cancer Center, Houston, TX, USA; ²Memorial Sloan Kettering Cancer Center, New York, NY, USA; ³Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA; ⁴Mayo Clinic in Florida, Jacksonville, FL, USA; ⁵Sarcoma Oncology Center, Santa Monica, CA, USA; ⁶Hospital Universitario Virgen Del Rocio, Seville, Spain; ⁷University of Michigan, Ann Arbor, MI, USA; ⁸Candiolo Cancer Institute, Candiolo, Italy; ⁹Policlinico Universitario Campus Biomedico, Rome, Italy; ¹⁰Stanford University, Stanford, CA, USA; ¹¹The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom; ¹²Duke Institute of Cancer Institute, Durham, NC, USA; ¹³University of Pittsburg Medical Center, Hermitage, PA, USA; ¹⁴Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ¹⁵Oregon Health and Science University Knight Cancer Institute, Portland, OR, USA; ¹⁶Dana Farber Cancer Institute, Boston, MA, USA; ¹⁷Karyopharm Therapeutics Inc., Newton, MA, USA; ²¹Princess Margaret Cancer Centre, Toronto, ON, Canada

3:00 pm - 3:30 pm

Afternoon Break & Poster Viewing

3rd Floor

3:30 pm - 5:30 pm

– SESSION 4 –

Kiku Ballroom

Bone

3229546

TRAINED AND TESTED DECISION TREE OF RADIOGRAPHIC PARAMETERS RELIABLY PREDICTS ASEPTIC FAILURE OF COMPRESSIVE OSSEOINTEGRATION ENDOPROSTHESES

Lindsay Parlee¹; Yee-Cheen Doung¹; James Hayden¹; Ryland Kagan¹; **Kenneth R. Gundle, MD**²
¹Orthopaedics & Rehabilitation, Oregon Health & Science University, Portland, OR, USA; ²Operative Care Division, Portland VA Medical Center, Portland, OR, USA

3256557

NAVIGATED EXTREMITY SARCOMA RESECTION: ACCURACY AND REPRODUCIBILITY USING A NOVEL FLUOROSCOPY-BASED REGISTRATION TECHNIQUE FOR JOINT-SPARING BONE CUTS

Ibrahim S. Alshaygy; Jean-Camille Mattei; Georges Basile; Anthony Griffin; Xun Lin; Peter Ferguson; Jay Wunder

Orthopaedic Department, Mount Sinai Hospital, Toronto, ON, Canada

3235120

ROLE OF EMT TRANSCRIPTION FACTORS IN THE METASTATIC POTENTIAL OF OSTEOSARCOMA

Sana Mohiuddin, MBBS¹; Salah-Eddine Lamhamedi Cherradi²; Dhruva K. Mishra⁴; Kristi Pence⁴; Standhya Krishnan²; Brian A. Menegaz²; David McCall¹; Alejandra R. Velasco²; Danh D. Truong²; Branko Cuglievan¹; Amelia Vetter²; Eric R. Molina³; Min P. Kim⁴; Joseph A. Ludwig²
¹Pediatrics, MD Anderson Cancer Center, Houston, TX, USA; ²Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; ³Rice University, Houston, TX, USA; ⁴Houston Methodist, Houston, TX, USA

3249338

VACCINATION TO ENHANCE THE ANTI-TUMOR ACTIVITY OF GD2 CHIMERIC ANTIGEN RECEPTOR EXPRESSING VZV-SPECIFIC T CELLS IN RELAPSED OSTEOSARCOMA

Sarah Whittle, MD¹; Natalia N. Lapteva²; Margaret Gilbert²; Mina Al-Sabbagh²; Bambi Grilley²; Carlos A. Ramos²; Bilal Omer²; Tao Wang²; Hao Liu²; Stephen Gottschalk³; Helen Heslop²; Cliona Rooney²; Lisa L. Wang¹

¹Pediatrics, Baylor College of Medicine, Houston, TX, USA; ²Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA; ³St. Jude Children's Research Hospital, Memphis, TN, USA

3256545

SOLITARY BONE METASTASES FROM SARCOMAS: IS THERE ANY PLACE FOR CURATIVE SURGERY?

Jean-Camille Mattei, MD, PhD; Ibrahim S. Alshaygy; Georges Basile; Anthony Griffin; Peter Ferguson; Jay Wunder
AP-HM, Aix-Marseille University, Marseille, France

3255440

COMPARISON OF MAP VERSUS MAPIE (POOR HISTOLOGIC RESPONSE) OR MAP PLUS PEGYLATED INTERFERON- α (GOOD HISTOLOGIC RESPONSE) IN NEWLY-DIAGNOSED RESECTABLE OSTEOSARCOMA: RESULTS FROM THE EURAMOS-1 TRIAL WITH LONG-TERM FOLLOW-UP

Katherine A. Janeway, MD¹; Fiona C. Ingleby²; Sigbjorn Smeland³; Jeremy Whelan⁴; Neyssa Marina⁵; Mark Bernstein⁶; Trude Butterfass-Bahloul⁷; Gabriele Calaminus⁸; Lor Randall⁹; Karen Sanders²; Babasola Popoola²; Mark Krailo¹⁰; Matthew R. Sydes²; Stefan Bielack¹¹

¹Dana Farber Cancer Institute, Boston, MA, USA; ²University College London, London, United Kingdom; ³Lund University, Lund, Sweden; ⁴University College London Hospitals, London, United Kingdom; ⁵Five Prime Therapeutics, Inc, San Francisco, CA, USA; ⁶University of Toronto, Toronto West Hospital, Toronto, ON, Canada; ⁷Centre for Clinical Trials, University Hospital Muenster, Muenster, Germany; ⁸UKB University of Bonn, Bonn, Germany; ⁹UC Davis Health, Sacramento, CA, USA; ¹⁰Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; ¹¹Stuttgart Cancer Center, Olgahospital, Stuttgart, Germany

3228794

APATINIB PLUS CAMRELIZUMAB (SHR-1210) FOR UNRESECTABLE HIGH-GRADE OSTEOSARCOMA (APFAO) PROGRESSING AFTER CHEMOTHERAPY: A SINGLE ARM, OPEN-LABEL, PHASE 2 TRIAL

Lu Xie, MD¹; Jie Xu¹; Wei Guo¹; Jin Gu²; Xin Sun¹; Kuisheng Liu¹; Xiaodong Tang¹; Kunkun Sun³; Danhua Shen³; Yuan Li⁴

¹Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China; ²Surgical Oncology, Peking University Shougang Hospital, Beijing, China; ³Pathology Department, Peking University People's Hospital, Beijing, China; ⁴Radiology Department & Nuclear Medicine Department, Peking University People's Hospital, Beijing, China

3255674

DEVELOPMENT AND VALIDATION OF A NOVEL SODIUM FLUORIDE-PET RESPONSE CRITERIA FOR SOLID TUMORS (NAFCIST) IN A PHASE 1 CLINICAL TRIAL OF ALPHA PARTICLE RADIUM 223 IN OSTEOSARCOMA

Vivek Subbiah, MD¹; Pete Anderson²; Eric Rohren³; Gregory Ravizzini⁴; Homer Macapinlac⁴; Kalevi Kairemo⁴

¹Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ²Cleveland Clinic, Cleveland, OH, USA; ³Baylor, Houston, TX, USA; ⁴Nuclear Medicine, MD Anderson Cancer, Houston, TX, USA

6:00 am - 5:30 pm Registration Kiku Lobby, 4th Floor
6:15 am - 7:30 am Sunrise in Tokyo Kiku Ballroom

8:00 am - 8:30 am

– SESSION 5 –

Kiku Ballroom

Sarcoma of the Year: DSRCT

3251509

WHOLE ABDOMINOPELVIC RADIOTHERAPY AND RADIOIMMUNOTHERAPY AFTER COMPLETE RESECTION OF DESMOPLASTIC SMALL ROUND CELL TUMOR (DSRCT): MAJOR IMPACT ON SURVIVAL

Shakeel Modak, MD¹; James Saltsman¹; Neeta Pandit-Taskar²; Emily Slotkin¹; Todd Heaton¹;

Justin T. Gerstle¹; Suzanne Wolden³; Michael P. LaQuaglia¹

¹Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ³Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

3254390

SINGLE-CELL RNA-SEQUENCING IDENTIFIES DISTINCT TUMOR CELL SUBPOPULATIONS AND IMMUNE INFILTRATE IN DESMOPLASTIC SMALL ROUND CELL TUMORS (DSRCT)

Julien Vibert¹; **Clémence Hénon²**; Nadège Gruel¹; Léo Colmet-Daage²; Asuka Kawai-Kawashi²; Thomas Eychenne²; Joshua Waterfall¹; Julien Adam³; Axel Le Cesne⁴; Olivier Mir⁵; Charles Honoré⁶; Olivier Delattre¹; Sarah Watson¹; Sophie Postel-Vinay²

¹INSERM, UMR830, Cancer, Hétérogénéité, Instabilité et Plasticité, Institut Curie, Paris, France;

²INSERM, UMR981, ATIP-Avenir Group, Gustave Roussy Cancer Campus, Villejuif, France;

³Department of Pathology, Gustave Roussy Cancer Campus, Villejuif, France; ⁴Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France; ⁵Department of Ambulatory Care, Gustave Roussy Cancer Campus, Villejuif, France; ⁶Department of Cancer Surgery, Gustave Roussy Cancer Campus, Villejuif, France

Multi-Disciplinary Care

3253497

A PHASE III RANDOMISED CONTROLLED TRIAL COMPARING HISTOTYPE-TAILORED NEOADJUVANT CHEMOTHERAPY AND STANDARD CHEMOTHERAPY IN PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS (ISG-1001): A SARculator-BASED PROGNOSTIC RISK STRATIFICATION ANALYSIS

Sandro Pasquali¹; Emanuela Palmerini²; Vittorio Quagliuolo³; Javier Martin-Broto⁴; Antonio López Pousa⁵; Giovanni Grignani⁶; Antonella Brunello⁷; Jean-Yves Blay⁸; Oscar Tendero⁹; Roberto D. Beveridge¹⁰; Virginia Ferraresi¹¹; Iwona Lugowska¹²; Domenico Merlo¹³; Valeria Fontana¹³; Emanuela Marchesi¹⁴; Davide M. Donati²; Elena Palassini¹; Silvia Stacchiotti¹; Silvia Baguè¹⁵; Jean M. Coindre¹⁶; Angelo Paolo Dei Tos¹⁷; Piero Picci¹⁴; Paolo Bruzzi¹³; Paolo Casali¹; Alessandro Gronchi¹

¹Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; ²Istituto Ortopedico Rizzoli, Bologna, Italy; ³Humanitas Cancer Centre, Rozzano, Italy; ⁴Virgen del Rocío University Hospital, Valencia, Spain; ⁵Hospital Sant Pau, Barcellona, Spain; ⁶Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy; ⁷Veneto Institute of Oncology, Padova, Italy; ⁸Centre Léon Bérard, Lyon, France; ⁹Hospital Universitario Son Espases, Palma de Mallorca, Spain; ¹⁰Hospital Universitario y Politécnico La Fe, Valencia, Spain; ¹¹Istituto Nazionale Tumori Regina Elena, Rome, Italy; ¹²Instytut im. Marii Skłodowskiej-Curie, Warsaw, Poland; ¹³IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy; ¹⁴Italian Sarcoma Group, Bologna, Italy; ¹⁵Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; ¹⁶Institut Bergonie, Bordeaux, France; ¹⁷University of Padova, Padova, Italy

3253041

THERAPEUTIC RELEVANCE OF MOLECULAR SCREENING PROGRAM FOR PATIENTS WITH SARCOMA? ANALYSIS FROM THE PROFILER TRIAL

Armelle Dufresne; Patrick Arnaud-Coffin; Mehdi Brahmi; Olivier Tredan; Pierre Meeus; Daniel Pissaloux; Valery Attignon; David Perol; Jean-Yves Blay
Centre Leon Berard, Lyon, France

3253370

PERSONALISED MEDICINE FOR HIGH-RISK PAEDIATRIC AND AYA SARCOMA PATIENTS

Emmy D. Fleuren, PhD¹; Jinhan Xie¹; Paulette Barahona¹; Alexandra Sherstryuk¹; Daniel Batey¹; Jin Yi Lim¹; Loretta Lau¹; Dong Anh Khuong Quang¹; Tim Failes¹; Shu-Oi Chow¹; Chelsea Mayoh¹; Marie Wong¹; Amit Kumar¹; ZERO Omics Team¹; ZERO Preclinical Drug Testing Team¹; ZERO Senior Management Team¹; David Thomas²; Toby Trahair¹; Michelle Haber¹; Emily Mould¹; Richard Lock¹; David Ziegler¹; Vanessa Tyrrell¹; Mark Cowley¹; Paul Ekert¹

¹Children's Cancer Institute, Sydney, New South Wales, Australia; ²Garvan Institute of Medical Research, Sydney, New South Wales, Australia

3256280

RE-IRRADIATION FOR RECURRENT CHORDOMAS OF THE SPINE AND SACRUM WITH HIGH DOSE STEREOTACTIC BODY RADIATION THERAPY

Chinzi J. Jin¹; Anne Reiner²; Adam Schmitt¹; Daniel Higginson¹; Ilya Laufer³; Eric Lis⁵; Ori Barzilai³; Patrick Boland⁴; Mark H. Bilsky³; **Yoshiya Yamada, MD, FRCPC**¹

¹Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ³Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁴Orthopedics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁵Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Radiation

3242507

SPATIALLY-FRACTIONATED STEREOTACTIC BODY RADIOTHERAPY FOR LOCALIZED UNRESECTABLE, OLIGO-METASTATIC OR WIDELY-METASTATIC CONVENTIONAL TYPE CHONDROSARCOMA: A PROSPECTIVE PHASE I TRIAL**Sai Duriseti, MD, PhD¹**; James Kavanaugh¹; Sreekrishna Goddu¹; Tammy Senter¹; Jennifer Harris¹; Michael Watts¹; Clifford Robinson¹; Angela Hirbe²; Brian A. Van Tine²; Matthew Spraker¹¹Radiation Oncology, Washington University in St. Louis, St. Louis, MO, USA; ²Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA

3250148

THE RADIO-ENHANCER HAFNIUM OXIDE NANOPARTICLE, NBTXR3 ACTIVATED BY RADIATION THERAPY IN PATIENTS WITH LOCALLY ADVANCED SOFT TISSUE SARCOMA: A PHASE II/III TRIAL**Sylvie Bonvalot¹**; Piotr Rutkowski²; Juliette Thariat³; Sébastien Carrère⁴; Anne Ducassou⁵; Marie-Pierre Sunyach⁶; Peter Agoston⁷; Angela Hong⁸; Augustin Mervoyer⁹; Marco Rastrelli¹⁰; Victor Moreno¹¹; Rubi Li¹²; Béatrice Tiangco¹³; Vincent Servois¹; Patricia Saïd¹⁴; Mikaela Dimitriu¹⁴; Eva Wardelmann¹⁵; Philippe Terrier¹⁶; Alexander Lazar¹⁷; Judith Bovee¹⁸; Cécile Le Péchoux¹⁶; Zsusanna Papai¹⁹¹Institut Curie, Paris, France; ²Maria Sklodowska-Curie Institute -Oncology Center, Warsaw, Poland;³Centre François Baclesse, Caen, France; ⁴Centre Regional De Lutte Contre Le Cancer Paul Lamarque, Montpellier, France; ⁵Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Toulouse, France;⁶Léon Bérard Cancer Center, Lyon, France; ⁷Országos Onkológiai Intézet, Budapest, Hungary;⁸The University of Sydney, Camperdown, New South Wales, Australia; ⁹Institut de Cancerologie de l'Ouest- Rene Gauducheau, Saint-Herblain, France; ¹⁰Istituto Oncologico Veneto IRCCS, Padua, Italy;¹¹Hospital Fundación Jimenez Diaz, Madrid, Spain; ¹²St. Luke's Medical Center, Quezon City, Philippines;¹³The Medical City APS Cancer Institute, Pasig City, Philippines; ¹⁴Nanobiotix, SA, Paris, France;¹⁵University Hospital Münster, Münster, Germany; ¹⁶Institute Gustave Roussy, Villejuif, France;¹⁷MD Anderson Cancer Center, Houston, TX, USA; ¹⁸Leiden University Medical Center, Leiden,Netherlands; ¹⁹Hungarian Defence Forces, Budapest, Hungary

3255664

SPATIALLY FRACTIONATED GRID RADIOTHERAPY PRIOR TO NEOADJUVANT CONVENTIONALLY FRACTIONATED RADIOTHERAPY FOR VERY HIGH-RISK SOFT TISSUE AND OSTEO- SARCOMAS: PROMISING PATHOLOGIC RESPONSE WITH SAFE DOSE ESCALATION**James W. Snider, MD¹**; Jason Molitoris¹; Susan Shyu²; Stephanie Rice²; Emily Kowalski²; Cristina Decesaris²; Jill Remick²; Lori Campbell²; Nader Hanna¹; Vincent Ng¹; William Regine¹¹Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA;²Department of Radiation Oncology, University of Maryland Medical Center, Baltimore, MD, USA

3250473

ANGIOSARCOMA OF THE SCALP AND FACE: COMPARING RADIATION DOSE DISTRIBUTIONS BETWEEN HIGH-DOSE-RATE SURFACE APPLICATOR (HDR-SA) BRACHY THERAPY AND VOLUMETRIC MODULATED ARC THERAPY (VMAT)**Devarati Mitra, MD, PhD²**; Yaguang Pei¹; Ivan Buzurovic¹; Philip Devlin¹; Elizabeth Baldini¹; Miranda Lam¹¹Radiation Oncology, Dana Farber Cancer Institute, Boston, MA, USA; ²Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA

East Meets West

3247634

**PREVALENCE AND PROGNOSTIC IMPACT OF COMORBIDITIES IN SARCOMAS:
A POPULATION-BASED STUDY OF 3746 PATIENTS IN HONG KONG**

Herbert H. Loong, MBBS, MRCP, FHKCP, FHKAM¹; Carlos K. Wong²; Chu-wa Ho²; Teresa Tse³;
SC Sampson Kwan⁴; Linda K. Leung³; Yat Ming Lau³

¹Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, Hong Kong;

²Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong; ³Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong; ⁴Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong

3255511

**CLINICAL OUTCOME OF CLEAR CELL CHONDROSARCOMA: A MULTICENTER STUDY FROM
JAPANESE MUSCULOSKELETAL ONCOLOGY GROUP**

Robert Nakayama, MD, PhD¹; Keiko Hayakawa²; Makoto Endo⁴; Eisuke Kobayashi³; Shunsuke Hamada⁵;
Tsukasa Yonemoto⁶; Hiroyuki Kawashima⁷; Kenichiro Hamada⁸; Itsuo Watanabe⁹; Hiroyuki Futani¹⁰;
Takahiro Goto¹¹; Toshifumi Ozaki¹²

¹Department of Orthopaedic Surgery, Keio University, Shinjuku, Tokyo, Japan; ²Department of Orthopaedic Surgery, Cancer Institute Hospital for JFCR, Tokyo, Japan; ³Department of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital, Tokyo, Japan; ⁴Department of Orthopaedic Surgery, Kyushu University, Hakata, Japan; ⁵Department of Orthopaedic Surgery, Nagoya University, Nagoya, Japan; ⁶Department of Orthopaedic Surgery, Chiba Cancer Center, Chiba, Japan; ⁷Department of Orthopaedic Surgery, Niigata University, Niigata, Japan; ⁸Department of Orthopaedic Surgery, Osaka University, Osaka, Japan; ⁹Department of Orthopaedic Surgery, Tokyo Dental College Ichikawa General Hospital, Ichikawa, Japan; ¹⁰Department of Orthopaedic Surgery, Hyogo College of Medicine, Kobe, Japan; ¹¹Department of Orthopaedic Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan; ¹²Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Okayama, Japan

3255902

**CHEMOTHERAPY UTILIZATION AND TIMING IN PRIMARY, LOCALIZED, HIGH-GRADE SOFT TISSUE
SARCOMA: PATTERNS OF CARE IN THE NATIONAL CANCER DATABASE**

Danielle S. Graham, MD, MBA¹; Mykola Onyshchenko²; Mark A. Eckardt³; Benjamin DiPardo¹;
Srirnam Venigalla⁴; Scott Nelson⁵; Bartosz Chmielowski⁶; Arun Singh⁶; Jacob Shabason⁴; Fritz C. Eilber⁷;
Anusha Kalbasi⁸

¹Surgery, University of California, Los Angeles, Los Angeles, CA, USA; ²Hematology & Oncology, Harbor-UCLA, Los Angeles, CA, USA; ³Surgery, Yale School of Medicine, Los Angeles, CA, USA; ⁴Radiation Oncology, University of Pennsylvania Health System, Philadelphia, PA, USA; ⁵Pathology, University of California, Los Angeles, Los Angeles, CA, USA; ⁶Hematology & Oncology, University of California, Los Angeles, Los Angeles, CA, USA; ⁷Surgical Oncology, University of California, Los Angeles, Los Angeles, CA, USA; ⁸Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA

3217091

CLINICIANS' ADHERENCE TO PRACTICE GUIDELINES FOR SOFT TISSUE SARCOMA ANALYZED WITH QUALITY INDICATOR

Shintaro Iwata¹; Tomone Watanabe²; Yoko Kato³; Fumihiko Nakatani¹; Eisuke Kobayashi¹
Naoyo Takakura³; Naohiro Higashi²; Akira Kawai¹

¹Dept. Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital, Tokyo, Japan;

²Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan;

³Rare Cancer Center, National Cancer Center Hospital, Tokyo, Japan

12:00 pm - 1:00 pm

Lunch

Second Floor

1:00 pm - 2:00 pm

– SESSION 9 –

Kiku Ballroom

GIST

3254072

INVICTUS: A PHASE 3, INTERVENTIONAL, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF RIPRETINIB (DCC-2618) IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES (NCT03353753)

Jean-Yves Blay¹²; Steven Attia¹; Sebastian Bauer¹³; Ping Chi²; Gina D'Amato³; Suzanne George⁴; Hans Gelderblom¹⁴; Michael Heinrich⁵; Robin L. Jones⁶; Peter Reichardt¹⁵; Patrick Schöffski⁷; César Serrano⁸; John Zalcborg⁹; Julie Meade¹⁰; Kelvin Shi¹⁰; Rodrigo Ruiz Soto¹⁰; **Margaret von Mehren**¹¹
¹Mayo Clinic, Jacksonville, FL, USA; ²Memorial Sloan Kettering, Manhattan, NY, USA; ³University of Miami Health System, Miami, FL, USA; ⁴Dana-Farber Cancer Institute, Boston, MA, USA; ⁵Portland VA Health Care System and Knight Cancer Institute, Portland, OR, USA; ⁶Royal Marsden and Institute of Cancer Research, London, United Kingdom; ⁷Leuven Cancer Institute, Leuven, Belgium; ⁸Vall D'Hebron Institute of Oncology, Barcelona, Spain; ⁹Medical Oncology, Monash University and Alfred Health, Melbourne, Victoria, Australia; ¹⁰Deciphera Pharmaceuticals, LLC, Waltham, MA, USA; ¹¹Fox Chase Cancer Center, Philadelphia, PA, USA; ¹²Centre Léon Bérard, Lyon, France; ¹³Sarcoma Center, West German Cancer Center, University Hospital Essen, Essen, Germany; ¹⁴Leiden University Medical Center, Leiden, Netherlands; ¹⁵Department of Oncology and Palliative Care, Helios Klinikum Berlin-Buch, Berlin, Germany

3258046

CLINICAL RESPONSE TO AVAPRITINIB BY RECIST AND CHOI CRITERIA IN ≥4TH LINE (4L+) AND PDGFRA EXON 18 GASTROINTESTINAL STROMAL TUMORS (GIST)

Michael Heinrich, MD¹; Robin L. Jones²; Margaret von Mehren³; Sebastian Bauer⁴; Yoon-Koo Kang⁵; Patrick Schöffski⁶; Ferry Eskens⁷; Olivier Mir⁸; Philippe Cassier⁹; César Serrano¹⁰; William D. Tap¹¹; Jonathan C. Trent¹²; Piotr Rutkowski¹³; Shreyaskumar Patel¹⁴; Sant Chawla¹⁵; Eyal Meiri¹⁶; Teresa Zhou¹⁷; Maria Roche¹⁷; Suzanne George¹⁸

¹OHSU Knight Cancer Institute, Portland, OR, USA; ²Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; ³Fox Chase Cancer Center, Philadelphia, PA, USA; ⁴University of Duisburg-Essen, Essen, Germany; ⁵Asan Medical Centre, Seoul, Korea (the Democratic People's Republic of); ⁶University Hospitals Leuven Leuven Cancer Institute, Leuven, Belgium; ⁷Erasmus MC Cancer Institute, Rotterdam, Netherlands; ⁸Institut Gustave Roussy, Villejuif, France; ⁹Centre Léon Bérard, Lyon, France; ¹⁰Vall d' Hebron Institute of Oncology, Barcelona, Spain; ¹¹Memorial Sloan Kettering Cancer Center, New York, NY, USA; ¹²Sylvester Comprehensive Cancer Center University of Miami, Miami, FL, USA; ¹³Maria Sklodowska-Curie Institute–Oncology Center, Warsaw, Poland; ¹⁴MD Anderson Cancer Center, Houston, TX, USA; ¹⁵Sarcoma Oncology Center, Santa Monica, CA, USA; ¹⁶Cancer Treatment Center of America, Atlanta, GA, USA; ¹⁷Blueprint Medicines Corporation, Cambridge, MA, USA; ¹⁸Dana Farber Cancer Institute, Boston, MA, USA

3214982

GENOTYPE-SPECIFIC ACTIVITY AND SAFETY OF CABOZANTINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR AFTER FAILURE OF IMATINIB AND SUNITINIB. EARLY MOLECULAR DATA FROM EORTC PHASE 2 TRIAL 1317 "CABOGIST"

Patrick Schöffski¹; Olivier Mir⁵; Bernd Kasper⁹; Zsuzsanna Papai¹⁰; Jean-Yves Blay¹¹; Antoine Italiano¹²; Charlotte Benson³; Katerina Kopeckova⁶; Nasim Ali⁴; Palma Dileo⁷; Axel Le Cesne⁵; Franka Menge⁹; Sophie Cousin¹²; Céline Charon-Barra¹³; Agnieszka Wozniak¹; Sandrine Marreaud⁸; Saskia Litiere⁸; Axelle Nzokirantevye⁹; Hans Gelderblom²

¹General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; ²Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands; ³Sarcoma Unit, Royal Marsden Hospital, London, United Kingdom; ⁴Clatterbridge Cancer Centre, Wirral, United Kingdom; ⁵Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France; ⁶Department of Oncology of the 2nd Faculty of Medicine, Charles University and University Hospital in Motol, Praha, Czechia; ⁷University College London, London, United Kingdom; ⁸European Organization for Research and Treatment of Cancer, Brussels, Belgium; ⁹Sarcoma Unit - Interdisciplinary Tumor Center, Mannheim University Medical Center, Mannheim, Germany; ¹⁰State Medical Centre Budapest, Budapest, Hungary; ¹¹Centre Léon Bérard, Lyon, France; ¹²Sarcoma Unit, Institut Bergonié, Bordeaux, France; ¹³Centre Georges François Leclerc, Dijon, France

3247216

GASTROINTESTINAL STROMAL TUMOR LOCATION WITHIN THE STOMACH CORRELATES WITH TUMOR MUTATION PROFILE

Jason K. Sicklick¹; **Jorge R. de la Torre Medina**¹; Sudeep Banerjee¹; Vi Nguyen⁴; Maha Alkhuziem³; Santiago Horgan³; Chih-Min Tang¹; Mayra Yebra¹; Hyunho Yoon¹; Robert Mallory¹; Hitendra Patel²; Shumei Kato²; Wilson Kwong⁵; Micheal Chang⁵; Syed Fehmi⁵; Thomas Savides⁵; Adam Burgoyne²; Paul Fanta²

¹Department of Surgery, Division of Surgical Oncology, University of California, San Diego, La Jolla, CA, USA; ²Medical Oncology, UC San Diego, San Diego, CA, USA; ³Department of Surgery, UC San Diego, San Diego, CA, USA; ⁴Medical School, UC San Diego, San Diego, CA, USA; ⁵Department of Gastroenterology, UC San Diego, San Diego, CA, USA

2:00 pm - 3:00 pm

– HERMAN SUIT LECTURE –

Kiku Ballroom

Jay Wunder

(Mount Sinai Hospital, Toronto, Ontario, Canada)

3:00 pm - 3:30 pm

Afternoon Break

3rd Floor

Retroperitoneal / Pelvic

3253011

PATTERNS OF RECURRENCE AND SURVIVAL PROBABILITY FOLLOWING SECOND RELAPSE OF RETROPERITONEAL SARCOMA: A STUDY FROM TARPSWG

Winan van Houdt¹; Marco Fiore²; Francesco Barretta²; Piotr Rutkowski³; Jean-Yves Blay⁴; Guy Lahat⁵; Dirk Strauss⁶; Ricardo J. Gonzalez⁷; Nita Ahuja⁸; Giovanni Grignani⁹; Vittorio Quagliuolo¹⁰; Eberhard Stoeckle¹¹; Antonino De Paoli¹²; Venu Pillarisetty¹³; Carolyn Nessim¹⁴; Carol J. Swallow¹⁵; Sanjay P. Bagaria¹⁶; Robert Canter¹⁷; John Mullen¹⁸; Dario Callegaro²; Mark Fairweather¹⁹; Rosalba Miceli²; Chan Raut¹⁹; Alessandro Gronchi²; **Rebecca Gladdy, MD, PhD¹⁵**

¹Netherlands Cancer Institute, Amsterdam, Netherlands; ²Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ³Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland; ⁴Centre Leon Berard, Lyon, France; ⁵Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; ⁶Royal Marsden Hospital, London, United Kingdom; ⁷Moffitt Cancer Center, Tampa, FL, USA; ⁸Yale School of Medicine, New Haven, CT, USA; ⁹Candiolo Cancer Institute – FPO, IRCCS, Torino, Italy; ¹⁰Istituto Clinico Humanitas IRCCS, Milan, Italy; ¹¹Institut Bergonie, Regional Cancer Centre, Bordeaux Cedex, France; ¹²Centro di Riferimento Oncologico, Aviano, Italy; ¹³Seattle Cancer Care Alliance, University of Washington School of Medicine, Seattle, WA, USA; ¹⁴The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; ¹⁵Mount Sinai Hospital, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada; ¹⁶Mayo Clinic Jacksonville, Jacksonville, FL, USA; ¹⁷University of California-Davis School of Medicine, Davis, CA, USA; ¹⁸Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; ¹⁹Brigham and Women's Hospital, Dana-Farber Institute, Harvard Medical School, Boston, MA, USA

3254877

POST-OPERATIVE MORBIDITY AFTER RESECTION OF RECURRENT RETROPERITONEAL SARCOMA: A REPORT FROM THE TRANS-ATLANTIC AUSTRALASIAN RPS WORKING GROUP (TARPSWG)

Carolyn Nessim, MD, MSc¹; Chan Raut²⁰; Dario Callegaro¹⁹; Francesco Barretta²; Piotr Rutkowski³; Jean-Yves Blay⁴; Dirk Strauss⁵; Ricardo J. Gonzalez⁶; Nita Ahuja⁷; Giovanni Grignani⁸; Vittorio Quagliuolo⁹; Eberhard Stoeckle¹⁰; Antonino De Paoli¹¹; Venu Pillarisetty¹²; Carol J. Swallow¹³; Sanjay P. Bagaria²²; Robert Canter¹⁴; John Mullen¹⁵; Elisabetta Pennacchioli¹⁶; Frits van Coevorden¹⁷; Kenneth Cardona¹⁸; Marco Fiore¹⁹; Mark Fairweather²⁰; Alessandro Gronchi¹⁹; Guy Lahat²¹

¹Surgery, The Ottawa Hospital, Ottawa, ON, Canada; ²Surgery, Istituto di tumori di Milan, Milan, Italy; ³Surgery, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland; ⁴Surgery, Lyon Cancer Center, Lyon, France; ⁵Surgery, Royal Marsden, London, United Kingdom; ⁶Surgery, Moffitt Cancer Center, Tampa, FL, USA; ⁷Surgery, Yale University, New Haven, CT, USA; ⁸Surgery, Istituto di Candiolo, Torino, Italy; ⁹Surgery, Istituto Clinico Humanitas IRCCS, Milan, Italy; ¹⁰Institut Bergonie, Bordeaux, France; ¹¹Surgery, Centro di Riferimento Oncologico di Aviano, Aviano, Italy; ¹²Surgery, Seattle Cancer Center Alliance, Seattle, WA, USA; ¹³Surgery, University of Toronto, Toronto, ON, Canada; ¹⁴Surgery, UC Davis Health, Davis, CA, USA; ¹⁵Surgery, Massachusetts General Hospital, Boston, MA, USA; ¹⁶Surgery, European Institute of Oncology, Milan, Italy; ¹⁷Surgery, Netherlands Cancer Institute, Amsterdam, Netherlands; ¹⁸Surgery, Winship Cancer Institute, Emory, Atlanta, GA, USA; ¹⁹Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ²⁰Surgery, Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, USA; ²¹Surgery, Cancer Biology Research Center Tel Aviv University, Tel Aviv, Israel; ²²Mayo Clinic, Jacksonville, FL, USA

3247745

COMPARISON OF TOTAL (IPSILATERAL) RETROPERITONEAL LIPECTOMY VERSUS STANDARD COMPLETE RESECTION IN PATIENTS WITH RETROPERITONEAL LIPOSARCOMA: A RETROSPECTIVE FIVE-INSTITUTION STUDY

Shahbaz Hanif¹; Cheng Li Miao²; Fa Bo Qiu³; Wei Qi Lu⁴; Dai You Guo⁵; Xiao Song Rao⁶; Gao Kui Zhang⁷; Jun Chen²; Wen Jie Li²; Wen Qing Liu²; Xiao Bing Chen²; Meng Meng Xiao²; Li Chao Cha³; Jiong Yuan Wang⁴; Yu Bo Ren⁶; Hao Yun Yang⁷; William W. Tseng⁸; **Cheng Hua Luo**²

¹Beijing Spanal Medical Scientific Co. Ltd., Beijing, China; ²Dept. of Retroperitoneal Tumor Surgery, Peking University International Hospital, Beijing, China; ³Dept. of Retroperitoneal Tumor Surgery, Affiliated Hospital of Qingdao University, Qingdao, China; ⁴Dept. of General Surgery, Zhongshan Hospital of Fudan University, Shanghai, China; ⁵Department of Abdominal Surgery, Yunnan Cancer Hospital, Kunming, China; ⁶Department of Pathology, Peking University International Hospital, Beijing, China; ⁷HBR Data Science Ltd., Beijing, China; ⁸Department of Surgery, Section of Surgical Oncology, University of Southern California, Keck School of Medicine, Los Angeles, CA, USA

3253843

PREOPERATIVE LEIOMYOSARCOMA RISK-SCORE FOR DISCRIMINATION OF LEIOMYOSARCOMA VS. LEIOMYOMA OF THE UTERUS

Günther Köhler²; Marcus Vollmer⁴; Neetika Nath⁴; Philipp-Andreas Hessler⁵; **Peter Hohenberger, MD, PhD**¹; Matthias Evert³; Dominika Trojnarska²; Katja Evert³; Katarina Dennis⁵; Marek Zygmunt²; Lars Kaderali⁴

¹Dept. of Surgery, Div. of Surgical Oncology and Thoracic Surgery, Mannheim, Germany; ²Department of Obstetrics and Gynecology, University Medicine Greifswald, Greifswald, Germany; ³Institute of Pathology, University of Regensburg, Regensburg, Germany; ⁴Institute of Bioinformatics, University Medicine Greifswald, Greifswald, Germany; ⁵Hospital Sachsenhausen, Department of Gynecologic Surgery, Frankfurt/Main, Germany

3256471

THE EFFECT OF PREOPERATIVE TREATMENT ON THE PERFORMANCE OF PREDICTIVE NOMOGRAMS IN PRIMARY RETROPERITONEAL SARCOMA (RPS)

Deanna Ng¹; David Cyr¹; Dario Callegaro¹; Alessandro Gronchi²; David Shultz³; Savtaj Brar¹; Peter Chung³; Rebecca Gladdy¹; Charles Catton³; Carol J. Swallow¹

¹Department of Surgery, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada;

²Surgical Oncology, Fondazione IRCCS Istituto Nazionale Tumori Milano, Milan, Italy;

³Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

3253748

OUTCOMES ANALYSIS OF THE MULTIMODALITY TREATMENT OF PATIENTS WITH CAVAL LEIOMYOSARCOMA

Malcolm H. Squires, MD, MS¹; Stephen Politano¹; Raphael Pollock¹; James L. Chen²; Valerie Grignol¹

¹Division of Surgical Oncology, The Ohio State University, Columbus, OH, USA; ²Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA

3256534

FUNCTIONAL DURABILITY OF ACETABULAR RECONSTRUCTION FOLLOWING RESECTION OF PELVIC SARCOMAS

Tomohiro Fujiwara; Koichi Ogura; Alexander Christ; Mohamed Yakoub; Yusuke Tsuda; John H. Healey; Nicola Fabbri

Memorial Sloan Kettering Cancer Center, New York, NY, USA

Friday, 15 November, 2019

3256805

CARBON ION RADIOTHERAPY FOR SACRAL SARCOMAS

Reiko Imai; Hiroshi Tsuji; Tadashi Kamada

QST NIRS Hospital, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan

6:00 pm – 10:00 pm

GALA - Reception and Dinner at Happo En
Cocktail Attire

Happo En

Saturday, 16 November, 2019

6:00 am - 6:00 pm

Registration

Kiku Lobby, 4th Floor

6:15 am - 7:30 am

Sunrise in Tokyo

Kiku Ballroom

8:00 am - 10:00 am

– **SESSION 11** –

Kiku Ballroom

Paediatric

3253869

FIRST RESULTS OF THE EURO EWING 2012 TRIAL COMPARING TWO CHEMOTHERAPY REGIMENS IN NEWLY DIAGNOSED EWING SARCOMA

Keith Wheatley, DPhil¹; Veronica Moroz¹; Perrine Marec-Berard²; Javier Martin-Broto⁹;

Hans Gelderblom³; Sandra J. Strauss⁴; Nathalie Gaspar⁵; Jennifer Anderton¹; Jean-Pierre Mahieu¹;

Ana Sastre⁶; Valerie Laurence⁷; Jeremy Whelan⁴; Bernadette Brennan⁸

¹CRCTU, University of Birmingham, Birmingham, United Kingdom; ²Centre Léon Bérard, Lyon, France;

³European Organisation for Research and Treatment of Cancer, Brussels, Belgium; ⁴University College

London Hospitals NHS, London, United Kingdom; ⁵Gustave Roussy cancer campus, Paris, France;

⁶La Paz Hospital, Madrid, Spain; ⁷Institute Curie, Paris, France; ⁸Royal Manchester Children's Hospital,

Manchester, United Kingdom; ⁹Universitary Hospital Virgen del Rocio, Sevilla, Spain

3222400

RANDOMIZED PHASE 3 TRIAL OF GANITUMAB ADDED TO INTERVAL COMPRESSED CHEMOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED METASTATIC EWING SARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG)

Steven DuBois¹; Julia Glade Bender²; Allen Buxton³; Nadia Laack⁴; Lor Randall⁵; Helen Chen¹⁷;

Nita Seibel¹⁷; Stephanie Terezakis⁶; Christine Hill-Kayser⁷; Andrea Hayes-Jordan⁸; Joel Reid⁴; Lisa Teot⁹;

Dinesh Rakheja¹⁰; Richard Womer⁷; Carola Arndt⁴; Stephen Lessnick¹¹; Brian Crompton¹; Edward Kolb¹²;

Heike Daldrup-Link¹³; Eric Eutsler¹⁴; Damon Reed¹⁵; Katherine A. Janeway¹; Mark Krailo³;

Richard Gorlick¹⁶

¹Dana-Farber Cancer Institute, Boston, MA, USA; ²Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ³Children's Oncology Group, Monrovia, CA, USA; ⁴Mayo Clinic, Rochester, MN, USA;

⁵UC Davis, Sacramento, CA, USA; ⁶University of Minnesota, Minneapolis, MN, USA; ⁷Children's Hospital of Philadelphia, Philadelphia, PA, USA; ⁸University of North Carolina, Chapel Hill, NC, USA;

⁹Boston Children's Hospital, Boston, MA, USA; ¹⁰UT Southwestern, Dallas, TX, USA; ¹¹Nationwide

Children's Hospital, Columbus, OH, USA; ¹²Nemours Children's Hospital, Wilmington, DE, USA;

¹³Stanford Universtiy, Palo Alto, CA, USA; ¹⁴Washington University, St. Louis, MO, USA; ¹⁵Moffitt Cancer

Center, Tampa, FL, USA; ¹⁶MD Anderson Cancer Center, Houston, TX, USA; ¹⁷National Cancer Institute, Bethesda, MD, USA

A PHASE III RANDOMIZED TRIAL OF ADDING VINCRISTINE-TOPOTECAN-CYCLOPHOSPHAMIDE TO STANDARD CHEMOTHERAPY IN INITIAL TREATMENT OF NON-METASTATIC EWING SARCOMA – A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP

Patrick Leavey; Mark Krailo; Steven Dubois, Holcombe Grier; Douglas Hawkins; Bruce Pawel; Helen Nadal; Richard Womer; Del Stringham; Kenneth Brown; Damon Reed; Mark Bernstein; Katherine Janeway; Neyssa Marina; Nadia Laack; R Lor Randall; Richard Gorlick; Leo Mascarenhas

3223938

OUTCOME OF PATIENTS WITH RELAPSED OR PROGRESSIVE EWING SARCOMA ENROLLED ON PHASE 2 CLINICAL TRIALS: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG)

Anderson B. Collier, MD¹; Mark Krailo²; Ha Dang²; Steven DuBois³; Douglas S. Hawkins⁴; Mark Bernstein⁵; Lisa Bomgaars⁶; Damon Reed⁷; Richard Gorlick⁸; Katherine A. Janeway³

¹Pediatrics, University of Mississippi Medical Center, Jackson, MS, USA; ²University of Southern California, Los Angeles, CA, USA; ³Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA; ⁴Seattle Children's Hospital, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ⁵IWK Health Centre, Port Williams, NS, Canada; ⁶Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, TX, USA; ⁷Moffitt Cancer Center, Tampa, FL, USA; ⁸MD Anderson Cancer Center, Houston, TX, USA

3253193

DO CHILDREN AND ADOLESCENTS WITH COMPLETELY RESECTED ALVEOLAR RHABDOMYOSARCOMA (RMS) REQUIRE RADIATION? A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG)

Jamie Aye, MD¹; Yueh-Yun Chi²; Jing Tian²; Suzanne Wolden³; Douglas S. Hawkins⁴; Abha Gupta⁵

¹Pediatric Hematology Oncology, Children's of Alabama, University of Alabama at Birmingham, Birmingham, AL, USA; ²Biostatistics, University of Florida, Gainesville, FL, USA; ³Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁴Pediatric Hematology Oncology, Seattle Children's Hospital, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA; ⁵Pediatric Hematology Oncology, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

3253900

ASSESSING THE PROGNOSTIC VALUE OF EARLY ANATOMIC RESPONSE TO INDUCTION CHEMOTHERAPY IN PEDIATRIC RHABDOMYOSARCOMA: A SYSTEMATIC REVIEW

Bas Vaarwerk¹; **Roelof van Ewijk, Fellow in Pediatric Oncology, MD¹**; Willemijn B. Breunis²; Rick R. van Rijn³; Johanna H. van der Lee⁴; Hans Merks¹

¹Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; ²Oncology and Children's Research Center, University Children's Hospital, Zurich, Switzerland; ³Department of Radiology and Nuclear Medicine, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; ⁴Paediatric Clinical Research Office, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands

3256271

EUROPEAN PEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP MTS2008 STUDY: RESULTS OF A PROTOCOL FOR METASTATIC RHABDOMYOSARCOMA

Hans Merks, MD, PhD¹; Gianni Bisogno²; Gian Luca de Salvo³; Ilaria Zanetti²; Daniel Orbach⁴; Veronique Minard-Colin⁵; Anna Kelsey⁶; Helene Martelli⁷; Kieran McHugh⁸; Alison Cameron⁹; Heidi Glosli¹⁰; Andrea Ferrari¹¹; Christophe Bergeron¹²; Meriel Jenney¹³; Julia Chisholm¹⁴

¹Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands; ²Division of Haematology-Oncology- Department of Woman's and Child's Health, Padova University Hospital, Padova, Italy; ³Clinical Trial and Biostatistics Unit, Istituto Oncologico Veneto, Padova, Italy; ⁴SIREDO Oncology Center Care- Innovation and Research for Children- Adolescents and Young Adults with Cancer, Institut Curie-PSL University, Paris, France; ⁵Department of Child and Adolescent Cancer, Institute Gustave Roussy, Paris, France; ⁶Department of Diagnostic Paediatric Histopathology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; ⁷Department of Pediatric Surgery, Hôpital Universitaire Bicêtre, Paris, France; ⁸Department of Pediatric Radiology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom; ⁹Department of Clinical Oncology, University Hospitals Bristol, Bristol, United Kingdom; ¹⁰Department of Pediatric Oncology, Rikshospitalet, Oslo, Norway; ¹¹Department of Pediatric Oncology, Istituto Tumori Milano, Milan, Italy; ¹²Institut d'Hématologie et d'Oncologie Pédiatrique, Centre Léon Bérard, Lyon, France; ¹³Department of Pediatric Oncology, Children's Hospital for Wales, Cardiff, United Kingdom; ¹⁴Children and Young Peoples Unit, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

3251949

SAFETY AND FEASIBILITY OF MAGNETIC RESONANCE-GUIDED HIGH INTENSITY FOCUSED ULTRASOUND (MR-HIFU) FOR THE ABLATION OF RELAPSED OR REFRACTORY PEDIATRIC SOLID TUMORS INCLUDING DESMOID TUMORS

AeRang Kim, MD, PhD¹; Karun V. Sharma²; Pavel Yarmolenko³; James I. Geller⁴; Joseph G. Pressey⁴; John M. Racadio⁵; Haydar Celik³; Avinash Eranki³; Matthew Lanier⁶; Caitlin Tydings¹; Ari Partanen⁷; Peter C. Kim⁸

¹Oncology, Childrens National Medical Center, Washington, USA; ²Interventional Radiology, Children's National Medical Center, Washington, , USA; ³The Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Medical Center, Washington, USA; ⁴Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; ⁵Interventional Radiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; ⁶Imaging Research Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; ⁷Profound Medical Inc., Mississauga, ON, Canada; ⁸Surgery, George Washington School of Medicine, Washington, USA

10:00 am - 10:30 am

Morning Break

3rd Floor

10:30 am - 11:30 am

– NINA AXELRAD LECTURE –

Kiku Ballroom

Richard Gorlick

(MD Anderson Cancer Center, Houston, Texas, USA)

11:30 am - 12:00 pm

– SESSION 12 –

Kiku Ballroom

Young Investigator Awards

3256173

LONGITUDINAL PROGNOSTICATION IN PATIENTS WITH PRIMARY RETROPERITONEAL SARCOMA TREATED WITH SURGERY: DEVELOPMENT AND EXTERNAL VALIDATION OF A DYNAMIC PROGNOSTIC NOMOGRAM

Dario Callegaro, MD¹; Francesco Barretta²; Carol J. Swallow³; Dirk Strauss⁴; Sylvie Bonvalot⁵; Charles Honoré⁶; Eberhard Stoeckle⁷; Frits van Coevorden⁸; Rick Haas⁹; Piotr Rutkowski¹⁰; Yvonne Schrage¹¹; Mark Fairweather¹²; Lorenzo Conti¹; Nikolaos Vassos⁴; Rebecca Gladdy³; Deanna Ng³; Winan van Houdt⁸; Rosalba Miceli²; Chan Raut¹²; Alessandro Gronchi¹

¹Surgical Oncology, Fondazione IRCCS Istituto Nazionale Tumori Milano, Milan, Italy; ²Clinical Epidemiology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; ³Surgery, University of Toronto, Toronto, ON, Canada; ⁴Surgery, Royal Marsden Hospital, London, United Kingdom; ⁵Surgery, Institut Curie, Paris, France; ⁶Surgery, Institut Gustave Roussy, Villejuif, France; ⁷Surgery, Institut Bergonie, Bordeaux, France; ⁸Surgery, The Netherlands Cancer Institute, Amsterdam, Netherlands; ⁹Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands; ¹⁰Surgery, Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland; ¹¹Surgery, Leiden University Medical Center, Leiden, Netherlands; ¹²Surgery, Brigham and Women's Hospital, Boston, MA, USA

3254081

DISSECTING THE ROLE OF FUS-DDIT3 IN MYXOID LIPOSARCOMA RESPONSE TO RADIATION THERAPY

Mark Chen¹; Nathan Leisenring¹; Andrea R. Daniel¹; Joseph Foster²; Eric Xu¹; Andrea Ventura³; Ian J. Davis²; David Kirsch¹

¹Duke University, Durham, NC, USA; ²University of North Carolina - Chapel Hill, Chapel Hill, NC, USA; ³Memorial Sloan Kettering Cancer Center, New York, NY, USA

12:00 pm - 1:00 pm

Lunch

Second Floor

1:00 pm - 1:30 pm

LSERA Award

Kiku Ballroom

1:30 pm - 3:30 pm

– SESSION 13 –

Kiku Ballroom

Soft Tissue Sarcomas: Biology

3255107

COMPREHENSIVE GENOMIC ANALYSIS OF EWSR1-NFATC2 FUSION SARCOMAS IDENTIFY DISTINCTIVE GENOMIC ALTERATIONS AND UPREGULATION OF THE MTOR PATHWAY

Nathan D. Seligson, PharmD¹; Richard Maradiaga²; John Hays²; Sherri Millis³; James L. Chen²

¹University of Florida, Jacksonville, FL, USA; ²Ohio State University, Columbus, OH, USA;

³Foundation Medicine, Phoenix, AZ, USA

3256379

EXPRESSION OF CIC-DUX4 IN HEK293FT CELLS INCREASES THE LEVELS OF THE ONCOMETABOLITES L-2-HYDROXYGLUTARATE AND D-2-HYDROXYGLUTARATE

Kelsi R. Willis¹; Richard L. Boriack²; **Dinesh Rakheja, MD¹**

¹Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA;

²Pathology and Laboratory Medicine, Children's Health, Dallas, TX, USA

3254542

GENE EXPRESSION CHANGES ASSOCIATED WITH DEDIFFERENTIATION IN LIPOSARCOMA PREDICT OVERALL SURVIVAL

Nicholas Shannon; Xuan Qiu; Joey W. Tan; Josephine Hendrikson; Deanna Ng; Chin-Ann J. Ong; Grace Hwei Ching Tan; Claramae Shulyn Chia; Melissa Ching Ching Teo
<http://www.nccs.com.sg/>, Singapore, Singapore

3256131

ARGININE STARVATION AND DOCETAXEL INDUCE C-MYC DRIVEN HENT1 SURFACE EXPRESSION TO OVERCOME GEMCITABILE TRASPORTER LEVEL RESISTANCE IN ASS1 NEGATIVE SARCOMAS

Bethany C. Prudner; Richa Rathore; Angela Hirbe; **Brian A. Van Tine**
Washington University in St. Louis, Saint Louis, MO, USA

3253588

ALTERATIONS IN DNA DAMAGE RESPONSE PATHWAY GENES ACROSS SARCOMA SUBTYPES

Evan J. Rosenbaum, MD¹; Philip Jonsson²; Ping Chi¹; Mark Dickson¹; Ciara Kelly¹; Mary Louise Keohan¹; Mrinal M. Gounder¹; Benjamin A. Nacev¹; Jason E. Chan¹; Sandra P. D'angelo¹; Zsofia K. Stadler³; Marc Ladanyi⁴; Cristina Antonescu⁴; Sam Singer⁵; William D. Tap¹; Sujana Movva¹
¹Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ³Clinical Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁴Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁵Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

3253095

SLFN11 IS NECESSARY - BUT NOT SUFFICIENT - TO SENSITIZE PEDIATRIC SARCOMAS TO DNA DAMAGING AGENTS

Jessica Gartrell, MD; Marcia Mellado-Largarde; Michael Clay; Jia Xie; Nathaniel Twarog; Nancy Martinez; Michele Connelly; Koon-Kiu Yan; Jiyang Yu; Shaina Porter; Shondra Miller; Lauren Hoffman; Hyekyung Plumley; April Sykes; Natasha Sahr; Kaley Blankenship; Armita Bahrami; Christopher Tinkle; Sara Federico; Elizabeth Stewart; Anang Shelat
Oncology, St. Jude Children's Research Hospital, Southaven, MS, USA

3255481

SURVEY OF ACTIONABLE GENOMIC ALTERATIONS IN A COHORT OF SOFT TISSUE AND BONE SARCOMAS

Maya Kansara¹; Subotheni Thavaneswaran¹; John Grady¹; Mandy Ballinger¹; Lucille Sebastian²; Audrey Silvestri¹; Christine Napier¹; Katrin Sjoquist²; Wendy Hague²; Anthony Joshua¹; John Simes²; David Thomas¹
¹Garvan Institute, Sydney, New South Wales, Australia; ²Sydney Medical School, NHMRC Clinical Trials Centre, Sydney, New South Wales, Australia

3:30 pm - 4:00 pm

Afternoon Break

3rd Floor

Soft Tissue Sarcomas: Novel Therapy

3250355

A PHASE 1 DOSE ESCALATION STUDY OF INTRAVENOUS TK216 IN PATIENTS WITH RELAPSED OR REFRACTORY EWING SARCOMA**Paul Meyers, MD**¹; Joseph A. Ludwig²; Noah C. Federman³; Najat C. Daw⁴; Margaret E. Macy⁵; Richard F. Riedel⁶; Jodi A. Muscal⁷; Xen Ianopoulos⁸; James Breitmeyer⁹; Jeffrey Toretsky⁸¹Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ²Internal Medicine, MD Anderson Cancer Center, Houston, TX, USA; ³Pediatrics, UCLA Medical Center, Los Angeles, CA, USA; ⁴Pediatrics, MD Anderson Cancer Center, Houston, TX, USA; ⁵Pediatrics, Children's Hospital of Colorado, Aurora, CO, USA; ⁶Internal Medicine, Duke University Medical Center, Durham, NC, USA; ⁷Pediatrics, Texas Children's Hospital, Houston, TX, USA; ⁸Pediatrics, George Washington University Medical Center, Washington, DC, USA; ⁹Oncternal Therapeutics, San Diego, CA, USA

3254636

EFFECTIVE TREATMENT OF ALVEOLAR SOFT PART SARCOMA WITH SINGLE AGENT ATEZOLIZUMAB**Geraldine O'Sullivan Coyne**¹; Nancy Moore¹; Elad Sharon²; Naoko Takebe¹; Lamin Juwara³; William Read¹⁴; Richard F. Riedel¹⁵; James Hu⁴; Melissa Burgess⁵; Brian A. Van Tine⁶; Priscilla Merriam¹³; Elizabeth Davis⁷; Anthony Conley¹⁶; John Glod¹¹; Brian Ladle⁹; Scott Okuno¹²; Scott Christensen¹⁷; Larry R. Rubinstein¹⁰; James Doroshow⁸; Alice Chen¹¹Developmental Therapeutics Clinic, Division of Cancer Research and Diagnosis, National Cancer Institute, Bethesda, MD, USA; ²Cancer Therapy Evaluation Program, National Cancer Institute, Shady Grove, MD, USA; ³Clinical Research Directorate/Clinical Monitoring Research Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Bethesda, MD, USA; ⁴Medical Oncology, University of Southern California, Los Angeles, CA, USA; ⁵Hematology/Oncology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; ⁶Division of Oncology, Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO, USA; ⁷Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; ⁸Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA; ⁹Pediatric Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, MD, USA; ¹⁰Biometrics Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Shady Grove, MD, USA; ¹¹Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA; ¹²Medical Oncology, Mayo Clinic, Rochester, MN, USA; ¹³Dana-Farber Cancer Institute, Boston, MA, USA; ¹⁴Winship Cancer Institute, Emory University, Atlanta, GA, USA; ¹⁵Duke Cancer Institute, Duke University Health System, Durham, NC, USA; ¹⁶The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ¹⁷UC Davis Comprehensive Cancer Center, Sacramento, CA, USA

3212975

THE SYNOVIAL SARCOMA SUBSET ANALYSIS OF THE MULTI-HISTOLOGY PHASE I TRIAL OF ADP-A2M4 (MAGE-A4)**Brian A. Van Tine**¹; David S. Hong²; Dejka Araujo²; Melissa Johnson³; Jeffrey Clarke⁴; David Liebner⁵; Kunle Odunsi⁶; Anthony Olszanski⁷; Samik Basu⁸; Francine Brophy⁸; Tom Holdich⁸; Malini Iyengar⁸; Rafael Amado⁸; Marcus Butler⁹¹Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA; ²MD Anderson Cancer Center, Houston, TX, USA; ³Sarah Cannon, Nashville, TN, USA; ⁴Duke University, Durham, NC, USA; ⁵Ohio State University Medical Center, Columbus, OH, USA; ⁶Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA; ⁷Fox Chase Cancer Center, Philadelphia, PA, USA; ⁸Adaptimmune, Philadelphia, PA, USA; ⁹Princess Margaret Cancer Centre, Toronto, ON, Canada

3255157

IMMUNOSARC: A COLLABORATIVE SPANISH (GEIS) AND ITALIAN (ISG) SARCOMA GROUPS PHASE I/II TRIAL OF SUNITINIB PLUS NIVOLUMAB IN ADVANCED SOFT TISSUE AND BONE SARCOMAS: RESULTS OF THE PHASE II SOFT TISSUE SARCOMA COHORT

Javier Martin-Broto¹; **Nadia Hindi**¹; **Giovanni Grignani**²; **Javier Martinez-Trufero**³; **Andres Redondo**⁴; **Claudia Valverde**⁵; **Antonio López Pousa**⁶; **Silvia Stacchiotti**⁷; **Emanuela Palmerini**⁸; **Enrique de Alava**⁹; **David d. Moura**¹⁰; **Herminia Perez-Vega**¹¹; **Paola Collini**⁷; **Irene Otero**¹²; **Patricio Ledesma**¹³; **Emanuela Marchesi**¹⁴; **Lorenzo D'Ambrosio**²; **Jose A Lopez-Martin**¹²

¹Medical Oncology, Hospital Universitario Virgen del Rocío/Instituto de Biomedicina de Sevilla (IBIS), Seville, Spain; ²Medical Oncology, Candiolo Cancer Institute, Turin, Italy; ³Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain; ⁴Medical Oncology, Hospital Universitario La Paz- IdiPAZ, Madrid, Spain; ⁵Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain; ⁶Medical Oncology, Hospital Sant Pau, Barcelona, Spain; ⁷Istituto Nazionale dei Tumori, Milan, Italy; ⁸Istituto Ortopedico Rizzoli, Bologna, Italy; ⁹Pathology, Hospital Universitario Virgen del Rocío, Seville, Spain; ¹⁰Institute of Biomedicine of Sevilla (IBiS, HUVR, CSIC, University of Sevilla, Seville, Spain; ¹¹Radiology, Hospital Universitario Virgen del Rocío, Seville, Spain; ¹²Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain; ¹³Sofpromed, Palma de Mallorca, Spain; ¹⁴Italian Sarcoma Group, Bologna, Italy

3255439

MOLECULAR ANALYSIS OF ARCHIVAL INFLAMMATORY MYOFIBROBLASTIC TUMOR TISSUE SAMPLES FROM EORTC 90101 "CREATE" AND CORRELATION WITH RESPONSE TO CRIZOTINIB

Che-Jui Lee¹; **Patrick Schöffski**²; **Elodie Modave**³; **Bram Boeckx**³; **Diether Lambrechts**³; **Jozef Sufliarsky**⁴; **Hans Gelderblom**⁵; **Jean-Yves Blay**⁶; **Agnieszka Wozniak**¹

¹Department of Oncology, KU Leuven, Leuven, Belgium; ²Department of General Medical Oncology and Department of Oncology, UZ Leuven and KU Leuven, Leuven, Belgium; ³VIB Center for Cancer Biology and Department of Human Genetics, VIB and KU Leuven, Leuven, Belgium; ⁴National Cancer Institute, Bratislava, Slovakia; ⁵Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands; ⁶Department of Medical Oncology, Centre Léon Bérard/Université Claude Bernard Lyon Institute, Lyon, France

5:00 pm - 6:00 pm

– SESSION 15 –

Kiku Ballroom

Challenges in MPNST and NF1

CHALLENGES IN THE DIAGNOSIS OF NF1-MPNSTS: PATHOLOGY PERSPECTIVE

Alex Lazar

MD Anderson, Houston, TX, USA

3253627

GENOMICS OF MPNST (GEM) CONSORTIUM: IN-DEPTH GENOMIC CHARACTERIZATION OF NF1-ASSOCIATED AND SPORADIC MPNSTS

Angela Hirbe, MD, PhD¹; Isidro Ciriano-Cortes²; Nischalan Pillay³; Matija Snuderl⁴; Alyaa Al-Ibraheemi⁵; Marilyn Bui⁶; Brendan Dickson⁷; James Gusella⁸; Jesse Hart⁹; Kevin B. Jones¹⁰; Justin Jordan⁸; Raymond Kim⁷; Daniel Lindsay³; Yoshihiro Nishida¹¹; Katherine Piculell⁵; Diane Shao⁵; Nicole J. Ullrich⁵; Xia Wang⁶; Peter Park¹²; Adrienne Flanagan³; David T. Miller⁵

¹Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA; ²European Bioinformatics Institute, Cambridge, United Kingdom; ³Royal National Orthopaedic Hospital and University College London Cancer Institute, London, United Kingdom; ⁴New York University, New York, NY, USA; ⁵Boston Children's Hospital, Boston, MA, USA; ⁶Moffitt Cancer Center, Tampa, FL, USA; ⁷Mount Sinai Hospital, Toronto, ON, Canada; ⁸Massachusetts General Hospital, Boston, MA, USA; ⁹Lifespan, Providence, RI, USA; ¹⁰Huntsman Cancer Institute, Salt Lake City, UT, USA; ¹¹Nagoya University, Nagoya, Japan; ¹²Harvard Center for Biomedical Informatics, Boston, MA, USA

CURRENT STATUS OF MANAGEMENT FOR NF1-MPNST IN JAPAN

Yoshihiro Nishida

Nagoya University Hospital

6:00 pm - 6:30 pm	Members Business Meeting	Kiku Ballroom
6:30 pm	ADJOURN	Kiku Ballroom

Poster Presentations Listing

3241719

COMPARISON OF CACHECTIC AND NON-CACHECTIC SARCOMA PATIENTS REVEALS AN IMPORTANT ROLE OF NOTCH SIGNALING IN METASTASIS AND MYOGENESIS

Feiqi Lu²; David Osei²; Jonathan Mandell¹; Alejandro Morales¹; Margaret L. Hankins¹; Jared Crasto¹; Ruichen Ma²; Vu Dinh²; Rebecca Watters¹; Kurt R. Weiss¹

¹Dept. of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA, USA; ²School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA

3243870

METABOLIC REPROGRAMMING IN HIGH-GRADE SARCOMAS, REPURPOSING ANTI-CHOLESTEROL AGENTS AS A NOVEL THERAPEUTIC STRATEGY

Jennifer Dorsey, Master's Candidate¹; Yael Babichev²; Rosemarie Venier²; Richard Marcellus³; Rima Al-awar³; Linda Z. Penn⁴; Albiruni Razak⁵; Brendan Dickson⁶; Eric Chen⁵; Jay Wunder⁷; Rebecca Gladly²

¹Institute of Medical Science, University of Toronto, Toronto, ON, Canada; ²Lunenfeld Tanenbaum Research Institute, Toronto, ON, Canada; ³Drug Discovery Group, Ontario Institute for Cancer Research, Toronto, ON, Canada; ⁴Medical Biophysics, University of Toronto, Toronto, ON, Canada; ⁵Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada; ⁶Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada; ⁷Department of Surgery, University of Toronto, Toronto, ON, Canada

3249741

DUAL INHIBITION OF DISTINCT METABOLIC FEATURES TARGETS OSTEOSARCOMA STEM-LIKE CELLS BY PHYTOCHEMICAL PTEROSTILBENE AND C-MYC INHIBITORS

Shingo Kishi²; Kanya Honoki¹; Hiromasa Fujii³; Shinji Tsukamoto⁴; Yumiko Kondo³; Hiroki Kuniyasu²; Yasuhito Tanaka³

¹Department of Orthopedic Oncology & Reconstructive Medicine, Nara Medical University, Kashihira, Nara, Japan; ²Department of Molecular Pathology, Nara Medical University, Kashihara, Nara, Japan; ³Department of Orthopedic Surgery, Nara Medical University, Kashihara, Nara, Japan; ⁴Department of Rehabilitation Services, Nara Medical University, Kashihara, Nara, Japan

3256372

IMPROVING ONCOLYTIC VIROTHErapy USING VANADIUM-BASED COMPOUNDS IN SARCOMAS

Anabel Bergeron, MSc¹; Nouf Alluqmani¹; Mohammed Selman¹; Andrew Chen¹; Fanny Tzelepis¹; Rozanne Arulanandam¹; Hesham Abdelbary²; Joel Werier²; Debbie Crans³; Jean-Simon Diallo¹

¹Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, ON, Canada; ²Department of Surgery Orthopaedics, The Ottawa Hospital, Ottawa, ON, Canada; ³Department of Chemistry, Colorado State University, Fort Collins, CO, USA

3256516

IMPROVING ONCOLYTIC VIROTHErapy USING VANADIUM-BASED COMPOUNDS IN SARCOMAS

Anabel Bergeron, MSc¹; Nouf Alluqmani¹; Mohammed Selman¹; Andrew Chen¹; Fanny Tzelepis¹; Rozanne Arulanandam¹; Hesham Abdelbary²; Joel Werier²; Debbie Crans³; Jean-Simon Diallo¹

¹Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, ON, Canada; ²Department of Surgery Orthopaedics, The Ottawa Hospital, Ottawa, ON, Canada; ³Department of Chemistry, Colorado State University, Fort Collins, CO, USA

3256542

INHIBITORY EFFECTS OF INDOMETHACIN ON HUMAN OSTEOSARCOMA TUMOR CELLS

Saied Mirshahidi²; Rosalia de Necochea Campion²; Anne Moretta²; **Nadine L. Williams**¹; Mark Reeves³; Salman Otoukesh⁴; Hamid Mirshahidi⁴; Penelope Duerksen-Hughes²; Lee M. Zuckerman¹

¹Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, CA, USA; ²Cancer Center, Loma Linda University Medical Center, Loma Linda, CA, USA; ³Surgical Oncology, Loma Linda University Medical Center, Loma Linda, CA, USA; ⁴Hematology/Oncology, Loma Linda University Medical Center, Loma Linda, CA, USA

Poster Presentations Listing

3243435

HUMAN BONE MARROW-DERIVED STEM CELLS INDUCE EPITHELIAL-MESENCHYMAL TRANSITION AND ENHANCE STEMNESS FEATURES IN LOW-INVASIVENESS LUNG CANCER CELLS

Wei-Hsin E. Lin, MD¹; Jia-Lin Lee²; Jui-Sheng Sun¹; Chia-Che Lee¹; Hsiang-Chieh Hsieh³; Rong-Sen Yang¹

¹Orthopedics, National Taiwan University Hospital, Taipei city, Taiwan; ²Institute of Molecular and Cellular Biology, National Tsing-Hua University, Hsinchu City, Taiwan; ³Orthopedics, National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan

3220620

XANTHOMOL INDUCE APOPTOSIS THROUGH P38 MAPK SIGNALING PATHWAY IN HUMAN NASOPHARYNGEAL CANCER CELLS

Yu-Sheng Lo²; Mu-Kuan Chen¹

¹Department of Otorhinolaryngology, Head and Neck Surgery, Changhua Christian Hospital, Changhua City, Taiwan; ²Oral Cancer Research Center, Changhua Christian Hospital, Changhua City, Taiwan

3232396

OSTEONECROSIS OF JAW AFTER USE OF DENOSUMAB IN PATIENTS WITH GIANT CELL TUMOR OF BONE

Hiroshi Urakawa³; Eisuke Arai¹; Kunihiro Ikuta¹; Tomohisa Sakai¹; Hiroshi Koike¹; Naoki Ishiguro¹; Yoshihiro Nishida²

¹Orthopaedic Surgery, Nagoya University, Nagoya, Aichi, Japan; ²Orthopaedic surgery/ Rehabilitation, Nagoya University, Nagoya, Japan; ³Orthopaedic Surgery/ Chemotherapy and Clinical Oncology, Nagoya University, Nagoya, Japan

3249808

TREATMENT OF OSTEOFIBROUS DYSPLASIA IN A 13-MONTH OLD CHILD WITH CURETTAGE AND PLACEMENT OF ALLOGRAFT BONE

Brendon Bauer; **Nadine L. Williams**; Stephen Morris; Alex Mierke; Omar Ramos; Lee M. Zuckerman
Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, CA, USA

3250654

DESMOID TUMOR VOLUMETRIC ANALYSIS FOR DISEASE RESPONSE POST ABLATION WITH MAGNETIC RESONANCE GUIDED HIGH INTENSITY FOCUSED ULTRASOUND (MR-HIFU)

Caitlin Tydings¹; Pavel Yarmolenko¹; James I. Geller²; Joseph G. Pressey²; John M. Racadio²; Haydar Celik¹; Avinash Eranki¹; Matthew Lanier²; Karun V. Sharma¹; AeRang Kim¹

¹Children's National Medical Center, Washington, , USA; ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

3253315

CLINICAL FEATURES OF CHONDROBLASTOMA: A REVIEW OF 19 CASES

Toru Hirozane¹; Naofumi Asano¹; Kazutaka Kikuta²; Michiro Susa³; Itsuo Watanabe⁴; Takeshi Morii⁵; Masaya Nakamura¹; Morio Matsumoto¹; Robert Nakayama¹

¹Department of Orthopedic Surgery, Keio University School of Medicine, Tokyo, Tokyo, Japan; ²Department of Musculoskeletal Oncology and Orthopedic Surgery, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan; ³Department of Orthopedic Surgery, National Defense Medical College, Tokorozawa, Japan; ⁴Department of Orthopedic Surgery, Tokyo Dental College Ichikawa General Hospital, Ichikawa, Japan; ⁵Department of Orthopedic Surgery, Kyorin University Hospital, Mitaka, Japan

Poster Presentations Listing

3254301

TARGETABLE DRIVER MUTATIONS IN MULTICENTRIC RETICULOHISTIOCYTOSIS

Tomohisa Sakai¹; Norihiro Murakami²; Eisuke Arai¹; Hideaki Muramatsu²; Daisuke Ichikawa²; Shuji Asai¹; Yoshie Shimoyama³; Naoki Ishiguro¹; Yoshiyuki Takahashi²; Yusuke Okuno⁴; Yoshihiro Nishida⁵
¹Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Outside the United States or Canada, Japan; ²Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan; ³Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan; ⁴Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan; ⁵Orthopedic surgery and Rehabilitation, Nagoya University Graduate School of Medicine and Nagoya University Hospital, Nagoya, Japan

3254342

TWO WEEKS INTERVAL OF METHOTREXATE AND VINBLASTIN CHEMOTHERAPY SHOWS THE SIMILAR EFFECT AS WEEKLY ADMINISTRATION

Yoshihiro Nishida, MD, PhD¹; Tomohisa Sakai²; Hiroshi Koike²; Hiroshi Urakawa²; Eisuke Arai²; Kunihiro Ikuta²; Yuichi Ando³; Koki Shimizu⁴; Naoki Ishiguro²
¹Rehabilitation, Orthopaedic surgery, Nagoya University Hospital, Nagoya, Aichi, Japan; ²Orthopaedic surgery, Nagoya University Graduate School and School of Medicine, Nagoya, Aichi, Japan; ³Medical Oncology, Nagoya University Graduate School and School of Medicine, Nagoya, Japan; ⁴Orthopaedic Surgery, Tonokosei Hospital, Mizunami, Japan

3254507

PRIMARY BONE ROSAI-DRFMAN DISEASE ARISING IN INFANTILE ILEUM

Yuya Izubuchi; Akihiko Matsumine
Orthopaedics, University of Fukui, Yoshida-gun, Fukui, Japan

3255103

NANOSTRING ANALYSES OF TYROSINE KINASE FUSION GENES IN INFLAMMATORY MYOFIBROBLASTIC TUMOR/ INFLAMMATORY PSEUDOTUMOR

Taisei Kurihara; Yoshiyuki Suehara; Kei Sano; Keisuke Akaike; Takuo Hayashi; Nobuhiko Hasegawa; Tatsuya Takagi; Taketo Okubo; Takashi Yao; Kazuo Kaneko; Tsuyoshi Saito
Juntendo University, Tokyo, Japan

3255260

FACTOR ANALYSIS ASSOCIATED WITH LOCAL RECURRENCE AND LIMB FUNCTION OF 105 PATIENTS WITH DIFFUSE-TYPE TENOSYNOVIAL GIANT CELL TUMOR: A MULTINATIONAL STUDY OF AN ASIAN POPULATION

Akihiko Takeuchi, MD, PhD¹; Norio Yamamoto¹; Xiaohui Niu²; Wei M. Chen³; Tomoki Nakamura⁴; Saminathan S. Nathan⁶; Takafumi Ueda⁵; Shintaro Iwata⁷; Akira Kawai⁸; Yong K. Kang⁹; Apichat Asavamongkolkul¹⁰; Edward H. Wang¹¹; Vivek A. Singh¹²; Toshiharu Shirai¹³; Yang G. Chung¹⁴; Hiroyuki Tsuchiya¹
¹Orthopaedic Surgery, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan; ²Orthopedic Oncology Surgery, Beijing Jishuitan Hospital, Beijing, China; ³Orthopaedics and Traumatology, Taipei Veterans General Hospital, Taipei, Taiwan; ⁴Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu, Japan; ⁵Orthopaedic Surgery, Osaka National Hospital, Osaka, Japan; ⁶Orthopaedic Surgery, National University of Singapore, Singapore, Singapore; ⁷Orthopedic Surgery, Chiba Cancer Center, Chiba, Japan; ⁸Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan; ⁹Orthopaedic Surgery, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea (the Republic of); ¹⁰Orthopaedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; ¹¹Orthopedics, University of the Philippines Manila, Manila, Philippines; ¹²Orthopaedics (Noceral, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia); ¹³Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan; ¹⁴Orthopedic Surgery, Seoul St. Mary's Hospital, Seoul, Korea (the Republic of)

Poster Presentations Listing

3255673

SIMPLE BONE CYSTS TREATED BY INJECTION OF AUTOGENOUS BONE MARROW

Munehisa Kito¹; Masanori Okamoto¹; Shuichiro Suzuki¹; Atsushi Tanaka¹; Kaoru Aoki¹; Akira Takazawa²; Yasuo Yoshimura²

¹Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Nagano, Japan;

²Orthopaedic Surgery, Shinshu Ueda Medical Center, Ueda, Japan

3255781

DEVELOPMENT OF MULTIFOCAL EXTRA-ABDOMINAL DESMOID FIBROMATOSIS AFTER SURGICAL RESECTION

Brendon Bauer; **Nadine L. Williams**; Stephen Morris; Alex Mierke; Omar Ramos; Lee M. Zuckerman
Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, CA, USA

3255783

MASSIVE LOCALIZED LYMPHEDEMA (MLL) ASSOCIATED WITH MORBID OBESITY: A RARE, BENIGN CLINICAL ENTITY RESEMBLING A GLUTEAL LIPOSARCOMA

Mark Gimbel, MD

Banner MD Anderson Cancer Center, Phoenix, AZ, USA

3255921

NOVEL TREATMENT OF ZALTOPROFEN FOR DIFFUSE-TYPE TENOSYNOVIAL GIANT CELL TUMOR: A PILOT STUDY

Akihiko Takeuchi, MD, PhD; Norio Yamamoto; Katsuhiko Hayashi; Shinji Miwa; Kentaro Igarashi;

Yuta Taniguchi; Hirotaka Yonezawa; Yoshihiro Araki; Sei Morinaga; Hiroyuki Tsuchiya

Orthopaedic Surgery, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan

3256403

COMBINATION DRUG THERAPY AND AGGRESSIVE FIBROMATOSIS

Puviindran Nadesan, BSc¹; Raymond Poon²; Vijitha Puviindran¹; Mushriq Al-Jazrawe⁴; Sean Ryan¹; Alessandro Datti⁶; Robert Maki⁵; Alexander Lazar³; Benjamin Alman¹

¹Orthopaedic Surgery, Duke University, Durham, NC, USA; ²Developmental & Stem Cell Biology, The Hospital for Sick Children, Toronto, ON, Canada; ³MD Anderson, Houston, TX, USA;

⁴Broad Institute, Cambridge, ME, USA; ⁵Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA;

⁶Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada

3256572

CRYOABLATION FOR DESMOID TUMORS: THE FRENCH NATIONWIDE CRYODESMO-01, CURRENT PRACTICE AND PERSPECTIVES

Jen Wmmanuel Kurtz, MD, PhD⁹; Xavier Buy¹; Erik Sauleau⁸; Maud Toulmonde²; Frédéric Deschamps³; Charles Honoré⁴; Amine Bouhamama⁵; Jean-Yves Blay⁶; Afshin Gangi⁷

¹Interventional Radiology, Institut Bergonié, Bordeaux, France; ²Medical Oncology, Institut Bergonié, Bordeaux, France; ³Interventional Radiology, Institut Gustave Roussy, Villejuif, France; ⁴Surgery, Institut Gustave Roussy, Villejuif, France; ⁵Interventional radiology, Centre Léon Bérard, Lyon, France;

⁶Medical Oncology, Centre Léon Bérard, Lyon, France; ⁷Interventional radiology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; ⁸Statistics, Hôpitaux Universitaires de Strasbourg, Strasbourg, France;

⁹Medical Oncology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

3257659

CAN WAIT AND SEE BE THE STANDARD OF CARE FOR INITIAL APPROACH TO PRIMARY SPORADIC DESMOID TUMORS? PRELIMINARY DATA FROM MULTICENTER EUROPEAN PROSPECTIVE STUDIES

Chiara Colombo¹; Milea Timbergen⁴; Paola Boccone²; Dirk Grunhagen⁴; Erica Palesandro²; Marco Fiore¹; Alba Bianco¹; Federica Perrone¹; Elena Palassini¹; Lorenzo D'Ambrosio²; Silvia Stacchiotti¹; Paola Collini¹; Angelo Paolo Dei Tos³; Paolo Casali¹; Giovanni Grignani²; Alessandro Gronchi¹; Cornelis Verhoef⁴

¹Fondazione IRCCS Istituto Tumori Milano, Milan, Italy; ²IRCCS Istituto Candiolo, Candiolo, Italy;

³Ospedale di Treviso, Treviso, Italy; ⁴Erasmus MC Cancer Institute, Rotterdam, Netherlands

Poster Presentations Listing

3232140

ANLOTINIB, VINCRISTINE AND IRINOTECAN(AVI) FOR ADVANCED EWING SARCOMA AFTER FAILURE OF STANDARD MULTIMODAL THERAPY: A MULTICENTER, TWO - COHORT, PHASE IB/II TRIAL (NCT03416517)

Jie Xu¹; Wei Guo¹; Lu Xie¹; Xin Sun¹; Kuisheng Liu¹; Bingxin Zheng¹; Tingting Ren¹; Yi Huang¹; Taiqiang Yan¹; Xiaodong Tang¹; Rongli Yang¹; Jin Gu²

¹Peking University People's Hospital, Beijing, China; ²Peking University Shougang Hospital, Beijing, China

3256530

TWO YEARS IN, WHAT HAVE WE LEARNED ABOUT ATRX MUTATION IN OSTEOSARCOMA? THEY INCREASE AGGRESSIVENESS THROUGH MULTIPLE MECHANISMS

William C. Eward, MD, DVM; Suzanne Bartholf DeWitt; So Young Kim; Vidya Seshadri;

Sarah M. Hoskinson; Brian Brigman; Jason Somarelli; Benjamin Alman

Duke University Medical Center, Durham, NC, USA

3254140

MONOCLONAL ANTIBODY BLOCKADE OF SEMA4-PLXNB2 AXONAL GUIDANCE SIGNALING REDUCES TUMOR PROGRESSION AND METASTASIS IN ANIMAL MODELS OF OSTEOSARCOMA

Branden Smeester¹; Kelsie Becklin¹; Garrett Draper¹; Emily Pomeroy¹; Nicholas Slipek¹;

Joseph Peterson¹; Eric Rahrman²; Margaret Crosby¹; Branden Moriarity¹

¹University of Minnesota, Minneapolis, MN, USA; ²University of Cambridge, Cambridge, United Kingdom

3220213

PRECLINICAL TESTING OF A NOVEL TARGETED TRAIL THERAPEUTIC FOR DEDIFFERENTIATED CHONDROSARCOMA

Zakareya Gamie¹; Martin Siegemund²; Craig Gerrand⁴; Anja Krippner-Heidenreich³;

Roland Kontermann²; Kenneth Rankin¹

¹Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom;

²University of Stuttgart, Stuttgart, Germany; ³Prinses Máxima Center for Pediatric Oncology, Utrecht, Netherlands; ⁴The Royal National Orthopaedic Hospital, Stanmore, United Kingdom

3224408

PEMBROLIZUMAB IN ADVANCED OSTEOSARCOMA: RESULTS OF A SINGLE-ARM, OPEN-LABEL PHASE 2 TRIAL

Boye Kjetil, MD, PhD¹; Alessandra Longhi²; Tormod Guren¹; Stine Næss¹; Michela Pierini²;

Ingeborg Taksdal³; Ingvild Lobmaier⁴; Marilena Cesari²; Anna Paioli²; Elisabetta Setola²; Ivar Hompland¹;

Kirsten Sundby Hall¹; Emanuela Palmerini²

¹Department of Oncology, Oslo University Hospital, Oslo, Norway; ²IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy; ³Department of Radiology, Oslo University Hospital, Oslo, Norway; ⁴Department of Pathology, Oslo University Hospital, Oslo, Norway

Poster Presentations Listing

3241057

PHASE I COMBINATION DOSE-FINDING/PHASE 2 EXPANSION COHORTS OF LENVATINIB + ETOPOSIDE + IFOSFAMIDE IN PATIENTS AGED 2 TO ≤25 YEARS WITH RELAPSED/REFRACTORY OSTEOSARCOMA

Nathalie Gaspar¹; Francisco J. Bautista Sirvent²; Rajkumar Venkatramani³; Alessandra Longhi⁴; Cyril Lervat⁵; Michaela Casanova⁶; Isabelle Aerts⁷; Stefan Bielack⁸; Natacha Entz-Werle⁹; Sandra J. Strauss¹⁰; Cixin He¹¹; Estelle Thebaud¹²; Franco Locatelli¹³; Bruce Morland¹⁴; Soledad Gallego Melcon¹⁵; Adela Cañete Nieto¹⁶; Perrine Marec-Berard¹⁷; Marion Gambart¹⁸; Claudia Rossig¹⁹; Quentin Campbell-Hewson²⁰

¹Gustave Roussy Cancer Campus, Villejuif, France; ²Hospital Infantil Universitario Niño Jesus, Madrid, Spain; ³Texas Children's Hospital, Houston, TX, USA; ⁴Instituto Ortopedico Rizzoli, Bologna, Italy; ⁵Centre Oscar Lambret Lille, Lille, France; ⁶Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ⁷Institut Curie, PSL Research University, Oncology Center SIREDO, Paris, France; ⁸Klinikum Stuttgart - Olgahospital, Stuttgart, Germany; ⁹Chu Strasbourg-Hopital Hautepierre, Strasbourg, France; ¹⁰University College London Hospital, London, United Kingdom; ¹¹Eisai, Inc., Woodcliff Lake, NJ, USA; ¹²CHU Nantes - Hôpital Mère-Enfant, Nantes, France; ¹³Ospedale Pediatrico Bambino Gesù, University of Pavia, Pavia, Italy; ¹⁴Birmingham Children's Hospital, Birmingham, United Kingdom; ¹⁵University Hospital Vall d'Hebron, Barcelona, Spain; ¹⁶Hospital Universitario y Politecnico La Fe, Valencia, Spain; ¹⁷Centre Léon Bérard, Lyon, France; ¹⁸CHU de Toulouse - Hôpital des Enfants, Toulouse, France; ¹⁹Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany; ²⁰The Great North Children's Hospital, Royal Victoria Infirmary, Newcastle Upon Tyne, United Kingdom

3241713

IDENTIFICATION OF NOVEL THERAPEUTIC TARGETS FOR METASTATIC OSTEOSARCOMA

Margaret L. Hankins, MD¹; Ivy John²; David Boone³; Sarangarajan Ranganathan²; Rita Alaggio²; Vaidehi Patel⁴; Benjamin Martin⁵; Kurt R. Weiss¹; Rebecca Watters¹

¹Orthopaedic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; ²Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; ³Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA; ⁴School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; ⁵University of Pittsburgh, Pittsburgh, PA, USA

3245110

CLINIAL UTILITY OF BRCANESS TESTING OF PEDIATRIC OSTEOSARCOMA PATIENTS AT DIFFERENT STAGES OF THE DISEASE

Michal Kovac¹; Baptiste Ameline¹; Maxim Barenboim²; Andreas Krieg³; Michaela Nathrath²; Daniel Baumhoer¹

¹University Hospital Basel, Basel, Switzerland; ²Technical University Munich, Munich, Germany; ³University Children's Hospital Basel, Basel, Switzerland

3253025

ABCA6 AND ABCA7 ARE NOVEL BIOMARKERS OF PROGNOSIS IN EWING SARCOMA: ROLE OF INTRACELLULAR LEVELS OF CHOLESTEROL

Katia Scotlandi, PhD¹; Michela Pasello¹; Anna Maria Giudice¹; Alberto Righi²; Davide Donati³

¹Lab Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy; ²Anatomy Service, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy; ³III Orthopaedic Clinic, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy

3253251

UPFRONT SURGERY FOLLOWED BY ADJUVANT CHEMOTHERAPY MAY IMPROVE METASTASIS-FREE SURVIVAL OF PATIENTS WITH STAGE IIB OSTEOSARCOMA OF EXTREMITY

Yong Sung Kim; Wan Hyeong Cho; Hwan Seong Park; Kyunghoon Kim; Dae-Geun Jeon
Department of Orthopedic Surgery, Korean Cancer Center Hospital, Seoul, Korea (the Republic of)

Poster Presentations Listing

3254188

SINGLE-CELL TRANSCRIPTOMIC ANALYSES OF MUTANT IDH1 GROWTH PLATE CHONDROCYTES REVEAL DISTINCT CELL POPULATIONS

Vijitha Puvindran, BS²; Ga Ban²; Yu Xiang¹; Yarui Diao¹; Jianhong Ou¹; Hongyuan Zhang²; Benjamin Alman²

¹Cell Biology, Duke University, Durham, NC, USA; ²Orthopedics, Duke University, Durham, NC, USA

3254196

IMPACT OF LIMB SALVAGE VERSUS AMPUTATION ON OVERALL SURVIVAL IN PATIENTS WITH OSTEOSARCOMA OF THE EXTREMITIES

Daniel Evans; **Alexander L. Lazarides, MD**; Julia Visgauss; Brian Brigman; William Eward
Department of Orthopaedic Surgery, Duke University Medical Center, Durham, NC, USA

3254674

FEASIBILITY AND PREDICTIVE VALUE OF FUNCTIONAL PRECISION MEDICINE APPROACH FOR BONE SARCOMAS

Christina M. Linder Stragliotto, MD, PhD; Antroula Papakonstantinou; Panagiotis Tsagkosis; S. Potdar; J. Wilson; Asle Hesla; Henrik Bauer; Otto Brosjö; Berta Brodin
Karolinska Institute, oncology pathology, Stockholm, Spånga, Sweden

3256261

PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT EWING SARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION

Javier Oesterheld²; Damon Reed³; Bhuvana Setty⁴; Michael Isakoff⁵; Joanne Lagmay⁶; Masanori Hayashi⁷; David Loeb⁸; Tiffany Smith³; Rikesh Makanji³; Hong Yin⁹; Brooke Fridley³; **Lars Wagner, MD¹**

¹Pediatrics, Duke University, Durham, NC, USA; ²Levine Cancer Institute, Charlotte, NC, USA;

³Moffitt Cancer Institute, Tampa, FL, USA; ⁴Nationwide Children's Hospital, Columbus, OH, USA;

⁵Connecticut Children's Medical Center, Hartford, CT, USA; ⁶University of Florida, Gainesville, FL, USA;

⁷Children's Hospital Colorado, Denver, CO, USA; ⁸Montefiore Medical Center, Bronx, NY, USA;

⁹Children's Hospital of Atlanta, Atlanta, GA, USA

3256472

REDUCED BARD1 EXPRESSION ENHANCES PARP INHIBITOR-MEDIATED INCREASES IN PD-L1 EXPRESSION IN EWING SARCOMA

Lisa Maurer¹; Rose Venier²; Claire Julian¹; **Kelly M. Bailey, MD, PhD¹**

¹Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; ²School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA

3254462

AOST1321, A PHASE 2 TRIAL OF RANKL ANTIBODY, DENOSUMAB, IN 2 COHORTS OF PATIENTS WITH RECURRENT OR REFRACTORY OSTEOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP

Katherine A. Janeway, MD¹; Alexander J. Chou²; Pooja Hingorani³; Michael Isakoff⁴; Lisa Kopp⁷; Allen Buxton⁵; Laura Hall⁸; Timothy M. Fan¹⁶; Dinesh Rakheja¹¹; Heike Daldrup-Link¹²; Damon Reed¹³; John Doski¹⁴; Lor Randall¹⁵; Tony Wagner⁶; Steven DuBois¹; Mark Krailo⁹; Holcombe E. Grier¹; Richard Gorlick¹⁰

¹Dana Farber Cancer Institute, Boston, MA, USA; ²Montefiore Medical Center, Bronx, NY, USA;

³Phoenix Children's Hospital, Phoenix, AZ, USA; ⁴Connecticut Children's Medical Center, Hartford, CT, USA;

⁵Children's Oncology Group, Monrovia, CA, USA; ⁶Amgen Inc., Thousand Oaks, CA, USA;

⁷Banner University Medical Center, Tucson, AZ, USA; ⁸Vanderbilt University Medical Center, Nashville, TN, USA;

⁹Keck School of Medicine, University of Southern California, Los Angeles, CA, USA;

¹⁰MD Anderson Cancer Center, Houston, TX, USA; ¹¹UT Southwestern Medical Center, Dallas, TX, USA;

¹²Stanford University, Stanford, CA, USA; ¹³H. Lee Moffitt Cancer Center, Tampa, FL, USA;

¹⁴UT Health San Antonio, San Antonio, TX, USA; ¹⁵Orthopedic Surgery, UC Davis, Sacramento, CA, USA;

¹⁶University of Illinois at Urbana-Champaign, Urbana, IL, USA

Poster Presentations Listing

3242742

EWS-FLI1 MODULATED ALTERNATIVE SPLICING OF ARID1A REVEALS NOVEL ONCOGENIC FUNCTION THROUGH THE BAF COMPLEX

Jeffrey Toretsky; Saravana Selvanathan; Garrett Graham; Aykut Uren
Georgetown University, Washington, USA

3253291

THE ROLE OF R0 RESECTION IN INTERMEDIATE AND HIGH-GRADE OSTEOSARCOMA OF THE PELVIS

Cierra S. Hong¹; Alexander L. Lazarides²; David Kerr²; Jason Somarelli³; Julia Visgauss²; Brian Brigman²; William Eward²
¹Duke University School of Medicine, Durham, NC, USA; ²Department of Orthopaedics, Duke University, Durham, NC, USA; ³Duke University, Durham, NC, USA

3253310

ANTI-OSTEOCLAST THERAPY AS NEOADJUVANT IN TREATMENT OF CHONDROSARCOMA – PHASE 1B TRIAL

Varun Monga¹; Benjamin Miller²; Stephanie Chen³; Munir Tanas³; Jesse Otero²; Seth Maliske¹; **Sarah Bell**⁴; Mohammad Milhem¹
¹Internal Medicine, University of Iowa, Iowa City, IA, USA; ²Orthopedics, University of Iowa, Iowa City, IA, USA; ³Pathology, University of Iowa, Iowa City, IA, USA; ⁴Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA

3254086

INTRACELLULAR CHOLESTEROL BIOSYNTHESIS IN ENCHONDROMA AND CHONDROSARCOMA

Hongyuan Zhang¹; Qingxia Wei²; Hidetoshi Tsushima³; Vijitha Puvindran¹; Yuning Tang¹; Sinthu Pathmanapan²; Jay Wunder⁴; Benjamin Alman¹
¹Orthopaedic Surgery, Duke University, Durham, NC, USA; ²Hospital for Sick Children, Toronto, ON, Canada; ³Orthopaedic Surgery, Kyushu University, Fukuoka, Fukuoka, Japan; ⁴Mount Sinai Hospital, Toronto, ON, Canada

3254151

GROWTH PATTERN HETEROGENEITY IN EWING SARCOMA PATIENT-DERIVED CELLS REVEALS DIFFERENTIAL SENSITIVITY TO ANTICANCER AGENTS

Antroula Papakonstantinou, Consultant¹; Christina M. Linder Stragliotto¹; Carolina Brodin²; Bertha Brodin²
¹Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; ²Department of Microbiology Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden

3254873

DIFFERENTIAL REGULATION OF GLYCOGEN METABOLISM IN MUTANT IDH CHONDROSARCOMAS AND CHONDROCYTES

Sinthu Pathmanapan, PhD¹; Raymond Poon¹; Aakriti Pasricha¹; Vijitha Puvindran²; Hongyuan Zhang²; Christopher Newgard⁴; Jay Wunder³; Benjamin Alman²
¹Developmental Biology, Hospital for Sick Children, Toronto, ON, Canada; ²Department of Orthopaedic Surgery, Duke University, Durham, NC, USA; ³University Musculoskeletal Oncology Unit, Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada; ⁴Department of Pharmacology & Cancer Biology, Duke University, Durham, NC, USA

3255255

METASTATIC BONE DISEASE AT DIAGNOSIS IN EXTREMITY SOFT-TISSUE SARCOMAS: RISK FACTORS AND SURVIVAL ANALYSIS USING THE SEER REGISTRY

Manaf H. Younis, MD, MPH; Spencer Summers; Juan Pretell-Mazzini
Orthopedic Oncology, University of Miami, Miami, FL, USA

Poster Presentations Listing

3255261

TEMPORAL HETEROGENEITY OF *IDH1* AND *IDH2* MOLECULAR STATUS IN CONVENTIONAL CHONDROSARCOMA

Anne G. Brouchet¹; Anne-Charlotte Bissainthe¹; Elodie Martin²; Aurore Siegfried¹; Gonzague de Pinieux³; Pierre Brousset¹

¹Pathology, IUCT Oncopole Toulouse France, Toulouse, France; ²Biostatistics Unit, IUCT Oncopole Toulouse France, Toulouse, France; ³Pathology, CHU Tours, Tours, France

3255308

MITOCHONDRIAL OXIDATIVE PHOSPHORYLATION MARKERS IN CHONDROSARCOMA: EVIDENCE OF HIGH METABOLIC ACTIVITY

Atrayee Basu Mallick, MD¹; John Abraham²; Ubaldo Martinez-Outschoorn¹

¹Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA;

²Orthopedics, Rothman orthopedic Institute, Philadelphia, PA, USA

3255665

DNA DAMAGE RESPONSE DEFICIENCY IN OSTEOSARCOMA

Wei-Lien Wang, MD¹; Alexander Lazar¹; Chia-Chu Wu²; Hannah Beird²; Davis Ingram³; Samia Khan³; Khalida Wani³; Najat C. Daw⁴; Andrew Futreal²; J. Andrew Livingston⁵

¹Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

²Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

³Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ⁴Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

⁵Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

3256060

COMBINATION THERAPY OF MTOR INHIBITOR AND VEGFR INHIBITOR REGRESS A DOXORUBICIN-RESISTANT OSTEOSARCOMA IN A PATIENT-DERIVED ORTHOTOPIC XENOGRAFT MODEL AND IN VIVO ANGIOGENESIS ASSAY MODEL

Hiromichi Oshiro; Yasunori Tome; Takashi Toma; Hiroki Maehara; Kotaro Nishida
Orthopedic surgery, University of the Ryukyus, Nishihara-cho, Okinawa, Japan

3256334

LOCAL CONTROL WITH INTRALESIONAL CURETTAGE AND ADJUVANT CRYOPABLATION IN EWING'S SARCOMA OF THE APPENDICULAR SKELETON

Yair Gortzak¹; Amir Sternheim¹; Solomon Dadia¹; Osnat Sher²; Yehuda Kollander¹; Omri Merose¹; Dror Levin³

¹Orthopedic Oncology, Tel Aviv Sourasky Medical Center, Raanana, None, Israel; ²Pathology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; ³Pediatric Hemato-Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

3256389

THE TEMPORAL DEREGULATION OF THE BALANCE BETWEEN THE ACTION OF MACROPHAGES AND OSTEOCLASTS IS ESSENTIAL FOR THE EFFECTIVENESS OF TREATMENT IN OSTEOSARCOMAS

Anne G. Brouchet¹; Regis Brion³; Julia Gilhodes²; B. Ouvrard³; Corinne Bouvier⁴; Nathalie Gaspar⁵; Laurence Brugieres⁵; Sophie Piperno-Neumann⁶; Françoise Redini³

¹Pathology, IUCT Oncopole Toulouse France, Toulouse, France; ²Biostatistics, IUCT Oncopole, Toulouse, France; ³Inserm, UMR1238, univ Nantes, Nantes, France; ⁴Pathology, CHU La Timone, Marseille, Marseille, France; ⁵Dept of Children and Adolescent Oncology, GR Cancer Campus, Villejuif, Villejuif, Paris, France; ⁶Department of Medical Oncology, Curie Institute, Paris, Paris, France

Poster Presentations Listing

3256509

INTEGRIN-MEDIATED SIGNALING AS A NOVEL THERAPEUTIC TARGET IN METASTATIC EWING SARCOMA

Jade Wulff, MD¹; Gargi Ghosal²; Ha Ram Kim¹; Ryan Shuck¹; Lyazat Kurenbekova¹; Jason Yustein¹
¹Pediatrics, Baylor College of Medicine, Houston, TX, USA; ²University of Nebraska Medical Center, Omaha, NE, USA

3256519

SAFETY OF DISCHARGE AT HIGHER SERUM METHOTREXATE LEVELS IN PEDIATRIC OSTEOSARCOMA PATIENTS

Travis R. Hanson; Nathaniel Rice; Anna L. Tamulonis; Paul Kent
Pediatric Hematology and Oncology, Rush University Medical Center, Chicago, IL, USA

3229328

ATR EXPRESSION AS A PROGNOSTIC BIOMARKER AND POTENTIAL THERAPEUTIC TARGET IN OSTEOSARCOMA

Xiaoyang Li¹; Dylan Dean¹; Gregory Cote²; Francis Hornicek¹; **Zhenfeng Duan¹**
¹UCLA, Los Angeles, CA, USA; ²MGH, Boston, MA, USA

3240352

TARGETING SPINDLE ASSEMBLY CHECKPOINT AS A NOVEL THERAPEUTIC STRATEGY IN EWING SARCOMA

Shunya Ohmura¹; Martin Orth¹; Aruna Marchetto¹; Stein Stefanie¹; Julia Gerke¹; Julian Musa¹; Maximilian Knott¹; Fabienne Wehweck⁴; Tanja Paul⁴; Tilman Hölting¹; Laura Romero-Pérez¹; Florencia Cidre-Aranaz¹; Merve Kasan¹; Wolfgang Hartmann²; Uta Dirksen³; Thomas Kirchner⁵; Thomas Grünewald⁶

¹Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany; ²Gerhard-Domagk Institute of Pathology, University Hospital of Münster, Münster, Germany; ³Division of Hematology and Oncology, Department of Pediatrics III, West German Cancer Centre, University Hospital Essen, Essen, Germany; ⁴Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany; ⁵Institute of Pathology, Faculty of Medicine, LMU Munich, German Cancer Consortium (DKTK), partner site Munich, German Cancer Research Center (DKFZ), Munich, Germany; ⁶Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, German Cancer Consortium (DKTK), partner site Munich, German Cancer Research Center (DKFZ), Munich, Germany

3253293

A CROSS SPECIES PERSONALIZED MEDICINE PIPELINE IDENTIFIES THE CRM1 EXPORT PATHWAY AS A POTENTIALLY NOVEL TREATMENT FOR OSTEOSARCOMA

Alexander L. Lazarides, MD¹; Jason Somarelli¹; Erdem Altunel¹; Sneha Rao¹; Sarah M. Hoskinson¹; Maya O. Sheth¹; Serene Cheng¹; So Young Kim¹; Kathryn Ware¹; Laura Selmic²; Cindy Eward¹; David Hsu¹; William Eward¹

¹Duke University, Durham, NC, USA; ²Ohio State University, Columbus, OH, USA

3253294

THE ROLE OF SURGICAL RESECTIONS FOR INTERMEDIATE AND HIGH-GRADE PELVIC CHONDROSARCOMA

Cierra S. Hong¹; Alexander L. Lazarides²; David Kerr²; Jason Somarelli³; Julia Visgauss²; Brian Brigman²; William Eward²

¹Duke University School of Medicine, Durham, NC, USA; ²Department of Orthopaedics, Duke University, Durham, NC, USA; ³Duke University, Durham, NC, USA

Poster Presentations Listing

3253859

PRIMARY SOLITARY FIBROUS TUMORS OF BONE: A MONOCENTRIC RETROSPECTIVE ANALYSIS OF 22 PATIENTS

Giuseppe Bianchi; Andrea Sambri; Marco Gambarotti; Davide Donati
Istituto Ortopedico Rizzoli, Bologna, Italy

3254498

TARGETING BIG3-PHB2 PROTEIN INTERACTION TO SUPPRESS OSTEOSARCOMA PROGRESSION

Shunichi Toki¹; Tetsuro Yoshimaru¹; Hitoshi Aibara¹; Yosuke Matsushita¹; Koichi Sairyo²;
Toyomasa Katagiri¹

¹Division of Genome Medicine, Tokushima University, Tokushima, Japan;

²Division of Orthopedic Surgery, Tokushima University, Tokushima, Japan

3254783

SIGNALING CROSS-TALK BETWEEN HUMAN OSTEOSARCOMA AND MESENCHYMAL STEM CELLS VIA INTERLEUKIN-8 IN THE TUMOR MICROENVIRONMENT

Masanori Kawano; Kazuhiro Tanaka; Ichiro Itonaga; Tatsuya Iwasaki; Shogo Matsuda; Hiroshi Tsumura
Orthopaedic Surgery, Oita University, Yufu, Oita, Japan

3255251

POTENTIAL EWS-FLI1- FOXM1- BUB1B AXIS CONTRIBUTING TO MITOTIC CELL CYCLE CONTROL IN EWING SARCOMA

Christiane Schaefer, Dr. Rer. Nat.¹; Yasmine El Gourari El Gourari²; Birgit Lechtape¹;
Thomas Grünewald³; Wolfgang Hartmann⁴; Jenny Potratz²; Uta Dirksen¹

¹Pediatrics III, Hematology/ Oncology, University Hospital Essen, Essen, North Rhine-Westfalia,

Germany; ²Department of General Pediatrics, University Hospital Münster, Münster, Germany; ³Institute of Pathology, Ludwig-Maximilians-Universität München, München, Germany; ⁴Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany

3255313

COPPER LEVELS AND ALDH1A1 EXPRESSION VARIES BETWEEN LOW AND HIGHLY METASTATIC OSTEOSARCOMA CELL LINES AND HUMAN SAMPLES

Jonathan Mandell; Nerone Douglas; Jan Beumer; Rebecca Watters; Kurt R. Weiss
University of Pittsburgh, Pittsburgh, PA, USA

3255608

EPIGENETIC MODULATING DRUGS ON CARTILAGE AND CHONDROSARCOMA DIFFERENTIATION AND VIABILITY

Tyler Harasta; **Joseph B. Kuechle, MD, PhD**

Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA

3255652

DIABETES-ASSOCIATED ADVANCED GLYCATION END-PRODUCTS N ϵ -CARBOXYMETHYLLYSINE AND PENTOSIDINE EXERT MALIGNANCY ON BONE TUMORS VIA THE ACTIVATION OF SKELETAL CANCER STEMNESS

Rong-Sen Yang¹; Tsung-Han Yang²; Shing-Hwa Liu¹

¹National Taiwan University, Taipei, Taiwan; ²National Taiwan University Hospital, Hsinchu Branch, Hsinchu County, Taiwan

3255959

ARE INTRA-ARTICULAR RESECTIONS FOR PROXIMAL FEMUR SARCOMAS WITH INTRA-ARTICULAR DISEASE SAFE?

Prakash R. Nayak, MD¹; Srinath Gupta¹; Akshay Patil²; Ashish Gulia¹; Ajay Puri¹

¹Surgical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India; ²Biostatistics, Tata Memorial Centre, Mumbai, Maharashtra, India

Poster Presentations Listing

3256013

BASED ON THE POTENTIAL IMMUNOGENIC EFFECT OF TREATED TUMOR TISSUE REIMPLANTATION DOES EXTRA CORPOREAL RADIATION AND RE-IMPLANTATION (ECRT) FOR INTERCALARY OSTEOSARCOMA RESECTION PROVIDE OUTCOME BENEFITS?

Prakash R. Nayak, MD; Ashish Gulia; Ajay Puri

Surgical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India

3256546

IMPACT OF LOCAL TREATMENT STRATEGY FOR PRIMARY SITE ON OUTCOMES OF EWING SARCOMA

Yen-Lin Chen, MD¹; Saveli I. Goldberg¹; Ruoyu Miao¹; Edwin Choy²; Gregory Cote²; Kevin Raskin³; Santiago Lozano-Calderon³; Joseph Schwab³; Thomas DeLaney¹

¹Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; ²Medicine, Massachusetts General Hospital, Boston, MA, USA; ³Orthopedic Surgery, Massachusetts General Hospital, Boston, MA, USA

3222958

GENOMIC ANALYSIS DOES NOT SUPPORT 'MALIGNANT TRANSFORMATION' OF OSTEOBLASTOMA TO OSTEOSARCOMA

David Geller¹; Nicole L. Levine²; Bang Hoang¹; Rui Yang¹; Daniel Weiser³; Jonathan Morris⁴; Richard Gorlick⁵; Jonathan B. Gill⁵; Michael Roth⁵; Janet Tingling¹; Andrew S. Brohl⁶

¹Orthopaedic Surgery, Montefiore Medical Center, Bronx, NY, USA; ²Albert Einstein College of Medicine, Bronx, NY, USA; ³Pediatrics, Montefiore Medical Center, Bronx, NY, USA; ⁴Orthopaedic Surgery, Southeast Permanente Medical Group, Atlanta, GA, USA; ⁵Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX, USA; ⁶Medical Oncology, Moffitt Cancer Center, Tampa, FL, USA

3231545

GENETIC TRANSPOSITION OF TP53 REGULATORY ELEMENTS ELICITS ONCOGENE EXPRESSION IN OSTEOSARCOMA

Karim Saba¹; Louise Cornmark¹; Michal Kovac²; Hilda van den Bos³; Linda Magnusson¹; Jenny Nilsson¹; Jakob Hofvander¹; Diana C. Spierings³; Mahtab Bidgoli¹; Tord Jonson¹; Sumathi Vaiyapuri⁴; Otte Brosjö⁵; Johan Staaf¹; Emelie Styring⁶; Floris Foijer³; Michaela Nathrath⁷; Daniel Baumhoer²; Karolin Hansén Nord¹

¹Lund University, Lund, Sweden; ²University Hospital Basel, Basel, Switzerland; ³University Medical Centre Groningen, Groningen, Netherlands; ⁴Royal Orthopaedic Hospital, Birmingham, United Kingdom; ⁵Karolinska University Hospital, Stockholm, Sweden; ⁶Skåne University Hospital, Lund, Sweden; ⁷Klinikum Kassel, Kassel, Germany

3253039

SURVIVAL IN PATIENTS WITH CARCINOMAS PRESENTING WITH BONE METASTASIS AT DIAGNOSIS: A SEER POPULATION-BASED COHORT STUDY

Manaf H. Younis, MD, MPH; Juan Pretell-Mazzini

Orthopedic Oncology, University of Miami, Miami, FL, USA

3253213

PERCUTANEOUS CORE NEEDLE BIOPSY VERSUS OPEN BIOPSY OF MALIGNANT BONE TUMOR IN DIAGNOSTIC ACCURACY, COMPLICATIONS, AND COST-EFFECTIVENESS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Toshihiko Nishisho¹; Kunihiko Numoto²

¹Department of Orthopedics, Institute of Biomedical Sciences Tokushima University Graduate School, Tokushima, Tokushima, Japan; ²Department of Orthopedics, Kochi Health Sciences Centre, Kochi, Kochi, Japan

Poster Presentations Listing

3254536

CLINICAL PROGNOSTIC FACTORS AND TREATMENT OUTCOMES IN ADULT PATIENTS TREATED WITH EWING SARCOMA

Paulina Jagodzinska-Mucha²; Iwona Lugowska¹; Tomasz Switaj¹; Hanna Kosela-Paterczyk¹; Michal Wagrodzki¹; Anna Szumera-Cieckiewicz¹; Anna Dawidowska²; Piotr Rutkowski¹

¹ Department of Soft Tissue/Bone Sarcoma and Melanoma , Sklodowska-Curie Institute - Oncology Center, Warszawa, Poland; ²Early Phase Clinical Trials Unit, Maria Sklodowska-Curie Institute - Oncology Center, Warszawa, Poland

3254945

MICRORNA-451A-CMTM6 NETWORK IS A POTENTIAL METASTASIS REGULATOR OF EWING SARCOMA CELLS

Naofumi Asano, MD, PhD¹; Yuko Nishiyama²; Eisuke Kobayashi³; Robert Nakayama¹; Masaya Nakamura¹; Morio Matsumoto¹; Akira Kawai³; Tadashi Kondo⁴; Naoto Tsuchiya²

¹Orthopaedics surgery, Keio University, Tokyo, Japan; ²Laboratory of Molecular Carcinogenesis, National Cancer Center Research Institute, Tokyo, Japan; ³Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan; ⁴Rare Cancer Research, National Cancer Center Research Institute, Tokyo, Japan

3255070

IDENTIFICATION OF FSTL1 AS A POSSIBLE THERAPEUTIC TARGET FOR OSTEOSARCOMA

Fumihiko Nakatani; Makoto Nakagawa; Takeshi Hirose; Akira Kawai; Chie Kudo; Yamato Ogiwara
National Cancer Center Hospital, Tokyo, Japan

3255111

EFFICACY OF IRE1 α -XBP1 INHIBITORS IN OSTEOSARCOMAS

Taisei Kurihara; Yoshiyuki Suehara; Takuo Hayashi; Tatsuya Takagi; Keisuke Akaike; Kei Sano; Kazuo Kaneko; Tsuyoshi Saito

Juntendo University, Tokyo, Japan

3256081

DETECTION OF PULMONARY METASTASIS USING GFP TRANSFECTED PATIENT-DERIVED OSTEOSARCOMA CELLS IN A PATIENT-DERIVED ORTHOTOPIC XENOGRAFT (PDOX) MODEL

Hiromichi Oshiro; Yasunori Tome; Takashi Toma; Hiroki Maehara; Kotaro Nishida
Orthopedic Surgery, University of the Ryukyus, Nishihara-cho, Okinawa, Japan

3256400

MIRNA COMPONENTS OF MRNA TRANSCRIPTIONAL PATTERNS DISCOVERED USING DIMENSIONAL REDUCTION ANALYSES OF OSTEOSARCOMA TUMOR RNA-SEQ DATA

Aaron L. Sarver, PhD; Subbaya Subramanian; Logan Spector; Jaime Modiano; David A. Largaespada; Anne Sarver

Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA

3256446

UNUSUAL SITES OF OSTEOSARCOMA ISOLATED RELAPSE TO THE HEAD AND NECK REGION: PHARYNGEAL TONSIL AND THYROID

Janay McKnight; Anna Tamulonis; Paul Kent

Rush University, Chicago, IL, USA

3256479

CHANGES IN BODY MASS INDEX AMONG BONE SARCOMA SURVIVORS DURING LONG-TERM FOLLOW-UPS

Ruoyu Miao, MD¹; Gregory Cote²; Edwin Choy²; Kevin Raskin³; Joseph Schwab³; Thomas DeLaney¹; Yen-Lin Chen¹

¹Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; ²Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA; ³Department of Orthopedic Oncology, Massachusetts General Hospital, Boston, MA, USA

Poster Presentations Listing

3257333

OSTEONECROSIS OF THE JAW (ONJ) WITH DENOSUMAB (D'MAB) FOR GIANT-CELL TUMOR OF BONE (GCTB)

Noemi Simeone, Medicine¹; Anna Maria Frezza¹; Elena Palassini¹; Giacomo G. Baldi¹; Alessandra Raimondi¹; Rocio Lesta Mellid¹; Carlo Morosi²; Gabriella Greco²; Massimo Maniezzo³; Marco Guzzo⁴; Paolo Casali¹; Silvia Stacchiotti¹

¹Adult Mesenchymal and Rare Tumor Unit, Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Milan, Italy; ²Radiology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ³Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ⁴Department of Head and Neck Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

3240850

MUSCULOSKELETAL AND TRANSLATIONAL RESEARCH BIOBANK (MTRB): ESTABLISHMENT, MAINTENANCE AND CHARACTERIZATION OF PATIENT-DERIVED OSTEOSARCOMA CELLS

Pimpisa Teeyaksem¹; Dumnoensun Pruksakorn¹; Jongkolnee Settakorn²; Areerak Phanphaisarn¹; Piyaporn Budprom¹; Nutnicha Sirikaew¹; Viraporn Thepbundit¹; Jeerawan Klangjorhor¹; Parunya Chaipayawat¹

¹Department of Orthopedics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, Musculoskeletal Science and Translational Research Center, Chiang Mai, Muang Chiang Mai, Thailand; ²Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, Chiang Mai, Thailand

3241715

DEVELOPING A NOVEL SPHEROID MODEL FOR CHONDROSARCOMA RESEARCH AND DRUG SCREENING

Ruichen Ma; Feiqi Lu; Jonathan Mandell; Margaret L. Hankins; Anette Duensing; Rebecca Watters; Kurt R. Weiss
University of Pittsburgh, Pittsburgh, PA, USA

3252962

THREE-DIMENSIONAL CULTURE MODEL OF CHONDROSARCOMA FOR CHEMO/RADIOTHERAPEUTIC TREATMENT PREDICTION

Ieva Palubeckaite, PhD; Sanne Venneker; Brendy van den Akker; Inge Briaire - de Bruijn; Judith Bovee
Pathology, Leiden University Medical Centre, Leiden, Netherlands

3252983

A RARE CASE OF MALIGNANT PERIVASCULAR EPITHELIOID TUMOR (PECOMA) IN THE LUMBAR SPINE

Yoshikazu Tanzawa, PhD
Orthopaedic Surgery, Tokai University, Isehara, Kanagawa, Japan

3253046

NEUROTOXICITY IN OSTEOSARCOMA PATIENTS FOLLOWING TREATMENT WITH HIGH DOSE METHOTREXATE

Yair Peled
Pediatric Hematology and Oncology, Tel Aviv Medical Center Israel, Tel Aviv, Israel

3255697

APPROACHES IN IMMUNOTHERAPY CHECKPOINT INHIBITORS FOR CHILDREN WITH REFRACTORY BONE SARCOMAS

Janay McKnight; Anna Tamulonis; Paul Kent
Rush University, Chicago, IL, USA

Poster Presentations Listing

3256406

PROLONGED SURVIVAL AFTER SECOND RELAPSE OF OSTEOSARCOMA FOLLOWING REPEATED DOSES OF IMMUNOTHERAPY AND SAMARIUM

Connor Murphy; Caleb Oh; Anna L. Tamulonis; Paul Kent
Oncology, Rush University Medical Center, Plainfield, IL, USA

3239467

COMPREHENSIVE GENOMIC PROFILING (CGP) OF DESMOPLASTIC SMALL ROUND CELL TUMORS (DSRCT) IDENTIFIES PREDICTED NEOANTIGENIC GENE FUSIONS

Dexter X. Jin, PhD¹; Natalie Danziger⁴; Meagan Montesion¹; Dean C. Pavlick¹; Ethan S. Sokol¹; Jonathan K. Killian⁴; Justin Newberg¹; Sherri Millis²; Warren Chow⁵; Jeff S. Ross⁴; Vince A. Miller³; Mrinal M. Gounder⁶; Garrett Frampton¹; Siraj Ali³; Sally Trabucco¹
¹Cancer Genomics, Foundation Medicine, Inc., Stoneham, MA, USA; ²Clinical Collaborations, Foundation Medicine, Inc., Cambridge, MA, USA; ³Clinical Development, Foundation Medicine, Inc., Cambridge, MA, USA; ⁴Lab Operations, Foundation Medicine, Inc., Cambridge, MA, USA; ⁵Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA, USA; ⁶Developmental Therapeutics Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

3245715

OUTCOME OF PALLIATIVE CHEMOTHERAPY IN ADULT DESMOPLASTIC SMALL ROUND CELL TUMOR PATIENTS: A SINGLE CENTER EXPERIENCE

Hyehyun Jeong¹; Jeong Eun Kim¹; Yong Sang Hong¹; Young-Hoon Kim²; Chan-wook Kim³; Jin-hee Ahn¹
¹Department of Oncology, Asan Medical Center, Seoul, Korea (the Republic of); ²Division of Kidney Transplantation, Department of Surgery, Asan Medical Center, Seoul, Korea (the Republic of); ³Department of Colon and Rectal Surgery, Asan Medical Center, Seoul, Korea (the Republic of)

3249075

COMPREHENSIVE GENOMIC AND IMMUNE-PROFILING OF HYPERPROGRESSIVE DESMOPLASTIC SMALL ROUND CELL TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS

Roman Groisberg, MD¹; Jason Roszik²; Behrang Amini²; Vivek Subbiah²
¹Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA; ²University of Texas MD Anderson, Houston, TX, USA

3253564

LANDSCAPE OF GENOMIC ABERRATIONS IN DESMOPLASTIC SMALL ROUND CELL TUMORS AND EWING'S SARCOMAS REVEALS DIVERSE BIOLOGY: CLINICAL IMPLICATIONS

Jason Roszik¹; Joseph A. Ludwig¹; Anthony Conley¹; J. Andrew Livingston¹; Aung Naing¹; Roman Groisberg²; Alexander Y. Andreev-Drakhlin¹; Roberto Carmagnani Pestana¹; Vivek Subbiah¹
¹The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ²Rutgers Cancer institute of New Jersey, New Brunswick, NJ, USA

3255247

EWS-WT1 FUSION TRANSCRIPT STRUCTURE IS NOT PREDICTIVE OF PROGNOSIS IN DESMOPLASTIC SMALL ROUND CELL TUMOR

Emily Slotkin, MD¹; Neerav Shukla¹; Paul Meyers¹; Leonard Wexler¹; Anita S. Bowman²; Ahmet Zehir²; Jessie Hillsberg¹; Ryma Benayed²; Meera Hameed²; Narasimham Agaram²; Marc Ladanyi²; William D. Tap³; Cristina Antonescu²; Todd Heaton¹; Michael P. LaQuaglia¹; Shakeel Modak¹
¹Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ³Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Poster Presentations Listing

3255470

UPDATED RESULTS OF A PILOT TRIAL OF IRINOTECAN, TEMOZOLOMIDE AND BEVACIZUMAB FOR TREATMENT OF NEWLY DIAGNOSED DESMOPLASTIC SMALL ROUND CELL TUMOR

Emily Slotkin, MD; Heather Magnan; Leonard Wexler; Shakeel Modak; Anita Price; Audrey Mauguen; Jessie Hillsberg; Kelly Swanson; Justin T. Gerstle; Todd Heaton; Michael P. LaQuaglia; Paul Meyers Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA

3255482

IMPROVING THE EFFICACY OF ANDROGEN RECEPTOR-BASED ANTI-SENSE THERAPY BY TARGETING EWSR1 OR TAZ FOR THE TREATMENT OF DESMOPLASTIC SMALL ROUND CELL TUMOR

Salah-Eddine Lamhamedi Cherradi, PhD¹; Brian A. Menegaz¹; Branko Cuglievan²; Pamela Pamela²; Alejandra R. Velasco¹; Standhya Krishnan¹; Amelia Vetter¹; Youngsoo Kim³; Robert MacLeod⁴; Andrea Hayes-Jordan⁵; Joseph A. Ludwig¹

¹Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; ²Pediatrics, MD Anderson Cancer Center, Houston, TX, USA; ³Oncology, Ionis Pharmaceuticals, Inc, Carlsbad, CA, USA; ⁴Oncology, Ionis Pharmaceuticals, Inc., Carlsbad, CA, USA; ⁵UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA

3255856

RESULTS OF DESMOPLASTIC SMALL ROUND CELL TUMOR TREATMENT – SINGLE INSTITUTION EXPERIENCE

Pawel Teterycz; Hanna Kosela-Paterczyk; Katarzyna Kozak; Tomasz Switaj; Anna Klimczak; **Piotr Rutkowski, MD**

Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute - Oncology Center; Department of Soft Tissue/Bone Sarcoma and Melanoma, Warsaw, Poland

3255901

ADVANCED DESMOPLASTIC SMALL ROUND CELL TUMOR SUCCESSFULLY TREATED IN A 21 YEAR OLD WOMAN, A CASE REPORT

Dorota Goplen, MD, PhD¹; Hans Kristian Haugland²; Kjell Kåre Øvrebø³

¹Dept. of Oncology, Haukeland University Hospital, Bergen, Norway; ²Dept. of Pathology, Haukeland University Hospital, Bergen, Norway; ³Dept. of Surgery, Haukeland University Hospital, Bergen, Norway

3256316

INTRAPERITONEAL RADIOIMMUNOTHERAPY FOR DESMOPLASTIC SMALL ROUND CELL TUMOR: FINAL RESULTS OF A PHASE I STUDY (CLINICALTRIALS.GOV IDENTIFIER NCT01099644)

Shakeel Modak, MD¹; Pat Zanzonico²; Emily Slotkin¹; Todd Heaton¹; Nai-Kong Cheung¹; Michael P. LaQuaglia¹; Neeta Pandit-Taskar³

¹Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ³Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

3256475

MSK-IMPACT GENOMIC PROFILING OF DESMOPLASTIC SMALL ROUND CELL SARCOMA REVEALS RECURRENT COPY NUMBER ALTERATIONS

Anita S. Bowman, MS¹; Ahmet Zehir¹; Emily Slotkin²; Leonard Wexler²; William D. Tap³; Todd Heaton⁴; J. T. Gerstle⁴; Michael Berger¹; Michael P. LaQuaglia⁴; Shakeel Modak²; Marc Ladanyi¹

¹Pathology, Memorial Sloan Kettering Cancer Center, Yeadon, PA, USA; ²Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ³Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁴Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

3256523

COMPUTATIONAL SEARCH FOR GENE ABNORMALITIES IN DSRCT AND ASSOCIATED POSSIBLE THERAPEUTIC AGENTS

Michael P. LaQuaglia, MD¹; Emily Slotkin²; Neerav Shukla²; Shakeel Modak²

¹Surgery, MSKCC, New York, NY, USA; ²Pediatrics, MSKCC, New York, NY, USA

Poster Presentations Listing

3256525

GENERATION OF PATIENT DERIVED XENOGRAFT MODELS OF DESMOPLASTIC SMALL ROUND CELL TUMOR

Emily Slotkin, MD; Sagarika Pachhal; Paul Meyers; Kristina Guillan; Andoyo Ndengu; Jessie Hillsberg; Kelly Swanson; Shakeel Modak; Justin T. Gerstle; Todd Heaton; Michael P. LaQuaglia; Daoqi You; Andrew Kung; Filemon Dela Cruz
Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA

3256529

COMPASSIONATE USE OF BIVALENT ANTI-GD2/GD3 VACCINE WITH IMMUNOLOGICAL ADJUVANT OPT-821 IN COMBINATION WITH ORAL BETA-GLUCAN FOR THE TREATMENT OF RELAPSED GD2+ DESMOPLASTIC SMALL ROUND CELL TUMOR

Jessie Hillsberg; **Emily Slotkin, MD**; Shakeel Modak; Brian Kushner
Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA

3256531

CHK1 KINASE INHIBITION IN DESMOPLASTIC SMALL ROUND CELL TUMOR

Emily Slotkin, MD¹; Sagarika Pachhal¹; Peilin Ma¹; Filemon Dela Cruz¹; Alex Kentsis¹; William D. Tap²; Andrew Kung¹
¹Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA;
²Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

3256819

THERAPEUTIC POTENTIAL OF NTRK3 IN DESMOPLASTIC SMALL ROUND CELL TUMOR

Koichi Ogura, MD, PhD¹; Julija Hmeljak¹; Romel Somwar¹; Heather Magnan²; Marina Asher¹; Achim Jungbluth¹; Amir Momeni¹; Ryma Benayed¹; Alifiani B. Hartono³; Sean Bong Lee³; Lee Spraggon¹; Marc Ladanyi¹
¹Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA;
²Memorial Sloan Kettering Cancer Center, Department of Pediatrics, New York, NY, USA;
³Tulane University School of Medicine, New Orleans, LA, USA

3256561

ULTRA-HIGH FIELD MRI (7 TESLA): ARE WE HEADING TO THE FUTURE OF TUMOURS MUSCULOSKELETAL IMAGING?

Jean-Camille Mattei, MD, PhD
AP-HM, Aix-Marseille University, Marseille, France

3257777

COMPUTED-TOMOGRAPHY (CT) SCAN IN RETROPERITONEAL SARCOMAS (RPS): A RADIOMIC ANALYSIS OF THE SARCOMICS STUDY

Raffaella Vigorito¹; **Sandro Pasquali**¹; Marco Bologna²; Raffaella Greco¹; Rosalba Miceli¹; Francesco Barretta¹; Valentina Corino²; Paola Collini¹; Nicolò Rampello¹; Lorella Rusi¹; Luca Mainardi²; Dario Callegaro¹; Carlo Morosi¹; Alessandro Gronchi¹
¹Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; ²Politecnico Milano, Milan, Italy

3257781

MAGNETIC RESONANCE IMAGING (MRI) SCAN IN EXTREMITY SOFT TISSUE SARCOMAS (ESTS): A RADIOMIC ANALYSIS OF THE SARCOMICS STUDY

Sandro Pasquali¹; Antonella Messina¹; Marco Bologna²; Alessandra Casale¹; Rosalba Miceli¹; Francesco Barretta¹; Valentina Corino²; Paola Collini¹; Nicolò Rampello¹; Lorella Rusi¹; Luca Mainardi²; Dario Callegaro¹; Alessandro Gronchi¹
¹Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; ²Politecnico Milano, Milan, Italy

Poster Presentations Listing

3232369

APPLYING RADIOMICS IN PREDICTING OUTCOMES IN PATIENTS WITH RETROPERITONEAL SARCOMA TREATED WITH PREOPERATIVE RADIOTHERAPY

Jeremy Lewin¹; David Gyorki¹; Katrina Ingley¹; Krystal Tran¹; Shona Hendry²; Catherine Mitchell¹; Michael Henderson¹; Price Jackson¹; Sam Ngan¹; Sarat Chander¹; Alan Herschtal¹; Nicholas Hardcastle¹
¹Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; ²St Vincents Hospital, Melbourne, Victoria, Australia

3241854

DIMENSIONAL AND NON-DIMENSIONAL CHANGES WITH LOW-DOSE CHEMOTHERAPY IN SPORADIC DESMOID TUMORS (DT)

Edoardo Zanchetta¹; Chiara M. Ciniselli²; Chiara Colombo³; Silvia Stacchiotti⁴; Giacomo Baldi⁴; Salvatore Provenzano⁴; Rossella Bertulli⁴; Noemi Simeone⁶; Alessandra Casale⁵; Francesca G. Greco⁵; Paolo Verderio²; Marco Fiore³; Alessandro Gronchi³; Paolo Casali⁴; Carlo Morosi⁵; Elena Palassini⁴
¹Postgraduation School in Radiodiagnosics, Università degli Studi di Milano, Milan, Italy; ²Unit of Bioinformatics and Biostatistics - Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ³Oncological Surgery Unit 4, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ⁴Medical Oncology Unit 2, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ⁵Diagnostic and Interventional Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ⁶Postgraduation School in Medical Oncology, Università degli Studi di Milano, Milan, Italy

3253768

LINEAR MIXED EFFECTS MODELS FOR ESTIMATION OF PULMONARY METASTASIS GROWTH RATE: IMPLICATIONS FOR CHEST CT SCREENING IN PATIENTS WITH SARCOMA

Ulysses Isidro¹; Ronnie Sebro²
¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; ²Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

3254463

DISTINCTION BETWEEN BENIGN AND MALIGNANT SOFT TISSUE TUMORS BASED ON AN ULTRASONOGRAPHIC EVALUATION OF VASCULARITY AND ELASTICITY

Shusa Ohshika; Tetsuya Ogawa; Yasuyuki Ishibashi
Department of Orthopaedic Surgery, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan

3255562

MACHINE LEARNING ALGORITHM FOR IMAGING CLASSIFICATION OF SOFT TISSUE MASSES OF THE PELVIS

Behrang Amini, MD, PhD¹; James Cortez¹; Michael Richardson²
¹Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ²Diagnostic Radiology, University of Washington, Seattle, WA, USA

3255153

DIAGNOSTIC EFFICACY OF POSITRON EMISSION TOMOGRAPHY IN ADIPOCYTIC TUMORS

Yasunori Tome, MD, PhD; Hiromichi Oshiro; Takashi Toma; Hiroki Maehara; Kotaro Nishida
Department of Orthopedic Surgery, University of the Ryukyus, Nishihara, Okinawa, Japan

3253128

GEMCITABINE PLUS PACLITAXEL THERAPY AGAINST ADVANCED BONE AND SOFT TISSUE SARCOMA

Hiroyuki Kawashima¹; Akira Ogose¹; Takashi Ariizumi¹; Naoki Oike¹; Yasuo Saijo²; Yuki Sakai³; Naoto Endo¹
¹Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan; ²Medical Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan; ³Pharmacy, Niigata University Medical and Dental Hospital, Niigata, Japan

Poster Presentations Listing

3225830

THE ANALYSIS OF EPIDEMIOLOGICAL CHARACTERISTICS OF 1624 SOFT TISSUE SARCOMA CASES IN 2006-2016 IN HENAN PROVINCE CANCER HOSPITAL, CHINA

Peng Zhang; Jinyan Liu; Weitao Yao

Bone and Soft tissue sarcoma, The Affiliated Cancer Hospital of Zhengzhou University (Henan Province Cancer Hospital), Zhengzhou, Henan, China

3219647

REFERRAL PATTERN OF RETROPERITONEAL SARCOMAS TO A SURGICAL ONCOLOGY SERVICE WITH SARCOMA INTEREST IN A DEVELOPING COUNTRY

Raza H. Sayyed, MBBS, FRCSEd, EBSQ Surgical Oncology¹; Nasir Uddin²; Bilal M. Qureshi³;

Fahd Haroon⁴; Adeel Ahmed⁷; Fawad Qureshi⁵; Samiullah K. Niazi⁶; Marco Fiore⁸; Alessandro Gronchi⁸

¹Surgical Oncology, Patel Hospital, Karachi, Pakistan; ²Pathology, The Aga Khan University, Karachi, Pakistan; ³Radiation Oncology, The Aga Khan University, Karachi, Pakistan; ⁴Radiology, Karachi X-ray, Karachi, Pakistan; ⁵Medical Oncology, Dow University of Health Sciences, Karachi, Pakistan; ⁶Surgical Oncology, South City Hospital, Karachi, Pakistan; ⁷Clinical Oncology, Kiran Hospital, Karachi, Pakistan; ⁸Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

3252957

TUMOUR NECROSIS IS AN INDEPENDENT PROGNOSTIC FACTOR FOR OVERALL SURVIVAL AFTER CURATIVE RESECTION OF GIST

Robert Tyler, MBChB MRCS; Dominic Tan; Max Almond; Samuel Ford; Anant Desai

Sarcoma and General Surgery, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom

3255281

QUANTITATIVE MASS SPECTROMETRY IMAGING IN SECONDARY RESISTANT GIST LIVER METASTASIS DEMONSTRATES LACK OF IMATINIB DISTRIBUTION

Denis Abu-Sammour²; Peter Hohenberger¹; Christian Marsching²; Jan-Hinrich Rabe²; Alexander Marx³;

Alexander Geisel²; Katrin Erich²; Sandra Schulz²; Peter Findeisen⁴; Carsten Hopf²
¹Dept. of Surgery, Div. of Surgical Oncology and Thoracic Surgery, Mannheim, Germany; ²Center for Biomedical Mass Spectrometry and Optical Spectroscopy (CeMOS), Mannheim University of Applied Sciences, Mannheim, Germany; ³Institute of Pathology, Mannheim University Medical Center, Mannheim, Germany; ⁴Institute of Clinical Chemistry, Mannheim University Medical Center, Mannheim, Germany

3256201

EXON 9 MUTATED GIST AND ADJUVANT IMATINIB: A MULTICENTRIC RETROSPECTIVE STUDY

Bruno Vincenzi¹; Marianna Silletta¹; Andrea Napolitano¹; Alessandro Mazzocca¹; Alessandro Minelli¹;

Giovanni Grignani²; Antonella Brunello³; Giacomo G. Baldi⁴; Javier Martin-Broto⁵; NADIA HINDI⁵;

Elena Fumagalli⁶; Robin L. Jones⁷; Spyridon Gennatas⁷; Piotr Rutkowski⁸; Bernd Kasper¹³;

Margherita Nannini¹⁰; Peter Hohenberger¹³; Silvia Gasperoni¹¹; Giuseppe Badalamenti¹²;

Tommaso De Pas¹⁴; Alessandro Gronchi⁶; Angelo Paolo Dei Tos⁹; Maria Abbondanza Pantaleo¹⁰

¹Medical Oncology, Campus Biomedico, Rome, Italy; ²Istituto di Candiolo, Turin, Italy; ³IOV, Padova, Italy; ⁴Ospedale di Pisa/Prato, Pisa, Italy; ⁵Hospital Universitario Virgen del Rocío/Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain; ⁶Istituto Tumori di Milano, Milan, Italy; ⁷The Royal Marsden NHS, London, United Kingdom; ⁸Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; ⁹Università Degli Studi di Padova, Padova, Italy; ¹⁰Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy; ¹¹Ospedale Careggi, Firenze, Italy; ¹²Ospedale Giaccone Palermo, Palermo, Italy; ¹³Mannheim University Medical Center, Mannheim, Germany; ¹⁴Istituto Europeo di Oncologia, Milan, Italy

Poster Presentations Listing

3253758

MUTATIONAL PROFILING IS COST-EFFECTIVE FOR TAILORING FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC GASTROINTESTINAL STROMAL TUMOR: RESULTS OF A MARKOV MODEL ANALYSIS

Sudeep Banerjee¹; Abhishek Kumar²; Nicole E. Lopez³; Beiqun Zhao¹; Chih-Min Tang¹; Mayra Yebra¹; Hyunho Yoon¹; James D. Murphy²; **Jason K. Sicklick, MD¹**

¹Department of Surgery, Division of Surgical Oncology, University of California, San Diego, La Jolla, CA, USA; ²Department of Radiation Medicine and Applied Sciences, UC San Diego, La Jolla, CA, USA;

³Department of Surgery, Division of Colorectal Surgery, UC San Diego, La Jolla, CA, USA

3254407

PATTERNS OF MULTIDISCIPLINARY CARE AND OUTCOMES OF PATIENTS WITH METASTATIC GIST IN A REAL-LIFE SETTING: THE METAGIST OBSERVATIONAL STUDY FROM 3 COORDINATING CENTERS OF THE GSF-GETO

Maud Toulmonde¹; Mehdi Brahm²; Axel Le Cesne³; Derek Dinart¹; Armelle Dufresne²; Olivier Mir³; Pierre Meeus²; Eberhard Stoeckle¹; Amine Bouhamama²; Xavier Buy¹; Marie Karanian²; Julien Domont³; Carine Bellera¹; Antoine Italiano¹; Jean-Yves Blay²; Philippe Terrier³; Francois Le Loarer¹; Charles Honoré³
¹Institut Bergonié, Bordeaux, France; ²Centre Léon Bérard, Lyon, France; ³Gustave Roussy, Villejuif, France

3255128

PRECLINICAL ACTIVITY OF AXITINIB IN GIST CELL MODELS WITH CLINICALLY REPRESENTATIVE KIT PRIMARY AND SECONDARY MUTATIONS

Alfonso García-Valverde; Daniel Pilco-Janeta; Marina Polo; Jesse K. Fletcher; Claudia Valverde; Joan Carles; Joaquín Arribas; **César Serrano, MD, PhD**
Medical Department, Vall d'Hebron Institute of Oncology, Barcelona, Barcelona, Spain

3255526

ROLE OF PAZOPANIB IN METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST), PROGRESSING AFTER STANDARD OF CARE THERAPY

Aydah Al-Awadhi, MD¹; Cissimol Joseph²; Bridgette L. King²; Jocelyn Joseph²; Heather Lin³; Neeta Somaiah²

¹Cancer Medicine, University of Texas, MD Anderson Cancer Center, Houston, TX, USA;

²Sarcoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA;

³Biostatistics, University of Texas, MD Anderson Cancer Center, Houston, TX, USA

3255898

PRESERVATION OF ORGAN FUNCTION BY MINIMIZING SURGICAL RESECTION BY NEOADJUVANT IMATINIB THERAPY IN GASTROINTESTINAL STROMAL TUMORS (GIST)

Nikos Vassos¹; Jens Jakob²; Peter Reichardt⁶; Daniel Pink³; Alexander Marx⁵; Eva Wardelmann⁴; Peter Hohenberger¹

¹Dept. of Surgery, Div. of Surgical Oncology and Thoracic Surgery, Mannheim, Germany;

²Sarcoma Center, Dept. of Surgery, University of Göttingen, Göttingen, Germany; ³Helios Klinikum Bad Saarow, Hematology and Oncology, Bad Saarow, Germany; ⁴Dept. of Pathology, University of Münster, Münster, Germany; ⁵Institut of Pathology, Mannheim University Medical Center, Mannheim, Germany;

⁶Dept. of Hematology and Oncology/Sarcoma Center, Helios Klinikum Berlin, Berlin, Germany

3256451

CIRCULATING MIRNAS AS BIOMARKERS OF IMATINIB RESISTANCE IN GIST- LIQUID BIOPSIES AND FUNCTIONAL VALIDATION

Giovanni Grignani¹; Maria Laura Centomo¹; Alessandra Merlini¹; Valentina Martin¹; Giulia Chiabotto²; Enrico Berrino²; Tiziana Venesio³; Anna Sapino³; Massimo Aglietta¹; Lorenzo D'Ambrosio¹;

Ymera Pignochino¹

¹Sarcoma Unit, Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy; ²Medical Sciences, University of Turin, Torino, Italy; ³Unit of Pathology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy

Poster Presentations Listing

3258000

AVAPRITINIB FOR THE TREATMENT OF GIST: ANALYSIS OF EFFICACY, SAFETY, AND PATIENT MANAGEMENT STRATEGIES AT THE RECOMMENDED PHASE 2 DOSE

Cissimol Joseph¹; Sarah Abaricia²; Michelle Angelis³; Suzanne George⁴; Robin L. Jones⁵; Yoon-Koo Kang⁶; Richard F. Riedel⁷; Patrick Schöffski⁸; César Serrano⁹; Jonathan C. Trent¹⁰; Tuan Dong Si¹¹; Teresa Zhou¹¹; Ashley Doyle¹¹; Maria Roche¹¹; Tracy Havnaer¹²

¹University of Texas MD Anderson Cancer Center, Houston, TX, USA; ²Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA; ³Ohio State University Wexner Medical Center, Columbus, OH, USA; ⁴Dana Farber Cancer Institute, Boston, MA, USA; ⁵Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; ⁶Asan Medical Centre, Seoul, Korea (the Democratic People's Republic of); ⁷Duke Cancer Institute, Durham, NC, USA; ⁸University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; ⁹Vall d'Hebron Institute of Oncology, Barcelona, Spain; ¹⁰Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA; ¹¹Blueprint Medicines Corporation, Cambridge, MA, USA; ¹²OHSU Knight Cancer Institute, Portland, OR, USA

3231084

A DANISH PROSPECTIVE STUDY INCLUDING LIQUID BIOPSIES, PLASMA CONCENTRATION OF TYROSINE KINASE INHIBITORS (TKIS) AND QUALITY OF LIFE IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST)

Charlotte M. Brinch¹; Ninna Aggerholm-Pedersen⁵; Pieter de Heer⁴; Malene Møller Jørgensen³; Adile Orhan¹; Estrid Høgdall²; Anders Krarup-Hansen¹

¹Department of Oncology, Herlev & Gentofte Hospital, Herlev, Denmark; ²Department of Pathology, Herlev & Gentofte Hospital, Herlev, Denmark; ³Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark; ⁴Department of Surgical Gastroenterology, Rigshospitalet, Copenhagen, Denmark; ⁵Department of Oncology, Aarhus University Hospital, Aarhus, Denmark

3253856

PROTEIN EXPRESSION ANALYSIS BY REGULATING C-KIT AND KCTD12 EXPRESSION IN GASTROINTESTINAL STROMAL TUMOR

Keita Sasa¹; Yoshiyuki Suehara¹; Taketo Okubo¹; Takuo Hayashi²; Kei Sano¹; Taisei Kurihara¹; Keisuke Akaike¹; Midori Ishii¹; Youngji Kim¹; Kazuo Kaneko¹; Tsuyoshi Saito²

¹Orthopedic Surgery, Juntendo University, Tokyo, Japan; ²Human Pathology, Juntendo University, Tokyo, Japan

3246597

TYK2 PROMOTES MALIGNANT PERIPHERAL NERVE SHEATH TUMOR PROGRESSION THROUGH INHIBITION OF CELL DEATH

Xiaochun Zhang, MD; Wenjing Qin; Abigail Godec; Angela Hirbe

Internal Medicine/Oncology, Washington university, Saint Louis, MO, USA

3253528

GENOME ENGINEERING OF DISEASE SPECIFIC CELL TYPES REVEALS HIDDEN VULNERABILITIES AND NEW THERAPEUTIC APPROACHES FOR TREATMENT OF NEUROFIBROMATOSIS TYPE-1 RELATED CANCER

Kyle B. Williams, PhD¹; Bryant Keller²; Alex Larsson²; Christopher L. Moertel¹; David A. Largaespada¹

¹Pediatrics, University of Minnesota Masonic Cancer Center, Minneapolis, MN, USA;

²Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA

Poster Presentations Listing

3256376

ROLE OF FDG PET-CT IN MALIGNANT PERIPHERAL NERVE SHEET TUMOR (MPNST)

Shamim A. Shamim, MD¹; Divya Yadav¹; Sameer Rastogi²; Adarsh Barwad³; Ekta Dhamija⁴; Rambha Pandey⁵; Shah Alam Khan⁶; Venkatesan Sampat Kumar⁶

¹Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, Delhi, India;

²Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, Delhi, India;

³Department of Pathology, All India Institute of Medical Sciences, New Delhi, Delhi, India; ⁴Department of Radiology, All India Institute of Medical Sciences, New Delhi, Delhi, India; ⁵Department of Radiotherapy, All India Institute of Medical Sciences, New Delhi, Delhi, India; ⁶Department of Orthopedics, All India Institute of Medical Sciences, New Delhi, Delhi, India

3257924

ACTIVITY OF NEO-ADJUVANT CHEMOTHERAPY ALONE OR COMBINED WITH RADIATION-THERAPY IN SPORADIC VERSUS NF1-RELATED MPNST IN THE CONTEXT OF TWO INTERNATIONAL, PHASE III, RANDOMIZED CLINICAL TRIALS IN LOCALIZED HIGH-RISK SOFT TISSUE SARCOMA

Elena Palassini¹; Sara Pizzamiglio¹; Emanuela Palmerini²; Vittorio Quagliuolo³; Javier Martin-Broto⁴; Antonio Lopez-Pousa⁵; Giovanni Grignani⁶; Antonella Brunello⁷; Jean-Yves Blay⁸; Roberto D. Beveridge⁹; Virginia Ferraresi¹⁰; Iwona Lugowska¹¹; Angela Buonadonna¹²; Alessandro Comandone¹³;

Giuseppe Bianchi²; Paolo Verderio¹; Domenico Merlo¹⁴; Valeria Fontana¹⁵; Emanuela Marchesi²;

Silvia Stacchiotti¹; Angelo Paolo Dei Tos¹⁶; Piero Picci²; Paolo Bruzzi¹⁵; Paolo Casali¹; Alessandro Gronchi¹

¹IRCCS Fondazione Istituto Nazionale Tumori, Milan, Italy; ²Istituto Ortopedico Rizzoli, Bologna, Italy;

³Istituto Clinico Humanitas, Milano, Italy; ⁴Institute of Biomedicine Research (IBIS)/CSIC/Universidad de Sevilla, Seville, Spain; ⁵Hospital Sant Pau, Barcelona, Spain; ⁶Istituto di Candiolo-Fondazione del

Piemonte per l'Oncologia IRCCS Candiolo, Torino, Italy; ⁷Istituto Oncologico Veneto IOV-IRCCS,

Padova, Italy; ⁸Centre Léon Bérard, Lyon, France; ⁹University Hospital La Fe, Valencia, Spain; ¹⁰Regina

Elena National Cancer Institute, Roma, Italy; ¹¹Maria Sklodowska-Curie Institute - Oncology Center,

Warsaw, Poland; ¹²Centro di Riferimento Oncologico di Aviano (C.R.O)-IRCCS, Pordenone, Italy;

¹³Ospedale Humanitas Gradenigo, Torino, Italy; ¹⁴IRCCS Santa Maria Nuova, Reggio Emilia, Italy;

¹⁵IRCCS Azienda Ospedaliera Universitaria San Martino-IST Istituto Nazionale per la Ricerca sul Cancro,

Genova, Italy; ¹⁶General Hospital of Treviso, Treviso, Italy

3253329

EVALUATION OF CANCER-TESTIS ANTIGENS IN OSTEOSARCOMA AND DEDIFFERENTIATED LIPOSARCOMA AS TARGETS FOR IMMUNOTHERAPY

Ashley Flaman, MD¹; Anna Jirovec¹; Bibiana Purgina⁴; Fanny Tzelepis²; Joel Werier³;

Jean-Simon Diallo²

¹Pathology and Laboratory Medicine, University of Ottawa, Ottawa, ON, Canada; ²Centre for Innovative

Cancer Research, Ottawa Hospital Research Institute, Ottawa, ON, Canada; ³Orthopedic Surgery,

The Ottawa Hospital, Ottawa, ON, Canada; ⁴Pathology and Laboratory Medicine, The Ottawa Hospital,

Ottawa, ON, Canada

3223596

PROGNOSTIC SIGNIFICANCE OF PD-L1 EXPRESSION AND MICROSATELLITE INSTABILITY IN PATIENTS WITH RETROPERITONEAL LEIOMYOSARCOMAS

Vladislav Bugaev¹; Maxim Nikulin¹; Natalia Posphehova²; Safronova Vera²; Kokosadze Natalia³;

Yana Bozhchenko³; Sergey Nered¹; Ludmila Lyubchenko²; Ivan Stilidi¹

¹Abdominal Oncology, N.N. Blokhin National Cancer Research Center, Moscow, Russian Federation;

²Laboratory of Clinical Oncogenetics, N.N. Blokhin National Cancer Research Center, Moscow, Russian

Federation; ³Department of Human Tumor Pathological Anatomy, N.N. Blokhin National Cancer

Research Center, Moscow, Russian Federation

Poster Presentations Listing

3252978

CTNNB1 MUTATIONS AND AGGRESSIVE BEHAVIOR IN NEUROMUSCULAR CHORISTOMA-ASSOCIATED FIBROMATOSIS

Jodi M. Carter, MD, PhD; Andres Maldonado; Matthew Howe; Robert J. Spinner
Mayo Clinic, Rochester, MN, USA

3256176

MALIGNANT TRANSFORMATION OF LIPOSCLEROSING MYXOFIBROUS TUMOR: A CASE REPORT

Yoshihiro Araki¹; Norio Yamamoto¹; Katsuhiko Hayashi¹; Akihiko Takeuchi¹; Shinji Miwa¹; Kentaro Igarashi¹; Yuta Taniguchi¹; Hirotaka Yonezawa¹; Sei Morinaga¹; Takayuki Nojima²; Hiroyuki Tsuchiya¹

¹Orthopaedic Surgery, Kanazawa University Hospital, Kanazawa, Japan; ²Pathology, Kanazawa University Hospital, Kanazawa, Japan

3239164

AN ANALYSIS OF THE STAGE AT PRESENTATION AND OUTCOMES OF PEDIATRIC PATIENTS WITH OSTEOSARCOMA IN CANADA

Michael Horkoff, MD¹; Joseph K. Kendal²; Christopher Blackmore³; Tony H. Truong⁴; Gregory M. Guilcher⁴; Mary E. Brindle⁵

¹General Surgery, University of Calgary, Calgary, AB, Canada; ²Orthopaedic Surgery, University of Calgary, Calgary, AB, Canada; ³Pediatric Surgery, Dalhousie University, Halifax, NS, Canada; ⁴Oncology, Alberta Children's Hospital, Calgary, AB, Canada; ⁵Pediatric Surgery, Alberta Children's Hospital, Calgary, AB, Canada

3253373

A RETROSPECTIVE STUDY OF GEMCITABINE AND DOCETAXEL FOR RELAPSED OR REFRACTORY PEDIATRIC OSTEOSARCOMA AND SOFT TISSUE SARCOMAS

Miho Nakajima¹; Ayumu Arakawa¹; Naonori Kawakubo²; Kayoko Tao¹; Masanaka Sugiyama¹; Sae Ishimaru¹; Nami Shirakawa¹; Tadashi Kumamoto¹; Akira Kawai³; Chitose Ogawa¹

¹Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan; ²Pediatric Surgery, National Cancer Center Hospital, Tokyo, Japan; ³Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital, Tokyo, Japan

3255166

EVALUATION OF THE ANTIBODY-DRUG CONJUGATE ABBV-085 TARGETING LRRC15 IN THE PEDIATRIC PRECLINICAL TESTING CONSORTIUM OSTEOSARCOMA IN VIVO MODELS

Jonathan B. Gill²; Michael Roth²; Douglas Harrison²; Wendong Zhang²; Beverly Teicher¹; Stephen Erickson³; Malcolm Smith¹; Edward A. Kolb²; Richard Gorlick²

¹National Cancer Institute, Bethesda, MD, USA; ²MD Anderson, Houston, TX, USA; ³RTI International, Research Triangle Park, NC, USA

3255278

EXPLORING THE TP53 AXIS AS A THERAPEUTIC VULNERABILITY IN SYNOVIAL SARCOMA

Mushtaq Muhammad¹; Jennifer Wilson¹; Jamie Yu²; Ian Lock³; Toshihiko Nishisho^{2,4}; Torsten O. Nielsen²; Kevin B. Jones⁵; **Bertha Brodin, PhD**¹

¹Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet; ²Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; ³Huntsman Cancer Institute, Salt Lake City, Utah; ⁴Department of Orthopedics, Tokushima University Graduate School, Tokushima, Japan; ⁵Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden; ⁵Department of Orthopedics, University of Utah School of Medicine, Salt Lake City, Utah, USA

Poster Presentations Listing

3255557

SALVAGE CHEMOTHERAPY USING IRINOTECAN AND TEMOZOLOMIDE IN PAEDIATRIC, AYA AND ADULT POPULATIONS WITH RELAPSED EWING SARCOMA

Jeremy Lewin¹; Taleb Ismaeel²; Yat Hang To¹; Omar Khzouz²; Iyad Sultan²; Sameer Yaser²; Anoud Zaid Alnsour²; Ramiz Abuhijleh²; Omar Shahin²; Rasha Aldouri²; Samer Salah²

¹Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; ²King Hussein Cancer Centre, Amman, Jordan

3255563

HIGH ENGRAFTMENT RATE OF PEDIATRIC AND YOUNG ADULT BONE AND SOFT-TISSUE SARCOMA PATIENT-DERIVED XENOGRAFTS

Joseph G. Pressey, MD¹; David Milewski²; Brian Turpin¹; Rajaram Nagarajan¹; Neil Johnson³; Roshni Dasgupta⁶; Joel Sorger⁴; John Donovan²; Sara Szabo⁵; Tanya Kalin²

¹CBDI, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; ²Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; ³Radiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; ⁴Orthopedic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; ⁵Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; ⁶Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

3255614

CAN MUSCLE COMPOSITION AND METABOLISM BE USED AS PREDICTORS OF MORTALITY IN PATIENTS WITH EWING SARCOMA OF BONE?

Varun Nukala²; Usama Salem³; Colleen M. Costelloe¹; **Behrang Amini, MD, PhD**¹

¹Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ²Duke University, Durham, NC, USA; ³Diagnostic Radiology, University of Texas Medical Branch, Galveston, TX, USA

3254269

PRESERVING THE PHYSIS IN VERY YOUNG PEDIATRIC PATIENTS WITH LOWER EXTREMITY EWING SARCOMA

Alexander Rothy, MD, MS¹; Karthik Meiyappan¹; Nathan Donaldson²; Sheila Conway¹

¹Orthopaedic Oncology, University of Miami, Miami, FL, USA; ²University of Colorado, Aurora, CO, USA

3256327

ENUMERATION OF CELL SURFACE VIMENTIN POSITIVE CELLS AS A METHOD OF DETECTING TUMOR CELLS IN PEDIATRIC PATIENTS WITH SARCOMA

Long Dao, PhD; Jessica Foglesong; Izhar Batth; Wafik Zaky; Jonathan B. Gill; Diane Liu; Aisha Albert; Nancy Gordon; Winston Huh; Douglas Harrison; Cynthia Herzog; Eugenie Kleinerman; Richard Gorlick; Najat C. Daw; Shulin Li

Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

3227605

IDENTIFYING A NEED AND KNOWLEDGE GAP OF OSTEOPATHIC MEDICINE FOR PEDIATRIC SARCOMA PATIENTS

Jennifer A. Belsky, DO, MS¹; Joseph Stanek¹; Cynthia Gerhardt²; Melissa Rose¹

¹Hematology/Oncology, Nationwide Children's Hospital, Columbus, OH, USA; ²The Center for Biobehavioral Health, Nationwide Children's Hospital, Columbus, OH, USA

3253042

OFFERING GNRH AGONISTS FOR FERTILITY PRESERVATION IN FEMALE ADOLESCENT & YOUNG ADULT SARCOMA PATIENTS: A NEW STANDARD OF CARE?

Sharon M. Figliulo; Paul Kent

Pediatric Hematology/Oncology, Rush University Medical Center, Chicago, IL, USA

Poster Presentations Listing

3256229

EVALUATION OF THE TPO-RECEPTOR AGONIST ELTROMBOPAG IN THE PEDIATRIC PRECLINICAL TESTING CONSORTIUM OSTEOSARCOMA IN VIVO MODELS

Michael Roth¹; Grace Nevil⁴; **Jonathan B. Gill**¹; Wendong Zhang¹; Beverly Teicher²; Stephen Erickson³; Malcolm Smith²; Edward A. Kolb¹; Richard Gorlick¹

¹MD Anderson Cancer Center, Houston, TX, USA; ²National Cancer Institute, Bethesda, MD, USA;

³RTI International, Research Triangle Park, NC, USA; ⁴Smith College, Northampton, MA, USA

3229100

CLINICAL FEATURES AND OUTCOMES OF PRIMARY BONE AND SOFT TISSUE SARCOMAS IN ADOLESCENTS AND YOUNG ADULTS

Kazuhiko Hashimoto, MD; Shunji Nishimura; Naohiro Oka; Masao Akagi
Orthopedic Surgery, Kindai University Hospital, Osakasayama, Japan

3254677

FACTORS INFLUENCING SARCOMA ACT EFFICACY

Victoria Coward, Graduate¹; Alice Ko³; Nalan Gokgoz²; Jay Wunder²; Irene L. Andrulis²

¹Molecular Genetics, University of Toronto, Toronto, ON, Canada; ²The Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada; ³Laboratory Medicine and Pathobiology, The University of Toronto, Toronto, ON, Canada

3255443

DISCOVERY OF TARGETED EXPRESSION DATA FOR NOVEL ANTIBODY-BASED AND CHIMERIC ANTIGEN RECEPTOR- BASED THERAPEUTICS IN SOFT TISSUE SARCOMAS USING RNA-SEQ: CLINICAL IMPLICATIONS

Roberto Carmagnani Pestana¹; Jason Roszik¹; David McCall¹; Roman Groisberg³; Shiraj Sen²; Anthony Conley¹; Vivek Subbiah¹

¹MD Anderson Cancer Center, Houston, TX, USA; ²Sarah Cannon, Denver, CO, USA;

³Rutgers Cancer Center, Newark, NJ, USA

3255480

EVALUATING THE POTENTIAL OF TUMOUR INFILTRATING LYMPHOCYTES FOR THE TREATMENT OF ADULT SARCOMA

Alice Ko¹; Minji Lee²; Victoria Coward⁴; Kayley Xu⁵; Nalan Gokgoz²; Brendan Dickson³; Jay Wunder³; Irene L. Andrulis²

¹Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada;

²Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada; ³Mount Sinai Hospital, Toronto, ON, Canada; ⁴Molecular Genetics, University of Toronto, Toronto, ON, Canada; ⁵Queen's University, Kingston, ON, Canada

3256028

PREVALENCE OF GERMLINE VARIANTS AS DETERMINED BY EXPANDED MULTIGENE PANELS IN PATIENTS WITH SOFT TISSUE SARCOMA

Jennifer L. Geurts¹; Erin Strong¹; Austin Livingston¹; Harveshp Mogal¹; T. C. Gamblin¹; Susan Tsai¹; Kathleen Christians¹; Meena Bedi²; John Charlson⁴; John C. Neilson³; David King³;

Callisia N. Clarke, MD, MS¹

¹Surgery, The Medical College of Wisconsin, Milwaukee, WI, USA; ²Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; ³Orthopedic Surgery, Medical College of Wisconsin, Milwaukee, WI, USA; ⁴Medical Oncology, Medical College of Wisconsin, Milwaukee, WI, USA

3256473

GSTP1 EXPRESSION IS PREDICTIVE OF SARCOMA RESPONSE TO DOXORUBICIN BASED CHEMOTHERAPY

John Charlson, MD; Trevor Argall; Aniko Szabo

Medical College of Wisconsin, Wauwatosa, WI, USA

Poster Presentations Listing

3219544

IN SITU CRYO-ABLATION OF DESMOID TUMORS ASSISTED BY 3D MODELLING AND NAVIGATION BY O ARM

Ortal Segal; Ido Druckmann; Yehuda Kollander; Solomon Dadia; Amir Sternheim; Yair Gortzak
The National Unit for Orthopedic Oncology, Tel Aviv Medical Center, Tel Aviv, Israel

3228336

THERAPEUTIC IMPLICATION OF GENOMIC LANDSCAPE OF ADULT METASTATIC SARCOMA

Xiaolan Feng, MD, PhD⁶; Erin Pleasance¹; Eric Zhao¹; Tony Ng²; Jasleen Grewal¹; Mohammad Nissreen²; Sara K. Taylor⁴; Christine Simmons⁵; Srikanthan Amirtha⁵; Rod Rassekh³; Rebecca Deyell³; Yaoqing Shen¹; Emma Titmuss¹; Lim Howard⁵; Daniel Renouf⁶; Karen Gelmon⁵; Stephen Yip²; Steven Jones¹; Marco Marra¹; Janessa Laskin⁵

¹Canada's Michael Smith Genome Sciences Centre, Vancouver, BC, Canada; ²Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; ³Department of Pediatrics, BC Children's Hospital, Vancouver, BC, Canada; ⁴Medical Oncology, BC Cancer-Kelowna, Kelowna, BC, Canada; ⁵Medical Oncology, BC Cancer- Vancouver, Vancouver, BC, Canada; ⁶BC Cancer-Victoria, Victoria, BC, Canada

3245758

EXPLORATORY ANALYSIS OF HYBRID-CAPTURE BASED NEXT-GENERATION SEQUENCING CONFIRMS SUCCINATE DEHYDROGENASE DEFICIENCY AS THE SOLITARY GENOMIC DRIVER IN PARANGLIOMA, PHEOCHROMOCYTOMA, AND GIST

Dean C. Pavlick; Ethan S. Sokol; Garrett Frampton; Vince A. Miller; Jonathan K. Killian
Foundation Medicine, Cambridge, MA, USA

3254176

USING A CROSS-SPECIES PRECISION MEDICINE PIPELINE TO IDENTIFY PROMISING NEW THERAPIES FOR OSTEOSARCOMAS

Sarah M. Hoskinson¹; Alexander L. Lazarides¹; Erdem Altunel¹; Sneha Rao¹; Maya O. Sheth¹; Serene Cheng¹; So Young Kim¹; Kathryn Ware¹; Anika Agarwal¹; Laura Selmic¹; Cindy Eward²; David Hsu¹; Jason Somarelli¹; William Eward¹

¹Duke University, Durham, NC, USA; ²Triangle Veterinary Referral Hospital, Durham, NC, USA

3255682

EWS-FUSION PARTNERS IN SARCOMA AS REVEALED BY "REAL WORLD" GENOMIC SEQUENCING: CLINICAL IMPLICATIONS

David McCall, Doctorate of Medicine²; Jason Roszik¹; Branko Cuglievan²; Joseph A. Ludwig³; Maria A. Zarzour³; Jonathan B. Gill²; J. Andrew Livingston³; Vivek Subbiah⁴

¹Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; ²Pediatric Oncology, University of Texas MD Anderson, Houston, TX, USA; ³Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; ⁴Investigational Cancer Therapeutics, University of Texas MD Anderson, Houston, TX, USA

3229444

SAFETY AND FEASIBILITY OF CIVO PHASE 0 PLATFORM FOR SIMULTANEOUS EVALUATION OF MULTIPLE DRUGS AND DRUG COMBINATIONS IN THE TUMOR MICROENVIRONMENT OF SOFT TISSUE SARCOMA PATIENTS

Kenneth R. Gundle, MD¹; Gary Deutsch⁴; Seth Pollack⁵; Matthew Thompson⁶; Jessica Davis²; Mee-young Lee⁴; Daniel Ramirez⁴; William Kerwin³; Jessica Bertout³; Marc Grenley³; Kimberly Sottero³; Emily Beirne³; Richard Klinghoffer³; Robert G. Maki⁴

¹Orthopaedics & Rehabilitation, Oregon Health & Science University, Portland, OR, USA; ²Department of Pathology, Oregon Health & Science University, Portland, OR, USA; ³Presage Biosciences, Seattle, WA, USA; ⁴Northwell Health, Lake Success, NY, USA; ⁵Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ⁶Department of Orthopaedics and Sports Medicine, University of Washington, Seattle, WA, USA

Poster Presentations Listing

3230261

DIFFERENCES IN RESPONSE WITH PEMBROLIZUMAB IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA BASED ON PROSPECTIVE KNOWLEDGE OF PDL-1 EXPRESSION

Benjamin Powers, MD¹; Elizabeth Friedman⁴; Kyle Sweeney²; Howard Rosenthal²; Vickie Massey³; Laure Dubois⁵

¹Medical Oncology, U of Kansas Cancer Center, Overland Park, KS, USA; ²Orthopedic Surgery, U of Kansas Health System, Overland Park, KS, USA; ³Radiation Oncology, U of Kansas Cancer Center, Overland Park, KS, USA; ⁴Pathology and Laboratory Medicine, U of Kansas Health System, Kansas City, KS, USA; ⁵Pharmacy, U of Kansas Health System, Kansas City, KS, USA

3253907

MOLECULAR THERAPY FOR SOFT TISSUE SARCOMA

Yoichi Naito, MD

Department of Developmental Therapeutics/Breast and Medical Oncology, National Cancer Center Hospital East, Chiba, Japan

3256526

CELL CYCLE CHECKPOINT INHIBITION SYNERGIZES WITH MITOTIC SPINDLE INHIBITION IN LEIOMYOSARCOMA

Eddie Passen²; **Nathan D. Seligson, PharmD¹**; Colin Stets²; Bryce Demoret²; Achal Awasthi²; John Hays²; James L. Patrick²

¹University of Florida, Jacksonville, FL, USA; ²Ohio State University, Columbus, OH, USA

3258092

HIGH-THROUGHPUT DRUG SCREENING OF PATIENT-DERIVED TUMOR ORGANOID FROM OSTEOSARCOMA PULMONARY METASTASES

Jane Yanagawa, MD¹; Noah C. Federman²; Scott D. Nelson³; Sarah M. Dry³; Benjamin J. DiPardo¹; Huyen Nguyen-Thi-Lam⁴; Francis J. Hornicek⁴; Arun Singh⁴; Chmielowski Bartosz⁴; Fritz C. Eilber¹; Anusha Kalbasi⁵; Nicholas M. Bernthal⁴; Alice Soragni⁴

¹Surgery, UCLA, Los Angeles, CA, USA; ²Pediatrics, UCLA, Los Angeles, CA, USA; ³Pathology, UCLA, Los Angeles, CA, USA; ⁴Department of Medicine, Division of Medical Oncology, UCLA, Los Angeles, CA, USA; ⁵Department of Radiation Oncology, UCLA, Los Angeles, CA, USA

3256197

DEVELOPMENT OF AN IN VITRO DRUG PROFILING PLATFORM TO TAILOR PATIENT-SPECIFIC SARCOMA TREATMENTS

Willemjin Breunis; Marco Wachtel; **Beat W. Schaefer, PhD**

Oncology, University Childrens Hospital, Zuerich, Switzerland

3254985

PATIENT-CENTERED CARE AT THE NEW KAROLINSKA UNIVERSITY HOSPITAL SARCOMA CENTER IMPROVED CONTINUITY AND THE ROLE OF THE CONTACT NURSE

Helen Lernerdal

Sarcoma Center, Karolinska University Hospital, Stockholm, Sweden

3256277

A CROSS-SPECIES PERSONALIZED MEDICINE APPROACH TO TREAT LEIOMYOSARCOMA

Sarah M. Hoskinson¹; Sneha Rao¹; Erdem Altunel¹; Wayne Glover¹; Laura Selmic¹; Cindy Eward²; David Hsu¹; William Eward¹; Jason Somarelli¹

¹Duke University, Durham, NC, USA; ²Triangle Veterinary Referral Hospital, Durham, NC, USA

Poster Presentations Listing

3256378

QUANTIFICATION OF SERUM LEVEL OF CIRCULATING DNA AND DNASE I IN LOCALLY ADVANCED AND METASTATIC SYNOVIAL SARCOMA, PILOT STUDY. CORRELATION WITH RESPONSE TO TREATMENT

Jorge L. Martínez Tlahuel, MsC¹; Catalina Trejo²; Enrique Perez²; Eder Arango¹

¹Medical Oncology Department, Instituto Nacional de Cancerología, Mexico City, Mexico;

²Investigation Department, Instituto Nacional de Cancerología, Mexico, Mexico

3241353

PATIENT BURDEN AND MEDICAL CARE OF SARCOMA IN GERMANY: NATIONWIDE COHORT STUDY FOCUSING ON MODIFIABLE DETERMINANTS OF PATIENT-REPORTED OUTCOME MEASURES IN SARCOMA PATIENTS (PROSA) - BASELINE DESCRIPTION

Bernd Kasper, MD, PhD¹; Peter Hohenberger¹; Martin Eichler²; Stephan Richter²; Andreou Dimosthenis³; Daniel Pink⁴; Henriette Golcher⁵; Stephen Fung⁶; Eva Wardelmann⁷; Karin Arndt⁸; Leopold Hentschel⁹; Maria Eberlein-Gonska¹⁰; Martin Bornhäuser⁹; Jochen Schmitt¹²; Markus Schuler¹¹

¹Interdisciplinary Tumor Center, Mannheim University Medical Center, Mannheim, Germany;

²Department of Internal Medicine I, University Hospital and Medical Faculty Carl Gustav Carus, Dresden, Germany; ³Department of General Orthopedics and Tumor Orthopedics, University Hospital Muenster, Münster, Germany;

⁴Department of Hematology, Oncology and Palliative Care, Helios Klinikum Bad Saarow, Bad Saarow, Germany; ⁵Surgical Clinic, University Hospital Erlangen, Erlangen, Germany;

⁶Clinic for General, Visceral and Pediatric Surgery, University Hospital Düsseldorf, Düsseldorf, Germany;

⁷Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany;

⁸Das Lebenshaus e.V., Bad Nauheim, Germany; ⁹University Cancer Center, University Hospital and Medical Faculty Carl Gustav Carus, Dresden, Germany; ¹⁰Department of Quality- and Medical Risk Management, University Hospital and Medical Faculty Carl Gustav Carus, Dresden, Germany;

¹¹Clinic for Oncology, Helios Hospital Emil von Behring, Berlin, Germany; ¹²Center for Evidence-based Healthcare, University Hospital and Medical Faculty Carl Gustav Carus, Dresden, Germany

3253141

DEVELOPING HOLISTIC PERSONALISED MODELS OF REHABILITATION TO OPTIMISE SURVIVORSHIP OUTCOMES AFTER TREATMENT FOR LOWER EXTREMITY SARCOMA – A FEASIBILITY STUDY

Sherron Furtado, PhD¹; Silvia Del Din²; Jan Lecouturier³; Rana Zia Ur Rehman²; Kenneth Rankin⁴; Lynn Rochester²; Craig Gerrand¹

¹JRU, Royal National Orthopaedic Hospital NHS Trust, Stanmore, Greater London, United Kingdom;

²Institute of Neuroscience/Newcastle University, Newcastle Upon Tyne, United Kingdom; ³Institute of Health and Society, Newcastle University, Newcastle Upon Tyne, United Kingdom; ⁴Northern Institute of Cancer Institute, Newcastle University, Newcastle Upon Tyne, United Kingdom

3253147

CAN HOLISTIC PERSONALISED MODELS OF REHABILITATION IMPROVE SURVIVORSHIP OUTCOMES AFTER TREATMENT FOR LOWER EXTREMITY SARCOMAS? A PRELIMINARY EFFICACY STUDY

Sherron Furtado, PhD¹; Silvia Del Din²; Jan Lecouturier⁴; Rana Zia Ur Rehman²; Kenneth Rankin³; Lynn Rochester²; Craig Gerrand¹

¹JRU, Royal National Orthopaedic Hospital NHS Trust, Stanmore, Greater London, United Kingdom;

²Institute of Neuroscience/Newcastle University Institute for Ageing, Campus for Ageing and Vitality, Newcastle University Institute for Ageing, Campus for Ageing and Vitality, Newcastle University, Newcastle Upon Tyne, United Kingdom; ³Northern Institute of Cancer Institute, Newcastle University, Newcastle Upon Tyne, United Kingdom; ⁴Institute of Health and Society, Newcastle University, Newcastle Upon Tyne, United Kingdom

Poster Presentations Listing

3253216

INCORPORATING THE PATIENT VOICE IN SARCOMA RESEARCH: HOW CAN WE ASSESS HEALTH-RELATED QUALITY OF LIFE IN THIS HETEROGENEOUS GROUP OF PATIENTS?

Dide Den Hollander¹; Bernd Kasper²; Martin Eichler³; Marco Fiore⁴; Savtaj Brar¹⁹; Jaklin Eliott⁵; Joshua McDonough⁵; Emma Lidington⁷; Ingrid Desar⁸; Hans Gelderblom¹²; Alessandro Gronchi⁶; Robin L. Jones⁷; Aisha B. Miah⁷; Ioanna Nixon¹³; Antonio Casado¹⁴; Anna Estival¹⁵; Javier Martin-Broto¹⁶; Claudia Panciroli¹⁷; Anastasia Constantinidou¹⁸; Nikolaos Memos¹¹; Hanna Kosela-Paterczyk¹⁰; Armelle Dufresne⁹; Isabelle Ray-Coquard⁹; Winette van der Graaf⁴; **Olga Husson**¹

¹Psychosocial research and Epidemiology, Netherlands Cancer Institute, Amsterdam, NA, Netherlands; ²Sarcoma Unit, Mannheim University Medical Center, Mannheim, Germany; ³Department of Internal Medicine, University Hospital and Medical Faculty Carl Gustav Carus, Dresden, Germany; ⁴Medical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, NA, Netherlands; ⁵School of Public Health, University of Adelaide, Adelaide, South Australia, Australia; ⁶Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ⁷Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom; ⁸Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands; ⁹Medical Oncology, Centre Léon-Bérard, University Claude Bernard Lyon I, Lyon, France; ¹⁰Medical Oncology, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; ¹¹Surgery, Hippokratia General Hospital, Athens, Greece; ¹²Medical Oncology, Leiden University Medical Center, Leiden, Netherlands; ¹³Medical Oncology, The Beatson Cancer Center, Glasgow, United Kingdom; ¹⁴Medical Oncology, Hospital Universitario Clínico San Carlos, Madrid, Spain; ¹⁵Medical Oncology, Institut Catalá d'Oncologia, Barcelona, Spain; ¹⁶Medical Oncology, University Hospital Virgen del Rocío and Institute of Biomedicine of Sevilla, Sevilla, Spain; ¹⁷Medical Oncology, Institut Catalá d'Oncologia (ICO Badalona) – Hospital University Germans Trias i Pujol, c/ Canyet sn, Barcelona, Spain; ¹⁸Medical School University of Cyprus and BoC Oncology Centre, Nicosia, Cyprus; ¹⁹Surgery, Mount Sinai Hospital, Toronto, ON, Canada

3255137

KNOWLEDGE OF PATIENTS WITH SARCOMA FOR THEIR ILLNESS IN AN INDIAN SETTING (KNOWSARC STUDY)

Sameer Rastogi, MD, DM¹⁰; Vishwas Kumar Anand⁸; Nishkarsh Gupta¹; Simran Kaur²; Aditi Aggarwal³; Adarsh Barwad⁴; Rambha Pandey⁵; Ekta Dhamija⁶; Shamim Ahmed Shamim⁷; Venkatesan Sampat Kumar⁹; Shah Alam Khan⁹; Satyajit J. Pawar¹⁰

¹Oncoanaesthesia, AIIMS, Delhi, Delhi, India; ²Physiology, AIIMS, Delhi, Delhi, India; ³Radiation Oncology, NCI, AIIMS, Jhajjar, Delhi, India; ⁴Pathology, AIIMS, Delhi, Delhi, India; ⁵Radiation Oncology, AIIMS, Delhi, D, India; ⁶Radiology, AIIMS, Delhi, Delhi, India; ⁷Nuclear Medicine, AIIMS, Delhi, Delhi, India; ⁸Medical Student 2nd year, AIIMS, Delhi, Delhi, India; ⁹Orthopaedics, AIIMS, Delhi, Delhi, India; ¹⁰Medical Oncology, AIIMS, Delhi, Delhi, India

3255976

MOBILE APPLICATION FOR SARCOMA PATIENTS AND THEIR RELATIVES

Signe Ludvigsen, MProf

The Norwegian Radium Hospital, Oslo, Norway

3256393

PREVALENCE, TEMPORALITY AND ASSOCIATION WITH MORTALITY OF SYMPTOM CLUSTERS AMONG SARCOMA PATIENTS ON SYSTEMIC TREATMENT

Vanessa C. Copeland²; Jennifer Phun²; Kathryn Hammer²; Eve Segal²; Lee Cranmer²; Michael J. Wagner²; Seth Pollack¹; Erin Shade²; **Elizabeth T. Loggers, MD, PhD**¹

¹Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;

²University of Washington, Seattle, WA, USA

Poster Presentations Listing

3256444

HEALTH-RELATED QUALITY OF LIFE IN TENOSYNOVIHEALTH-RELATED QUALITY OF LIFE IN TENOSYNOVIAL GIANT CELL TUMORS (TGCT) PATIENTS IN EUROPE AND US: AN OBSERVATIONAL DISEASE REGISTRY

Julio Lopez Bastida²; Xin Ye¹; Petra Laeis¹; Eva-Maria Fronk¹; John H. Healey³; Silvia Stacchiotti⁴; Emanuela Palmerini⁵; Sebastian Bauer⁶; Nicholas M. Bernthal⁷; Bart Schreuder⁸; Andreas Leithner⁹; Michiel van de Sande¹⁰

¹Daiichi Sankyo, Inc., Basking Ridge, NJ, USA; ²University of Castilla-La Mancha, Castilla-La Mancha, Spain; ³Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁴Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; ⁵IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy; ⁶Sarcoma Center, West German Cancer Center, University Hospital Essen, Essen, Germany; ⁷David Geffen School of Medicine at UCLA, Santa Monica, CA, USA; ⁸Radboud University Medical Center, Nijmegen, Netherlands; ⁹Department of Orthopaedics and Trauma, Medical University of Graz, Graz, Austria; ¹⁰Leiden University Medical Center, Leiden, Netherlands

3258041

HOW BENEFICIAL IS VIDEO SEMINAR FOR SARCOMA PATIENTS?

Yoko Kato¹; Shintaro Iwata¹; Yasushi Goto¹; Water Munakata¹; Taro Shibata¹; Takuro Sakurai¹; Makoto Endo²; Eisuke Kobayashi¹; Emi Noguchi³; Ayumu Arakawa¹; Akihiko Yoshida¹; Fumihiko Nakatani³; Akira Kawai¹; Toshiro Nishida³

¹Rare Cancer Center, National Cancer Center, Tokyo, Japan; ²Kyusyu university, Fukuoka, Japan; ³National Cancer Center Hospital, Tokyo, Japan

3239614

FEMORAL FRACTURE IN PRIMARY SOFT-TISSUE SARCOMA OF THE THIGH AND GROIN TREATED WITH INTENSITY-MODULATED RADIATION THERAPY WITH AND WITHOUT DOSE CONSTRAINTS

Dana Casey¹; Michael Folkert²; Sean Berry¹; Aimee Crago¹; Nicola Fabbri¹; Sam Singer¹; Kaled Alektiar¹

¹Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²UT Southwestern Medical Center, Dallas, TX, USA

3241461

GENOMIC CHARACTERIZATION OF RADIATION-INDUCED SARCOMA USING WHOLE GENOME SEQUENCING

Hak Jae Kim¹; Han Soo Kim²; Ilhan Kim¹; Ji Hyun Chang¹

¹Radiation Oncology, Seoul National University Hospital, Seoul, Korea (the Republic of); ²Orthopedic Surgery, Seoul National University Hospital, Seoul, Korea (the Republic of)

3256155

MODELING GENOMIC ADJUSTED RADIATION DOSE (GARD) IN SOFT TISSUE SARCOMA

George Q. Yang²; Zhigang Yuan²; Kamran Ahmed²; Victoria Rizk¹; Jimmy Caudell²; Javier F. Torres-Roca²; Arash Naghavi²

¹Sarcoma, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; ²Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, AL, USA

3235168

EARLY OUTCOMES OF PREOPERATIVE 5-FRACTION RADIATION THERAPY FOR SOFT TISSUE SARCOMA WITH IMMEDIATE RESECTION

Shireen Parsai³; Joshua M. Lawrenz, MD¹; Scott Kilpatrick²; Brian Rubin²; Nathan Mesko¹; Lukas Nystrom¹; Chirag Shah³; Jacob Scott³

¹Orthopaedic Surgery, Cleveland Clinic, Cleveland Heights, OH, USA; ²Pathology, Cleveland Clinic, Cleveland, OH, USA; ³Radiation Oncology, Cleveland Clinic, Cleveland, OH, USA

Poster Presentations Listing

3239332

EFFICACY OF AN ESOPHAGEAL SPACER FOR HIGH-DOSE SINGLE-FRACTION RADIOSURGERY FOR DE NOVO SPINE CHORDOMA- FIRST EXPERIENCE

Chunzi Jenny Jin¹; Daniela Molena²; Rene Brito³; Mark H. Bilsky⁴; Yoshiya Yamada¹

¹Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Thoracic Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ³Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁴Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

3256255

CLINICAL OUTCOME OF NEOADJUVANT ALTERNATING CHEMORADIOTHERAPY FOR SOFT TISSUE SARCOMAS

Masato Sugawara, MD, PhD; Daiichiro Takahara; Michiaki Takagi

Orthopaedic Surgery, Yamagata University Faculty of Medicine, Yamagata, Japan

3244842

ADJUVANT INTENSITY MODULATED RADIATION THERAPY IN PRIMARY SOFT TISSUE SARCOMA OF THE SUPERFICIAL TRUNK

Minsi Zhang; Aimee Crago; Sam Singer; Kaled Alektiar

Memorial Sloan Kettering Cancer Center, New York, NY, USA

3246554

KAPOSI'S SARCOMA: EXPERIENCE OF A RADIOTHERAPY DEPARTMENT

André Figueiredo; Andre D. Florindo; Diogo Delgado; Helena Pais; Raquel Brás; **Isabel Fernandes**; Virgínia Mareco; André Abrunhosa-Branquinho; Vera Mendonça; Maria F. de Pina
Centro Hospitalar Universitário Lisboa Norte, Lisboa, Lisboa, Portugal

3255340

RETROPERITONEAL SARCOMA PATIENTS TREATED WITH RADIOTHERAPY AFTER R1 SURGERY – A SINGLE CENTER RETROSPECTIVE STUDY

Andre D. Florindo¹; João Ulrich¹; André Figueiredo¹; Raquel L. Brás²; **Isabel Fernandes**²;

Virgínia Mareco¹; André Abrunhosa-Branquinho¹; Vera Mendonça¹; Maria F. de Pina¹

¹Radiation Therapy Department, Centro Hospitalar Lisboa Norte, Lisbon, Portugal;

²Medical Oncology Department, Centro Hospitalar Lisboa Norte, Lisbon, Portugal

3223161

THERAPEUTIC VALUES OF RADIOTHERAPY IN THE TREATMENT OF DESMOID TUMORS

Yoo-Kang Kwak, MD, PhD¹; Chul Seung Kay¹; Yeon Sil Kim²; So Jung Lee¹; Ji Hyun Hong¹;

Eun Young Park²

¹Radiation Oncology, Incheon St. Mary's Hospital, Incheon, Korea (the Republic of);

²Radiation Oncology, Seoul St. Mary's Hospital, Seoul, Korea (the Republic of)

3239881

TARGETING PAX3-FOXO1 ONCOPROTEIN: AN INVESTIGATION OF SMALL MOLECULE INHIBITORS FOR RHABDOMYOSARCOMA

Marilyn Kouassi-Brou; Purushottam Tiwari; Jenny Han; **Aykut Uren, MD**

Oncology, Georgetown University, Washington, DC, USA

3256164

EPIGENETIC CHEMICAL SCREENS TO IDENTIFY NOVEL THERAPEUTIC STRATEGIES FOR RHABDOMYOSARCOMA (RMS)

Yael Babichev¹; Timothy McKinnon²; Richard Marcellus³; Rima Al-awar³; Brendan Dickson⁴;

Abha Gupta⁵; Rebecca Gladdy¹

¹Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada; ²Charles River Laboratories, Montreal, ON, Canada; ³Ontario Institute for Cancer Research, Toronto, ON, Canada; ⁴Mount Sinai Hospital, Toronto, ON, Canada; ⁵The Hospital for Sick Children, Toronto, ON, Canada

Poster Presentations Listing

3256678

CLONAL EVOLUTION OF CHEMOTHERAPY RESISTANT RHABDOMYOSARCOMA VIA MULTIFOCAL GENOMIC ANALYSIS OF PRE-TREATMENT AND TREATMENT-RESISTANT AUTOPSY SPECIMENS

Michael Kinnaman, MD¹; Alvin Makohon-Moore²; Nancy Bouvier²; Dominik Glodzik²; Max Levine²; Ellie Papaemmanuil³; Filemon Dela Cruz¹; Leonard Wexler¹; Andrew Kung¹; Christine Iacobuzio-Donahue⁴
¹Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Sloan Kettering Institute, New York, NY, USA; ³Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁴Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

3256484

INTERIM RESULTS FROM A PHASE I/II TRIAL OF GANITUMAB PLUS DASATINIB IN PATIENTS WITH RELAPSED RHABDOMYOSARCOMA (RMS)

Christine M. Heske¹; Donna Bernstein¹; John Glod¹; Rosie Kaplan¹; Jack Shern¹; Marielle Yohe¹; Andrea Gross¹; Joanne Derdak¹; **Isabel Palacio-Yance**¹; Eva Dombi¹; Markku Miettinen²; Seth Steinberg³; Lee Helman⁴; Brigitte Widemann¹
¹Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA; ²Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA; ³Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA; ⁴Children's Center for Cancer and Blood Diseases, Children's Hospital of Los Angeles, Bethesda, MD, USA

3255404

CELL-CELL INTERACTION IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA

Tomas Barrientos, PhD; Junjie Bao; Benjamin Alman
Orthopaedic Surgery, Duke University Medical Center, Hillsborough, NC, USA

3256145

E-CADHERIN REPRESSES ANCHORAGE-INDEPENDENT GROWTH IN SARCOMAS THROUGH BOTH SIGNALING AND MECHANICAL MECHANISMS

Suzanne Bartholf DeWitt, DVM³; Mohit Kumar Jolly²; Kathryn Ware³; Alexander L. Lazarides¹; David Kerr¹; William Eward¹; Herbert Levine²; Jason Somarelli³
¹Orthopaedic Surgery, Duke University, Durham, NC, USA; ²Center for Theoretical Biological Physics, Rice University, Houston, TX, USA; ³Department of Medicine, Duke University, Durham, NC, USA

3258044

REVIEW OF GENETIC ALTERATIONS IN SARCOMA PATIENTS OF HISPANIC ETHNICITY: ANALYSIS OF 167 PATIENTS, A SINGLE INSTITUTION EXPERIENCE

Emily Jonczak, MD; Junaid Arshad; Dino Fanfan; Jared Cotta; Neha Goel; Jonathan C. Trent; Gina D'Amato
Hematology/Oncology, Sylvester Comprehensive Cancer Center/ University of Miami, Miami, FL, USA

3258096

MUTATIONAL AND BIOMARKER CORRELATIVE ANALYSIS OF MTOR PATHWAY ABERRATIONS IN PATIENTS WITH ADVANCED MALIGNANT PERIVASCULAR EPITHELIOID CELL TUMORS (PECOMA) TREATED WITH NAB-SIROLIMUS: RESULTS FROM AMPECT, AN OPEN-LABEL PHASE 2 REGISTRATION TRIAL

Andrew Wagner²; Mark Dickson³; Vinod Ravi⁴; Richard F. Riedel⁵; Kristen Ganjoo⁶; Brian A. Van Tine⁷; Rashmi Chugh⁸; Lee Cranmer⁹; Erlinda Gordon¹⁰; Jason Hornick¹¹; Heng Du¹¹; Berta Grigorian¹; Anita N. Schmid¹; Shihe Hou¹; Katherine Harris¹; Neil Desai¹; David Kwiatkowski¹¹
¹Aadi Bioscience, Pacific Palisades, CA, USA; ²Dana-Farber Cancer Institute, Boston, CA, USA; ³Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁴MD Anderson Cancer Center, Houston, TX, USA; ⁵Duke Cancer Institute, Durham, NC, USA; ⁶Stanford University, Stanford, CA, USA; ⁷Washington University in Saint Louis, St. Louis, MO, USA; ⁸University of Michigan, Ann Arbor, MI, USA; ⁹Univ Washington/Fred Hutchinson Cancer Res Ctr, Seattle, WA, USA; ¹⁰Sarcoma Oncology Center, Santa Monica, CA, USA; ¹¹Brigham and Women's Hospital, Boston, MA, USA

Poster Presentations Listing

3255343

THE SAINT: RESULTS OF A PHASE 1/2 STUDY OF SAFETY/EFFICACY USING SAFE AMOUNTS OF IPILIMUMAB, NIVOLUMAB AND TRABECTEDIN AS FIRST LINE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA (NCT 03138161)

Erlinda M. Gordon, MD; Victoria Chua-Alcala; Katherine M. Kim; Nicole Angel; Rekha Baby; Ania Moradkhani; Doris M. Quon; Steven Wong; Sant P Chawla M. Inc
Sarcoma Oncology Center, Santa Monica, CA, USA

3255504

INITIAL RESULTS OF A PHASE 1/2 INVESTIGATION OF SAFETY/EFFICACY OF NIVOLUMAB AND ABI-009 (NAB-RAPAMYCIN) IN ADVANCED UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS), LIPOSARCOMA (LPS), CHONDROSARCOMA (CS), OSTEOSARCOMA (OS), AND EWING'S SARCOMA (NCT 03190174)

Erlinda M. Gordon, MD; Victoria Chua-Alcala; Katherine M. Kim; Nicole Angel; Rekha Baby; Doris Quon; Steven Wong; Ania Moradkhani; Sant P Chawla M. Inc
Sarcoma Oncology Center, Santa Monica, CA, USA

3256430

RESPONDER ANALYSIS OF PATIENT-REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS) PHYSICAL FUNCTION (PF) AND WORST STIFFNESS AMONG PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMORS (TGCT) IN THE ENLIVEN STUDY

William D. Tap²; Heather L. Gelhorn³; **Xin Ye**¹; Rebecca Speck³; Emanuela Palmerini⁴; Silvia Stacchiotti⁵; Jayesh Desai⁷; Andrew Wagner⁶; Thierry Alcindor⁸; Kristen Ganjoo⁹; Javier Martin-Broto¹⁰; Qiang Wang¹; Dale E. Shuster¹; Hans Gelderblom¹¹

¹Daichi Sankyo, Inc., Basking Ridge, NJ, USA; ²Memorial Sloan Kettering Cancer Institute, New York, NY, USA; ³Evidera, Bethesda, MD, USA; ⁴IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy; ⁵Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ⁶Dana-Farber Cancer Institute, Boston, MA, USA; ⁷Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; ⁸McGill University, Montreal, QC, Canada; ⁹Stanford Cancer Institute, Stanford, CA, USA; ¹⁰Hospital Universitario Virgen del Rocío, Seville, Spain; ¹¹Leiden University Medical Center, Leiden, Netherlands

3255349

DEVELOPMENT OF RAPID AND COST-EFFECTIVE ASSAY TO DETECT AMPLIFICATION OF CHROMOSOME 12Q13-15 IN WELL DIFFERENTIATED AND DE-DIFFERENTIATED LIPOSARCOMA

Xiu Qing Wang; **Angela Goytain**; Anika Hsu; Tony Ng; Torsten O. Nielsen
Pathology, University of British Columbia and Vancouver Coastal Health Research Institute, Vancouver, BC, Canada

3255331

CLINICAL OUTCOMES IN THE SETTING OF MULTIMODALITY TREATMENT OF PRIMARY ANGIOSARCOMA AND RADIATION-INDUCED ANGIOSARCOMA OF THE BREAST

Emily L. Ryon, MD, MPH¹; Sina Yadegarynia¹; Florou Vaia²; Susan Kesmodal¹; Raphael Yechieli²; Jonathan Trent²; Neha Goel¹
¹Surgical Oncology, University of Miami, Miami, FL, USA; ²Medical Oncology, University of Miami, Miami, FL, USA

3255375

DETECTION OF TRANSLOCATION ASSOCIATED SARCOMAS BY EXON EXPRESSION IMBALANCE AND GENE OVER-EXPRESSION

Angela Goytain; Torsten O. Nielsen; Tony Ng
Pathology, University of British Columbia and Vancouver Coastal Health Research Institute, Vancouver, BC, Canada

Poster Presentations Listing

3255558

RETROSPECTIVE ANALYSIS OF CT VERSUS XR SURVEILLANCE FOR METASTASIS AFTER SURGICAL RESECTION OF LOCALIZED SOFT TISSUE SARCOMA

Hilary Dietz; Cara Cipriano; Douglas McDonald; Brian A. Van Tine; Peter Oppelt; Angela Hirbe
Washington University in St Louis, Saint Louis, MO, USA

3255785

THE PROGNOSTIC INFLUENCE OF HYALURONIC ACID EXPRESSION IN RESECTED SOFT TISSUE SARCOMA

Dersheng Sun; Jihyun Yang; Seorhee Kim
Internal Medicine, Uijeongbu St Mary's Hospital, Uijeongbu City, Korea (the Republic of)

3256055

EVALUATION OF DYSTROPHIN EXPRESSION BY IMMUNOHISTOCHEMISTRY AS A PROGNOSTIC FACTOR IN LEIOMYOSARCOMAS

Raul Teres¹; Ruth Orellana²; Eduard Gallardo³; Isidro Gracia⁴; Ana Peiro⁴; Jose González⁵; Alberto Gallardo²; Sandra Valverde⁶; Jaume Llauger⁶; Diana Hernández⁶; Manuel Fernández⁷; Antonio Lopez-Pousa¹; **Ana Sebio, MD, PhD**¹

¹Medical Oncology, Hospital Santa Creu i Sant Pau, Barcelona, Spain; ²Pathology, Hospital Santa Creu i Sant Pau, Barcelona, Spain; ³Neurology, Hospital Santa Creu i Sant Pau, Barcelona, Spain; ⁴Traumatology, Hospital Santa Creu i Sant Pau, Barcelona, Spain; ⁵General Surgery, Hospital Santa Creu i Sant Pau, Barcelona, Spain; ⁶Radiology, Hospital Santa Creu i Sant Pau, Barcelona, Spain; ⁷Plastic Surgery, Hospital Santa Creu i Sant Pau, Barcelona, Spain

3256112

CLINICAL AND MOLECULAR CHARACTERISTICS AND OUTCOMES OF 59 PATIENTS WITH EXTRASKELETAL MYXOID CHONDROSARCOMA TREATED AT TWO INSTITUTIONS

Benedetta Chiusole⁷; Axel Le Cesne¹; Antonella Brunello⁷; Marco Rastrelli³; Marco Maruzzo⁷; Martina Lorenzi⁷; Rocco Cappellesso²; Paolo Del Fiore³; Marta Sbaraglia⁴; Philippe Terrier⁶; Pietro Ruggieri⁵; Angelo Paolo Dei Tos⁴; Carlo Riccardo Rossi³; Vittorina Zagonel⁷

¹Medical Oncology, Institut Gustave Roussy, Villejuif, Ile-de-France, France; ²Surgical Pathology and Cytopathology Unit, University of Padua, PADOVA, PD, Italy; ³Surgical Oncology, Istituto Oncologico Veneto IRCCS, PADOVA, PD, Italy; ⁴Pathology Department, Azienda ULSS2, TREVISO, TV, Italy; ⁵Orthopedic Clinic, University of Padua, PADOVA, PD, Italy; ⁶Department of Biology and Medical Pathology, Institut Gustave Roussy, Villejuif, Ile-de-France, France; ⁷Medical Oncology 1, Istituto Oncologico Veneto IRCCS, PADOVA, PD, Italy

3256175

NY-ESO-1 TCR T (GSK3377794)– CASE STUDIES – SARCOMA AND MRCLS – CORRELATES OF PREDICTABLE RESPONSE CHARACTERISTICS

Brian A. Van Tine¹; **Sandra P. D'angelo**²; Alex Gyurdieva³; Laura A. Johnson³; David C. Turner³; Jenna Tress³; M. Philip DeYoung³; Yuehui Wu³; Aisha N. Hasan³; Dejka Araujo⁴

¹Washington University, St. Louis, MO, USA; ²Memorial Sloan Kettering Cancer Center, New York, NY, USA; ³GlaxoSmithKline, Collegeville, PA, USA; ⁴MD Anderson Cancer Center, Houston, TX, USA

3256364

PHASE 1 TRIAL OF NY-ESO-1-SPECIFIC ADOPTIVE T-CELL THERAPY WITH GSK3377794 IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA

Sandra P. D'Angelo, MD⁸; George D. Demetri¹; Brian A. Van Tine²; Mihaela Druta³; John Glod⁴; Warren Chow⁵; Jenna Tress⁶; M. Philip DeYoung⁶; Aisha N. Hasan⁶; Yuehui Wu⁶; David C. Turner⁶; Dan Schramek⁶; Ran Ji⁶; Alex Gyurdieva⁶; Dejka Araujo⁷

¹Dana Farber Cancer Institute, Boston, MA, USA; ²Washington University in St. Louis, St. Louis, MO, USA; ³H. Lee Moffitt Cancer Center, Tampa, FL, USA; ⁴National Cancer Institute, Bethesda, MD, USA; ⁵City of Hope Comprehensive Cancer Center, Duarte, CA, USA; ⁶GlaxoSmithKline, Collegeville, PA, USA; ⁷University of Texas/MD Anderson Cancer Center, Houston, TX, USA; ⁸Memorial Sloan Kettering Cancer Center, New York, NY, USA

Poster Presentations Listing

3256543

OUTCOME AFTER SURGICAL TREATMENT OF DERMATOFIBROSARCOMA PROTUBERANCE (DFSP): DOES IT REQUIRE ALL THIS FOLLOW-UP? WHAT IS AN ADEQUATE RESECTION MARGIN?

Ibrahim S. Alshaygy; Jean-Camille Mattei; Georges Basile; Anthony Griffin; Rebecca Gladdy; Carol J. Swallow; Brendan Dickson; Peter Ferguson; Jay Wunder
Orthopaedic department, Mount Sinai Hospital, Toronto, ON, Canada

3257861

THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN THE MANAGEMENT OF ANGIOSARCOMA

Emily L. Ryon, MD, MPH¹; Sina Yadegarynia¹; Kristin Kelly¹; Gina D'Amato¹; Matthew Sussman²; Raphael Yechieli²; Andrew Rosenberg²; Dido Franceschi¹; Alan Livingstone¹; Nipun Merchant¹; Jonathan C. Trent²; Neha Goel¹
¹Surgical Oncology, University of Miami, Miami, FL, USA; ²University of Miami, Miami, FL, USA

3257892

ITALIAN SARCOMA GROUP (ISG) - SPANISH SARCOMA GROUP (GEIS) - FRENCH SARCOMA GROUP (FSG) - POLISH SARCOMA GROUP (PSG) CLINICAL TRIAL ON NEO-ADJUVANT CHEMOTHERAPY IN HIGH-RISK SOFT TISSUE SARCOMAS (STS): RESULTS OF NON-RANDOMIZED GROUP OF PATIENTS

Elena Palassini¹; Emanuela Palmerini¹⁴; Vittorio Quagliuolo²; Javier Martin-Broto³; Antonio Lopez-Pousa⁴; Giovanni Grignani⁵; Antonella Brunello⁶; Jean-Yves Blay⁷; Roberto D. Beveridge⁸; Virginia Ferraresi⁹; Iwona Lugowska¹⁰; Domenico Merlo¹¹; Luca Braglia¹¹; Valeria Fontana¹²; Davide M. Donati¹⁴; Andrea Marrari²; Carlo Morosi¹; Silvia Stacchiotti¹; Silvia Baguè¹⁶; Jean M. Coindre¹⁵; Angelo Paolo Dei Tos¹³; Piero Picci¹⁴; Paolo Bruzzi¹²; Paolo Casali¹; Alessandro Gronchi¹
¹IRCCS Fondazione Istituto Nazionale Tumori, Milan, Italy; ²Istituto Clinico Humanitas, Milano, Italy; ³Institute of Biomedicine Research (IBIS)/CSIC/Universidad de Sevilla, Seville, Spain; ⁴Hospital Sant Pau, Barcelona, Spain; ⁵Istituto di Candiolo-Fondazione del Piemonte per l'Oncologia IRCCS Candiolo, Torino, Italy; ⁶Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; ⁷Centre Léon Bérard, Lyon, France; ⁸University Hospital La Fe, Valencia, Spain; ⁹Regina Elena National Cancer Institute, Roma, Italy; ¹⁰Maria Skłodowska-Curie Institute, Warsaw, Poland; ¹¹IRCCS Santa Maria Nuova, Reggio Emilia, Italy; ¹²IRCCS Azienda Ospedaliera Universitaria San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; ¹³General Hospital of Treviso, Treviso, Italy; ¹⁴Istituto Ortopedico Rizzoli, Bologna, Italy; ¹⁵Institut Bergonie, Bordeaux, France; ¹⁶Royal Marsden, London, United Kingdom

3245645

GENETIC ANALYSIS OF SOFT TISSUE SARCOMAS REVEALS HISTOTYPE-SPECIFIC PATHWAY ALTERATIONS AND POTENTIAL PREDICTORS OF IMMUNOTHERAPY RESPONSE

Benjamin A. Nacev, MD PhD¹; Evan J. Rosenbaum¹; Mrinal M. Gounder¹; Timothy Bowler²; Ciara Kelly¹; Nicholas Socci¹; Mark Dickson¹; Sandra P. D'angelo¹; Mary Louise Keohan¹; Ping Chi¹; Sujana Movva¹; Emily Slotkin¹; Meera Hameed¹; Narasimham Agaram¹; Sam Singer¹; Marc Ladanyi¹; William D. Tap¹
¹Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Memorial Sloan Kettering Cancer Center *present address: Regeneron Pharmaceuticals, New York, NY, USA

3253973

THE ASSOCIATION OF CHEMOTHERAPY AND SURVIVAL IN PATIENTS WITH PRIMARY, LOCALIZED, HIGH-GRADE, EXTREMITY AND TRUNK SOFT TISSUE SARCOMA

Danielle S. Graham, MD, MBA¹; Mykola Onyshchenko⁹; Mark A. Eckardt²; Benjamin DiPardo¹; Srirnam Venigalla³; Nicholas Jackson⁴; Scott Nelson⁵; Bartosz Chmielowski⁶; Arun Singh⁶; Jacob Shabason³; Fritz C. Eilber⁷; Anusha Kalbasi⁸
¹Surgery, University of California, Los Angeles, Los Angeles, CA, USA; ²Surgery, Yale School of Medicine, New Haven, CT, USA; ³Radiation Oncology, University of Pennsylvania Health System, Philadelphia, PA, USA; ⁴Statistics, University of California, Los Angeles, Los Angeles, CA, USA; ⁵Pathology, University of California, Los Angeles, Los Angeles, CA, USA; ⁶Hematology & Oncology, University of California, Los Angeles, Los Angeles, CA, USA; ⁷Surgical Oncology, University of California, Los Angeles, Los Angeles, CA, USA; ⁸Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA; ⁹Hematology & Oncology, Harbor-UCLA, Los Angeles, CA, USA

Poster Presentations Listing

3254426

SAFETY AND EFFICACY OF TAZEMETOSTAT, A FIRST-IN-CLASS EZH2 INHIBITOR, IN PATIENTS WITH EPITHELIOID SARCOMA (ES) (NCT02601950)

Tom Wei-Wu Chen¹; Silvia Stacchiotti²; Patrick Schöffski³; Robin L. Jones¹⁷; Mark Agulnik⁴; Victor Villalobos⁵; Thierry Jahan⁶; Antoine Italiano⁷; George D. Demetri⁸; Gregory M. Cote⁹; Rashmi Chugh¹⁰; Steven Attia¹¹; Abha Gupta¹²; Elizabeth T. Loggers¹³; Brian A. Van Tine¹⁴; Laura Sierra¹⁵; Jay Yang¹⁵; Anand Rajarethinam¹⁵; Mrinal M. Gounder¹⁶

¹National Taiwan University Hospital, Taipei, Taiwan; ²Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; ³University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; ⁴Northwestern Memorial Hospital, Chicago, IL, USA; ⁵University of Colorado, Denver, CO, USA; ⁶University of California, San Francisco, San Francisco, CA, USA; ⁷Institut Bergonie, Bordeaux, France; ⁸Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA, USA; ⁹Massachusetts General Hospital, Boston, MA, USA; ¹⁰Michigan Medicine Comprehensive Cancer Center, Ann Arbor, MI, USA; ¹¹Mayo Clinic in Florida, Jacksonville, FL, USA; ¹²The Hospital for Sick Children and Princess Margaret Cancer Center, Toronto, ON, Canada; ¹³Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ¹⁴Washington University in St. Louis School of Medicine, St. Louis, MO, USA; ¹⁵Epizyme, Cambridge, MA, USA; ¹⁶Memorial Sloan Kettering Cancer Center, New York, NY, USA; ¹⁷The Royal Marsden Hospital and Institute for Cancer Research, London, United Kingdom

3220904

PLOCABULIN, A NOVEL TUBULIN INHIBITOR, HAS ANTITUMOR ACTIVITY IN A PATIENT-DERIVED XENOGRAFT (PDX) MODEL OF CIC-REARRANGED SARCOMA

Yannick Wang¹; Agnieszka Wozniak¹; María José Guillén²; Pablo M. Avilés²; Maria Debiec-Rychter³; Raf Sciot⁴; Patrick Schöffski⁵

¹Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Leuven, Belgium; ²PharmaMar, Madrid, Spain; ³Department of Human Genetics, KU Leuven and University Hospitals Leuven, Leuven, Belgium; ⁴Department of Pathology, KU Leuven and University Hospitals Leuven, Leuven, Belgium; ⁵Laboratory of Experimental Oncology, Department of Oncology, KU Leuven and Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium

3232641

INDIVIDUALIZATION OF FOLLOW-UP IN PATIENTS WITH HIGH-GRADE SOFT TISSUE SARCOMA

Joanna Szkandera³; Maria A. Smolle¹; Michiel van de Sande⁴; Dario Callegaro²; Jay Wunder⁵; Andrew Hayes⁶; Lukas Leitner¹; Marko Bergovec¹; Per-Ulf Tunn⁷; Veroniek van Praag⁴; Joannis Panotopoulos⁸; Madeleine Willegger⁸; Reinhard Windhager⁸; Jakob Riedl³; Michael Stotz³; Armin Gerger³; Martin Pichler³; Sander Dijkstra⁴; Winan van Houdt¹²; Herbert Stöger³; Bernadette Liegl-Atzwanger⁹; Josef Smolle¹⁰; Andreas Leithner¹; Alessandro Gronchi²; Rick Haas¹¹

¹Department of Orthopaedics and Trauma, Medical University of Graz, Graz, Austria; ²Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ³Division of Clinical Oncology, Medical University of Graz, Graz, Austria; ⁴Department of Orthopaedic Surgery, Leiden University Medical Centre, Leiden, Netherlands; ⁵Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada; ⁶Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; ⁷HELIOS Klinikum Berlin-Buch, Berlin, Germany; ⁸Department of Orthopaedics and Traumatology, Medical University of Vienna, Vienna, Austria; ⁹Institute of Pathology, Medical University of Graz, Graz, Austria; ¹⁰Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria; ¹¹Department of Radiotherapy, Leiden University Medical Centre, Leiden, Netherlands; ¹²The Netherlands Cancer Institute, Amsterdam, Netherlands

Poster Presentations Listing

3241036

A PHASE II STUDY OF PAZOPANIB AS FRONT-LINE THERAPY IN PATIENTS WITH NON-RESECTABLE OR METASTATIC SOFT TISSUE SARCOMAS WHO ARE NOT CANDIDATES FOR CHEMOTHERAPY

Angela Hirbe, MD, PhD²; Vanessa Eulo¹; Jingqin Luo¹; Chang In Moon²; Mahesh Seetharam⁴; Jacqui Toeniskoetter²; Tammy Kershner²; Mark Agulnik⁶; Varun Monga³; Mohammad Milhem³; Amanda Parkes⁵; Steven Robinson⁸; Scott Okuno⁷; Steven Attia⁸; Brian A. Van Tine²

¹Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA; ²Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA; ³Internal Medicine, University of Iowa, Iowa City, IA, USA; ⁴Medical Oncology, Mayo Clinic in Arizona, Phoenix, AZ, USA; ⁵Medical Oncology, University of Wisconsin, Madison, WI, USA; ⁶Medical Oncology, Northwestern University, Chicago, IL, USA; ⁷Medical Oncology, Mayo Clinic, Rochester, MN, USA; ⁸Medical Oncology, Mayo Clinic in Florida, Jacksonville, FL, USA

3242737

CONCURRENT PACLITAXEL AND RADIATION THERAPY FOR THE TREATMENT OF CUTANEOUS ANGIOSARCOMA

Prashant Gabani, MD¹; Peter Oppelt²; Ryan Jackson³; Jason Rich³; Jeff Michalski¹; Brian A. Van Tine²; Matthew Spraker¹

¹Radiation Oncology, Washington University in Saint Louis, Saint Louis, MO, USA; ²Medical Oncology, Washington University in Saint Louis, Saint Louis, MO, USA; ³Otolaryngology, Washington University in Saint Louis, Saint Louis, MO, USA

3245787

GLO1 AS NOVEL POTENTIAL TARGET TO OVERCOME TRABECTEDIN RESISTANCE IN SOFT TISSUE SARCOMAS

Francesco Pantano; Sonia Simonetti; Giulia Ribelli; Michele Iuliani; Andrea Napolitano; Daniele Santini; Giuseppe Tonini; **Bruno Vincenzi**
Campus Bio-Medico University, Rome, Italy

3247828

CIRCULATING TUMOR DNA LEVELS PREDICT PARTIAL RESPONSE IN A COHORT OF RELAPSED LEIOMYOSARCOMA PATIENTS

Laura Madanat-Harjuoja¹; Kelly Klega¹; Yao Lu²; Karla Ballman²; David S. Shulman¹; Denise Reinke³; William D. Tap⁴; Suzanne George⁵; **Brian Crompton¹**

¹Pediatric Oncology, Dana-Farber Cancer Institute/ Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA; ²Weill Cornell Medicine, New York, NY, USA; ³Sarcoma Alliance for Research through Collaboration, Ann Arbor, MI, USA; ⁴Sloan Kettering Cancer Center, New York, NY, USA; ⁵Harvard Medical School, Boston, MA, USA

3249535

THE PROGNOSTIC IMPACT OF PULMONARY METASTASECTOMY IN SOFT TISSUE SARCOMA PATIENTS

Teruya Kawamoto¹; Toshihiro Akisue²; Masayuki Morishita³; Hitomi Hara¹; Naomasa Fukase¹; Yohei Kawakami¹; Ikuo Fujita³; Takuya Fujimoto³; Toshiyuki Takemori¹; Shuichi Fujiwara¹; Kazumichi Kitayama¹; Shunsuke Yahiro¹; Ryosuke Kuroda¹

¹Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan; ²Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan, Japan; ³Orthopaedic Surgery, Hyogo Cancer Center, Akashi, Japan

Poster Presentations Listing

3253397

A PHASE IB STUDY OF THE SAFETY AND PRELIMINARY EFFICACY OF LENVATINIB (LENV) PLUS ERIBULIN (ERI) IN ADVANCED ADIPOCYTIC SARCOM (LPS) AND LEIOMYOSARCOM (LMS) (NCT03526679)

Tom Wei-Wu Chen¹; Ruey-Long Hong¹; Rong-Sen Yang²; Chueh-Chuan Yen³; San-Chi Chen¹; Jhe-Cyuan Guo¹; Meng-Chi Hsu¹; Ting-Fang Kung³

¹Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; ²Department of Orthopedic Surgery, National Taiwan University Hospital, Taipei, Taiwan; ³Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan

3253883

SYNERGISTIC ACTIVITIES OF THE HISTONE DEACETYLASE INHIBITORS WITH CONVENTIONAL CYTOTOXIC CHEMOTHERAPIES IN ANGIOSARCOMAS

Yingjun Zhang, Mphil¹; Connie W.C Hui³; C.H Wong²; C.T. Choy¹; Teresa Tse¹; Teresa Tan⁴; SC Sampson Kwan⁵; Herbert H. Loong¹

¹Department of Clinical Oncology, Department of Clinical Oncology, The Chinese University of Hong Kong, Hongkong, China; ²State Key Laboratory in Translational Oncology, The Chinese University of Hong Kong, Hongkong, China; ³Cancer Drug Testing Unit, Department of Clinical Oncology, The Chinese University of Hong Kong, Hongkong, China; ⁴Department of Surgery, The Chinese University of Hong Kong, Hongkong, China; ⁵Faculty of Medicine, The Chinese University of Hong Kong, Hongkong, China

3254568

XENOSARC: PATIENT-DERIVED XENOGRAFT MODELS OF SOFT TISSUE SARCOMA – AN UPDATE ON A PRECLINICAL PLATFORM FOR EARLY DRUG TESTING

Agnieszka Wozniak, PhD¹; Britt Van Renterghem¹; Jasmien Cornillie¹; Yannick Wang¹; Yemarshet K. Gebreyohannes¹; Che-Jui Lee¹; Jasmien Wellens¹; Ulla Vanleeuw¹; Madita Nysen¹; Daphne Hompes²; Marguerite Stas²; Friedl Sinnaeve³; Hazem Wafa³; Baki Topal⁴; Tom Verbelen⁵; Maria Debiec-Rychter⁶; Raf Sciot⁷; Patrick Schöffski¹

¹Laboratory of Experimental Oncology, Department of Oncology and Department of General Medical Oncology, KU Leuven and University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; ²Department of Surgical Oncology, University Hospitals Leuven, Leuven, Belgium; ³Department of Abdominal Surgery, University Hospitals Leuven, Leuven, Belgium; ⁵Department of Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium; ⁶Department of Human Genetics, KU Leuven and University Hospitals Leuven, Leuven, Belgium; ⁷Department of Pathology, KU Leuven and University Hospitals Leuven, Leuven, Belgium

3254669

INVESTIGATING THE CIRCULATING TUMOR DNA AS A BIOMARKER OF CANCER PROGRESSION AND RECURRENCE IN SARCOMA

Nalan Gokgoz, PhD¹; Ainaz Malekoltajari¹; Patrick Prochazka¹; Peter Ferguson²; Jay Wunder¹; Irene L. Andrulis¹

¹Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada; ²University of Toronto Musculoskeletal Oncology Unit, Sinai Health System, Toronto, ON, Canada

3254681

DURABLE RESPONSES TO COMBINATION ANTI-CTLA-4 AND ANTI-PD-1 THERAPY AMONG PATIENTS WITH CHEMOTHERAPY/TYROSINE KINASE INHIBITOR RESISTANT SOFT TISSUE AND BONE SARCOMAS

Andrew L. Pecora¹; Melinda Weber¹; Danielle Blair¹; Eileen Beysel¹; Themba Nyirenda²; Elli Gourna Paleoudis²

¹John Theurer Cancer Center at Hackensack Meridian Health, Hackensack, NJ, USA; ²Hackensack Meridian Health, Hackensack, NJ, USA

Poster Presentations Listing

3254823

LOW-DOSE PREOPERATIVE RADIATION THERAPY, RESECTION, AND REDUCED-FIELD POST-OPERATIVE RADIATION THERAPY FOR SOFT TISSUE SARCOMA

David J. Konieczkowski, MD, PhD¹; Saveli I. Goldberg¹; Kevin Raskin²; Santiago Lozano-Calderon²; John Mullen³; Yen-Lin Chen¹; Thomas DeLaney¹

¹Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; ²Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA, USA; ³Department of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA

3254961

HIGH-THROUGHPUT ANALYSIS OF TRANSCRIPTIONAL STARTING POINT AND IDENTIFICATION OF PROMOTER

Kei Sano¹; Yoshiyuki Suehara¹; Takuo Hayashi²; Taisei Kurihara¹; Keisuke Akaike¹; Akiko Oguchi³; Tatsuya Takagi¹; Youngji Kim¹; Taketo Okubo¹; Yasuhiro Murakawa³; Kazuo Kaneko¹; Tsuyoshi Saito²

¹Orthopaedic Surgery, Juntendo University School of Medicine, Tokyo, Japan; ²Human Pathology, Juntendo University School of Medicine, Tokyo, Japan; ³Institute of Physical and Chemical Research, Kanagawa, Japan

3255113

TRABECTEDIN WITH CONCURRENT LOW-DOSE OF RADIATION THERAPY FOR METASTATIC SOFT TISSUE SARCOMAS (TRASTS): A MULTICENTER EUROPEAN, SINGLE ARM PHASE II TRIAL OF SPANISH, FRENCH AND ITALIAN SARCOMA GROUPS

Javier Martin-Broto¹; Antoine Italiano²; Rosa Alvarez³; Inmaculada Rincon⁴; Javier Peinado⁴; Paul Sargos²; Ana Alvarez⁵; Pablo Luna⁶; Antonio López Pousa⁷; Andres Redondo⁸; Ignacio Alastuey⁹; Josep Isern¹⁰; Belen Belinchon¹¹; Antonio Gutierrez¹²; Cleofe Romagosa¹³; Marie Karanian¹⁴; Carlo Morosi¹⁵; Jean-Yves Blay¹⁶; Alessandro Gronchi¹⁵; Nadia Hindi¹

¹Medical Oncology, Virgen del Rocio University Hospital, Institute of Biomedicine Research (IBIS)/CSIC/Universidad de Sevilla, Seville, Spain; ²Institut Bergonié, Bordeaux, France; ³Medical Oncology, Hospital Universitario Gregorio Marañón, Madrid, Spain; ⁴Radiation Oncology, Virgen del Rocio University Hospital, Seville, Spain; ⁵Radiation Oncology, Hospital Universitario Gregorio Marañón, Madrid, Spain; ⁶Medical Oncology, Hospital Son Espases, Palma de Mallorca, Spain; ⁷Medical Oncology, Hospital Sant Pau, Barcelona, Spain; ⁸Medical Oncology, Hospital Universitario La Paz- IdiPAZ, Madrid, Spain; ⁹Radiation Oncology, Hospital Son Espases, Palma de Mallorca, Spain; ¹⁰Radiation Oncology, Hospital San Pau, Barcelona, Spain; ¹¹Radiation Oncology, Hospital Univesiario La Paz, Madrid, Spain; ¹²Hospital Son Espases, Palma de Mallorca, Spain; ¹³Hospital Vall d'Hebron, Barcelona, Spain; ¹⁴Pathology Department, Centre Léon Bérard, Lyon, France; ¹⁵Istituto Nazionale dei Tumori, Milan, Italy; ¹⁶Centre Léon Bérard, Lyon, France

Poster Presentations Listing

3255195

ACTIVITY OF CHEMOTHERAPY IN INFLAMMATORY MYOFIBROBLASTIC TUMOUR (IMT): RETROSPECTIVE ANALYSIS WITHIN EUROPEAN REFERENCE CENTRES

Giacomo G. Baldi, MD¹; Mehdi Brahmī²; Jean-Yves Blay²; Elena Cojocaru³; Robin L. Jones³; Olivier Mir⁴; Axel Le Cesne⁴; Daniela Katz⁵; Bruno Vincenzi⁶; Tommaso De Pas⁷; Maria Abbondanza Pantaleo⁸; Giovanni Grignani⁹; Michaela Casanova¹⁰; Andrea Ferrari¹⁰; Anna Maria Frezza¹; Noemi Simeone¹; Alessandro Gronchi¹¹; Angelo Paolo Dei Tos¹²; Marta Sbaraglia¹²; Paola Collini¹³; Carlo Morosi¹⁴; Salvatore Lo Vullo¹⁵; Luigi Mariani¹⁵; Paolo Casali¹; Silvia Stacchiotti¹
¹Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ²Department of Medical Oncology, Centre Leon Berard & Universite Claude Bernard Lyon I, Lyon, France; ³Sarcoma Unit, Royal Marsden NHS Foundation Trust/Institute of Cancer Research, London, United Kingdom; ⁴Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, Paris, France; ⁵Institute of Oncology, Assaf Harofeh Medical Center, Beer Yaakov, Israel; ⁶Department of Medical Oncology, Campus Biomedico University, Rome, Italy; ⁷Division of Medical Oncology for Melanoma and Sarcoma, IEO, European Institute of Oncology IRCCS, Milan, Italy; ⁸Department of Experimental Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy; ⁹Department of Medical Oncology, Sarcoma Unit, Candiolo Institute IRCCS, Candiolo, Turin, Italy; ¹⁰Pediatric Oncology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy; ¹¹Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ¹²Department of Pathology, General Hospital of Treviso, Treviso, Italy; ¹³Soft Tissue and Bone Pathology, Histopathology and Pediatric Pathology Unit, Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ¹⁴Department of Radiology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy; ¹⁵Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy

3255203

IMPROVEMENT IN PATIENT-REPORTED PAIN IN A PHASE III TRIAL OF PEXIDARTINIB (PLX3397) AMONG PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR (TGCT)

William D. Tap⁴; Heather L. Gelhorn²; Xin Ye¹; Rebecca Speck²; Emanuela Palmerini³; Silvia Stacchiotti⁵; Jayesh Desai⁶; Andrew Wagner⁷; Thierry Alcindor⁸; Kristen Ganjoo⁹; Javier Martin-Broto¹⁰; Qiang Wang¹; Dale E. Shuster¹; Hans Gelderblom¹¹
¹Daiichi Sankyo, Inc., Basking Ridge, NJ, USA; ²Evidera, Bethesda, MD, USA; ³IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy; ⁴Memorial Sloan Kettering Cancer Institute, New York, NY, USA; ⁵Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ⁶Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; ⁷Dana-Farber Cancer Institute, Boston, MA, USA; ⁸McGill University, Montreal, QC, Canada; ⁹Stanford Cancer Institute, Stanford, CA, USA; ¹⁰Hospital Universitario Virgen del Rocío, Seville, Spain; ¹¹Leiden University Medical Center, Leiden, Netherlands

3255213

LONG NON-CODING RNA NEAT1 PROMOTES SARCOMA METASTASIS BY REGULATING RNA SPLICING PATHWAYS

Jianguo Huang, PhD¹; Eric Xu¹; Mohit Sachdeva¹; Timothy Robinson¹; Xiaodi Qin¹; Dadong Zhang¹; Kouros Owzar¹; Nalan Gokgoz²; Andrew Seto²; Tomoyo Okada³; Sam Singer³; Irene L. Andrulis²; Jay Wunder²; Alexander Lazar⁴; Brian Rubin⁵; David Kirsch¹
¹Radiation Oncology, Duke University Medical Center, Durham, NC, USA; ²Samuel Lunenfeld Research Institute, Toronto, ON, Canada; ³Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁴MD Anderson Cancer Center, Houston, TX, USA; ⁵Cleveland Clinic, Cleveland, OH, USA

Poster Presentations Listing

3255242

ARE THERE PATIENTS WITH SOFT TISSUE SARCOMA OF TRUNK OR LIMBS WHO MAY NOT BENEFIT FROM RADIATION THERAPY?

A LARGE RETROSPECTIVE STUDY OF THE FRENCH SARCOMA GROUP

Anne Ducassou, MD¹; Amélie Lusque²; Cécile Le Péchoux⁴; Guy Kantor³; Paul Sargos³; Sylvie Helfre⁵; Laurence Moureau Zabotto⁶; Juliette Thariat⁷; Delphine Lerouge⁷; Carmen Llacer⁸; Augustin Mervoyer⁹; Guillaume Vogin¹⁰; Martine Delannes¹; Marie-Pierre Sunyach¹¹

¹Radiation oncology, Institut Claudius Regaud - IUCT-Oncopole, Toulouse, France; ²Biostatistics, Institut Claudius Regaud - IUCT-Oncopole, Toulouse, France; ³Radiation Oncology, Institut Bergonié, Bordeaux, France; ⁴Radiation Oncology, Gustave Roussy, Villejuif, France; ⁵Radiation oncology, Institut Curie Paris, Paris, France; ⁶Radiation Oncology, Institut Paoli Calmettes, Marseille, France; ⁷Radiation Oncology, Centre Francois Baclesse, Caen, France; ⁸Radiation Oncology, Institut du Cancer de Montpellier, Montpellier, France; ⁹Radiation Oncology, Institut de Cancérologie de l'Ouest, Nantes, France; ¹⁰Radiation Oncology, Institut de Cancérologie de Lorraine, Nancy, France; ¹¹Radiation Oncology, Centre Léon Bérard, Lyon, France

3255266

PRIMARY CUTANEOUS SARCOMAS - A RETROSPECTIVE ANALYSIS OF A 10-YEAR PERIOD AT A TERTIARY TEACHING HOSPITAL

Pedro Garrido¹; **Raquel L. Brás, Resident²**; Isabel Fernandes²; L M. Soares-Almeida¹; João Borges-Costa¹

¹Dermatology, Hospital Santa Maria, CHULN, Lisbon, Portugal; ²Medical Oncology, Hospital Santa Maria, CHULN, Lisbon, Portugal

3255287

EFFICACY AND SAFETY OF ANLOTINIB IN REFRACTORY METASTATIC SOFT-TISSUE SARCOMA: A RETROSPECTIVE STUDY IN CHINA

Wei Xiao; Bushu Xu; Xizhi Wen; Jingjing Zhao; Qiuzhong Pan; **Xing Zhang**

Department of Medical Melanoma and Sarcoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

3255311

EFFICACY AND SAFETY OF BEVACIZUMAB COMBINED WITH CHEMOTHERAPY IN REFRACTORY METASTATIC SOFT-TISSUE SARCOMA: A RETROSPECTIVE STUDY IN CHINA

Xizhi Wen; Wei Xiao; Bushu Xu; Jingjing Zhao; Qiuzhong Pan; **Xing Zhang**

Department of Medical Melanoma and Sarcoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

3255449

PERIVASCULAR EPITHELIOID CELL TUMOR (PECOMA) TREATMENT: 20 YEARS OF EXPERIENCE IN ONE REFERENCE SARCOMA CENTER

Tomasz Switaj¹; Anna M. Czarnecka¹; Aleksandra Sobiborowicz²; Katarzyna Jarzebinowska²; Hanna Kosela-Paterczyk¹; Anna Klimczak¹; Michal Wagrodzki³; **Piotr Rutkowski, MD¹**

¹Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland; ²Medical University of Warsaw, Warsaw, Poland; ³Department of Pathology, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland

3255705

SURGICAL RESULTS AND INFLUENTIAL FACTORS FOR COMPLICATIONS AND LIMB FUNCTION IN PATIENTS WITH SOFT TISSUE SARCOMA OF THE THIGH

Sei Morinaga; Norio Yamamoto; Katsuhiko Hayashi; Akihiko Takeuchi; Shinji Miwa; Kentaro Igarashi; Yuta Taniguchi; Hirotaka Yonezawa; Yoshihiro Araki; Hiroyuki Tsuchiya

Department of Orthopaedic Surgery, Graduate School of Medical Science, Kanazawa University, Ishikawa, Japan

Poster Presentations Listing

3256118

POOR TREATMENT OUTCOMES WITH SECOND-LINE CHEMOTHERAPY IN ADULT ADVANCED AND METASTATIC SYNOVIAL SARCOMA

Yuki Kojima, MD, PhD¹; Kan Yonemori¹; Takuji Seo¹; Shu Yazaki¹; Toshihiro Okuya¹; Yohei Ohtake¹; Tadaaki Nishikawa¹; Kazuki Sudo¹; Maki Tanioka¹; Akihiko Shimomura¹; Emi Noguchi¹; Tatsunori Shimoi¹; Akihiko Yoshida²; Akira Kawai³; Yasuhiro Fujiwara¹; Kenji Tamura¹

¹Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; ²Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan; ³Department of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital, Tokyo, Japan

3256204

A CLINICAL RANDOMIZED CONTROLLED TRIAL OF TOTAL (IPSILATERAL) RETROPERITONEAL LIPECTOMY WITH HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY FOR RETROPERITONEAL LIPOSARCOMA

Cheng Li Miao¹; **Shahbaz Hanif, MD²**; Xiao Bing Chen¹; Mei Huang¹; Cheng Hua Luo¹

¹Peking University International Hospital, Beijing, China; ²Beijing Spanal Medical Scientific Co. Ltd., Beijing, China

3256260

DOES RADIOTHERAPY BENEFIT PATIENTS WITH SUPERFICIAL SOFT TISSUE SARCOMAS?

Tomohiro Fujiwara; Yusuke Tsuda; Louis-Romee Le Nail; Scott Evans; Jonathan Stevenson; Michael Parry; Jonathan Gregory; Roger Tillman; Lee Jeys; Adesegun Abudu
Oncology Service, Royal Orthopaedic Hospital, Birmingham, United Kingdom

3256278

PROGNOSTIC ROLE OF INITIAL ELEVATED NEUTROPHIL-LYMPHOCYTE RATIO AND POOR PERFORMANCE STATUS IN SOFT TISSUE SARCOMA

Tatsunori Shimoi; Kan Yonemori; Yuki Kojima; Kazuki Sudo; Tadaaki Nishikawa; Maki Tanioka; Akihiko Shimomura; Emi Noguchi; Yasuhiro Fujiwara; Kenji Tamura
Breast and Medical Oncology, National Cancer Center, Tokyo, Japan

3256317

A PHASE 1B STUDY OF OLARATUMAB PLUS DOXORUBICIN AND IFOSFAMIDE IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA

Jonathan Trent, MD, PhD¹; Neeta Somaiah²; Silvia Stacchiotti³; Peter Reichardt⁴; Hector Soto Parra⁵; Rainer Hamacher⁶; Donna E. Levy⁸; Gary Mo⁷; Ashwin Shahir⁷; Jennifer Wright⁷; Sebastian Bauer⁶
¹Medical Oncology, Sylvester Comprehensive Cancer Center, Miami, FL, USA; ²The University of Texas, MD Anderson Cancer Center, Houston, TX, USA; ³Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ⁴HELIOS Klinikum Berlin Buch, Berlin, Germany; ⁵Oncology Unit, Azienda Ospedaliera Universitaria Policlinico Vittorio Emanuele, Catania, Sicilia, Italy; ⁶West German Cancer Center, University of Duisburg Essen, Essen, Germany; ⁷Eli Lilly and Company, Indianapolis, IN, USA; ⁸Syneos HealthTM, Morrisville, NC, USA

3256374

PROGNOSTIC ROLE OF PRE-TREATMENT NEUTROPHIL-TO-LYMPHOCYTE RATIO IN SOFT TISSUE SARCOMA: A RETROSPECTIVE ANALYSIS

Se Jun Park, MD; Ji-eun Lee; Seunghwan Lee

Internal medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea (the Republic of)

Poster Presentations Listing

3256398

CLINICOPATHOLOGIC PROFILE OF EXTREMITY SOFT TISSUE SARCOMAS TREATED AT NATIONAL CANCER INSTITUTE (MEXICO) FROM 1990-2017

Dorian Yarih Garcia Ortega, MD¹; Alethia Alvarez-Cano²; Claudia Haydee Sarai Caro-Sanchez³; Miguel Angel Clara-Altamirano¹

¹Skin And Soft Tissue Tumors, National Cancer Institute (Mexico), Tlalpan, Mexico City, Mexico;

²Private Practice, Nuevo Leon, Mexico; ³Pathology, National Cancer Institute (Mexico), Mexico City, Mexico

3256405

IVCSARC STUDY: INFERIOR VENA CAVA SARCOMA EXPERIENCE AT A TERTIARY CARE CENTER IN SOUTH INDIA

Beulah R. Samuel, MS¹; Coelho Victor¹; Titus DK¹; Abinaya Nadarajan¹; Suchita Chase¹; Sukria Nayak¹; Vimalin Samuel²; Philip Joseph³; Sitaram V³; Anne J. Prabhu⁴; Patricia Solomon⁵; Ashish Singh⁶

¹General Surgery, Christian Medical College Vellore, Vellore, Tamil Nadu, India; ²Vascular Surgery, Christian Medical College Vellore, Vellore, Tamil Nadu, India; ³HPB Surgery, Christian Medical College Vellore, Vellore, Tamil Nadu, India; ⁴Pathology, Christian Medical College Vellore, Vellore, Tamil Nadu, India; ⁵Radiation Therapy, Christian Medical College Vellore, Vellore, Tamil Nadu, India;

⁶Medical Oncology, Christian Medical College Vellore, Vellore, Tamil Nadu, India

3256503

PHASE 2 STUDY OF ALODOXORUBICIN WITH IFOSFAMIDE/MESNA IN TREATMENT SUBJECTS WITH METASTATIC, LOCALLY ADVANCED, OR UNRESECTABLE SOFT TISSUE SARCOMA

Sant Chawla, MD¹; Victoria Chua-Alcala¹; Doris V. Quon¹; Steven G. Wong¹; Neal Chawla¹; Ania Moradkhani¹; John Lee²; Katherine M. Kim¹; Rekha Baby¹; Erlinda Gordon¹

¹Medical Oncology, Sarcoma Oncology Research Center, Cancer Center of Southern California, Santa Monica, CA, USA; ²NantKwest, Los Angeles, CA, USA

3256549

WHAT CAN YOU EXPECT FROM LYMPH NODE METASTASES IN SOFT TISSUE SARCOMAS?

Georges Basile; Jean-Camille Mattei; Ibrahim S. Alshaygy; Anthony Griffin; Peter Ferguson; Jay Wunder

Orthopedic Surgery, Mount Sinai Hospital, Toronto, ON, Canada

Poster Presentations Listing

3257932

PRELIMINARY DATA ON A PHASE 2 STUDY ON TRABECTEDIN (T) IN ADVANCED RETROPERITONEAL LEIOMYOSARCOMA AND WELL DIFFERENTIATED/DEDIFFERENTIATED LIPOSARCOMA (TRAVELL)

Roberta Sanfilippo, MD¹; Giovanni Grignani²; Bruno Vincenzi³; Tommaso De Pas⁴; Toni Ibrahim⁵; Maria Abbondanza Pantaleo⁶; Antonella Brunello⁷; Giacomo G. Baldi⁸; Alessandro Comandone⁹; Sonia Fatigoni¹⁰; Andrea Marrari¹¹; Alfredo Berruti¹²; Monica Giordano¹³; Michele Guida¹⁴; Giuseppe Badalamenti¹⁵; Angela Buonadonna¹⁶; Marcella Occelli¹⁷; Elena Fumagalli¹; Matilde De Luca¹⁸; Luciano Carlucci¹⁸; Piero Picci¹⁹; Emanuela Marchesi²¹; Angelo Paolo Dei Tos²⁰; Paolo Casali¹

¹Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;

²Department of Medical Oncology Sarcoma Unit, Candiolo Institute IRCCS, Candiolo, Turin, Italy;

³Department of Medical Oncology, Campus Bio-medico University, Rome, Italy; ⁴Oncology Unit of Thymic cancer, Rare Tumors and Sarcomas, European Institute of Oncology IRCCS, Milan, Italy;

⁵Osteo-oncology and rare Tumours Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei

Tumori IRCCS, Meldola-Forlì, Italy; ⁶Department of Experimental, Diagnostic and Specialty Medicine,

University of Bologna, Bologna, Italy; ⁷Department of Medical Oncology, Istituto Oncologico Veneto

IRCCS, Padua, Italy; ⁸Department of Medical Oncology, "Stanto Stefano" Hospital, Prato, Italy;

⁹Department of Cancer Medicine, Presidio Sanitario Gradenigo, Turin, Italy; ¹⁰Department of Medical

Oncology, Azienda Ospedaliera Santa Maria, Terni, Italy; ¹¹Department of Medical Oncology and

Hematology, Humanitas Cancer Center and Research Hospital IRCCS, Rozzano-Milan, Italy;

¹²Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and

Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy; ¹³Department of Medical

Oncology, AZIENDA OSPEDALIERA S. ANNA, Como, Italy; ¹⁴Department of Medical Oncology,

Ospedale Oncologico "Giovanni Paolo II" IRCCS, Bari, Italy; ¹⁵Department of Medical Oncology,

Poliniclinico Universitario P.Giaccone, Palermo, Italy; ¹⁶Department of Medical Oncology, Centro di

Riferimento Oncologico CRO IRCCS, Aviano-Udine, Italy; ¹⁷Department of Medical Oncology, Azienda

Ospedaliera Santa Croce E Carle, Cuneo, Italy; ¹⁸Istituto Ricerche Farmacologiche Mario Negri IRCCS,

Milan, Italy; ¹⁹Laboratory of Experimental Oncology, Institute of Orthopedics Rizzoli, Bologna, Italy;

²⁰Department of Pathology, Civil Hospital of Treviso, Treviso, Italy; ²¹Italian Sarcoma Group Clinical Trial

Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy

3206529

DOXORUBICIN VS DOXORUBICIN+IFOSFAMIDE VS OBSERVATION FOR THE ADJUVANT TREATMENT OF PATIENTS WITH SOFT-TISSUE SARCOMA: AN UPDATED META-ANALYSIS

Lisa M. Hess, PhD; Alan J. Brnabic; Zbigniew Kadziola; Patrick Peterson; Volker Wacheck
Eli Lilly and Company, Indianapolis, IN, USA

3208650

PEXIDARTINIB FOR LOCALLY ADVANCED TENOSYNOVIAL GIANT CELL TUMOR (TGCT): OVERALL LONG-TERM POOLED EFFICACY AND SAFETY WITH CHARACTERIZATION OF HEPATIC ADVERSE REACTIONS FROM ENLIVEN AND OTHER STUDIES

John H. Healey¹; Hans Gelderblom²; Andrew Wagner³; Silvia Stacchiotti⁴; William D. Tap¹; Nicholas M. Bernthal⁵; Sebastian Bauer⁶; Chia-Chi Lin⁷; Laurie D. DeLeve⁸; Emanuela Palmerini⁹; Jayesh Desai¹⁰; Antonio López Pousa¹¹; Arun Singh⁵; Mihaela Druta¹²; Henry H. Hsu¹³; Dale E. Shuster¹⁴; Joseph McGill¹⁴; Qiang Wang¹⁴; James H. Lewis¹⁵; Michiel van de Sande²

¹Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Leiden University Medical Center, Leiden, Netherlands; ³Dana-Farber Cancer Institute, Boston, MA, USA; ⁴Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ⁵David Geffen School of Medicine at UCLA, Santa Monica, CA, USA;

⁶University Hospital Essen, University of Duisburg-Essen, Essen, Germany; ⁷National Taiwan University Hospital, Taipei, Taiwan; ⁸Keck School of Medicine, University of Southern California, Los Angeles, CA,

USA; ⁹IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy; ¹⁰Peter MacCallum Cancer Centre,

Melbourne, Victoria, Australia; ¹¹Hospital de la Santa Creu I Sant Pau, Barcelona, Spain; ¹²Moffitt Cancer

Center, Tampa, FL, USA; ¹³Plexxikon, Berkeley, CA, USA; ¹⁴Daiichi Sankyo, Inc., Basking Ridge, NJ, USA;

¹⁵Georgetown University Hospital, Washington, USA

Poster Presentations Listing

3217271

LONG-TERM OUTCOMES FOR EXTRASKELETAL MYXOID CHONDROSARCOMA (EMC): A POPULATION-BASED ANALYSIS

Michael J. Wagner, MD; Bonny Chau; Lee Cranmer
Medical Oncology, University of Washington, Seattle, WA, USA

3222026

LUNG SURVEILLANCE STRATEGY FOR HIGH-GRADE SOFT TISSUE SARCOMAS: CT SCAN OR CHEST X-RAY?

Adriana C. Gamboa, MD¹; Cecilia G. Ethun¹; Mohammad Y. Zaidi¹; Thuy B. Tran²; George A. Poultsides²; Valerie Grignol³; John H. Howard⁴; Meena Bedi⁵; T. C. Gamblin⁶; Kevin K. Roggin⁷; Konstantinos Chouliaras⁸; Konstantinos Votanopoulos⁸; Darren Cullinan⁹; Ryan C. Fields⁹; Shervin Oskouei¹⁰; David K. Monson¹⁰; Nickolas B. Reimer¹⁰; Shishir K. Maithel¹; Keith A. Delman¹; Kenneth Cardona¹

¹Surgery, Emory University, Atlanta, Georgia; ²Surgery, Stanford University, Palo Alto, CA, USA; ³Surgery, The Ohio State University, Columbus, OH, USA; ⁴Surgery, University of South Alabama, Mobile, AL, USA; ⁵Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; ⁶Surgery, Medical College of Wisconsin, Milwaukee, WI, USA; ⁷Surgery, University of Chicago, Chicago, IL, USA; ⁸Surgery, Wake Forest University, Winston-Salem, NC, USA; ⁹Surgery, Washington University School of Medicine, St. Louis, MO, USA; ¹⁰Orthopedic Surgery, Emory University, Atlanta, GA, USA

3229069

DISEASE RESPONSE WITH PD-1 IMMUNE CHECKPOINT INHIBITOR PEMBROLIZUMAB IN ADVANCED SARCOMA

Steven Bialick, DO; Lee Hartner; Laetitia Simeral
Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia, PA, USA

3239155

CHARACTERISING THE IMMUNE MICROENVIRONMENT IN LIPOSARCOMA, ITS IMPACT ON PROGNOSIS AND THE EFFECT OF RADIOTHERAPY

Hayden Snow¹; Shona Hendry²; Catherine Mitchell¹; Madeleine McKinley¹; Sam Ngan¹; Sarat Chander¹; Julie Chu¹; Susie Bae¹; Jayesh Desai¹; Peter Choong¹; Michael Henderson¹; David Gyorki¹
¹Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; ²St Vincent's Hospital, Melbourne, Victoria, Australia

3239422

SOFT TISSUE SARCOMA SURVIVAL RATES CORRELATE TO T-CELL RECEPTOR AND MUTANT AMINO ACID CHEMICAL COMPLEMENTARITIES

Michelle Yeagley; Boris Chobrutskiy; George Blanck
Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA

3240770

COMBINATION THERAPY WITH TETRAHYDROPYRANYL-ADRYAMICIN (PIRARUBICIN) + IFOSFAMIDE + ETOPOSIDE FOR ADVANCED SOFT TISSUE SARCOMA

Hisaki Aiba¹; Satoshi Yamada¹; Katsuhiro Hayashi²; Hiroaki Kimura²; Shinji Miwa²; Hideki Murakami¹
¹Orthopaedics, Nagoya City University, Nagoya, Aichi, Japan; ²Orthopaedics, Kanazawa University, Kanazawa, Ishikawa, Japan

Poster Presentations Listing

3241734

PHASE 1 STUDY OF DCC-3014 TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS IN PATIENTS WITH MALIGNANT SOLID AND DIFFUSE-TYPE TENOSYNOVIAL GIANT CELL TUMOR

Breelyn Wilky, MD¹; Matthew Taylor²; Todd Bauer³; Steven Leong¹; Ying Su⁴; Cynthia Leary⁵; Xiaoyan Li⁴; Keisuke Kuida⁴; Rodrigo Ruiz Soto⁴; Lara E. Davis⁶

¹Division of Medical Oncology, University of Colorado, Denver, CO, USA; ²Division of Hematology & Medical Oncology, Oregon Health & Science University, Portland, OR, USA; ³Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USA; ⁴Clinical Development, Deciphera Pharmaceuticals, Waltham, MA, USA; ⁵Deciphera Pharmaceuticals, Waltham, MA, USA; ⁶Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA

3253165

EXPANSION COHORT OF ADVANCED SARCOMA PATIENTS IN THE PHASE I TRIAL OF PEMBROLIZUMAB COMBINED WITH ZIV-AFLIBERCEPT

Sabrina Khan¹; Geraldine O'Sullivan Coyne¹; Jennifer Zlott¹; **Lamin Juwara²**; Anita Gobbie-Hurder³; Albiruni Razak⁴; Andrew S. Brohl⁵; Daniel Renouf⁶; Naoko Takebe¹; Arjun Mittra¹; Elad Sharon¹; James Doroshow¹; Stephen Hodi³; Alice Chen¹

¹Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA; ²Clinical Research Directorate/Clinical Monitoring Research Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA; ³Dana-Farber Cancer Institute, Boston, MA, USA; ⁴University Health Network-Princess Margaret Hospital, Toronto, ON, Canada; ⁵Moffitt Cancer Center, Tampa, FL, USA; ⁶BCCA-Vancouver Cancer Centre, Vancouver, BC, Canada

3253225

RARE MULTINUCLEATED GIANT CELLS IN HUMAN ANGIOSARCOMA CONFER WORSE CLINICAL OUTCOMES

Grace Fangmin Tan¹; Timothy Kwang Yong Tay²; Sathiyamoorthy Selvarajan²; Mikio Masuzawa³; Eileen Yi Ling Poon⁵; Nagavalli Somasundaram⁵; Mohamad Farid⁵; **Cedric Chuan-Young NG⁴**; Bin Tean Teh⁴; Jason Yong Sheng Chan⁵

¹Internal Medicine, Singhealth, Singapore, Singapore; ²Division of Pathology, Singapore General Hospital, Singapore, Singapore; ³Kitasato University School of Allied Health Sciences, Tokyo, Japan; ⁴National Cancer Centre Singapore, Singapore, Singapore; ⁵Department of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore

3253280

MULTIDISCIPLINARY INTERVENTION IN RADIATION-ASSOCIATED ANGIOSARCOMA OF THE BREAST: PATTERNS OF RECURRENCE AND RESPONSE TO TREATMENT

Sheena Guram, MBBS¹; Andrea Covelli¹; Anne O'Neill²; David Shultz⁴; Elizabeth Demicco⁵; Abha Gupta³; Rebecca Gladdy¹

¹Surgical Oncology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada; ²Division of Reconstructive Surgery, Mount Sinai Hospital and Princess Margaret Cancer Centre, Department of Surgery, University of Toronto, Toronto, ON, Canada; ³Division of Hematology/Oncology, The Hospital for Sick Children and Princess Margaret Cancer Centre, Toronto, ON, Canada; ⁴Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; ⁵Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada

3254044

POST-NEPHECTOMY OUTCOMES FOLLOWING EN BLOC RESECTION OF PRIMARY RETROPERITONEAL SARCOMA: A MULTICENTER ANALYSIS

Mark Fairweather, MD¹; Heather Lyu¹; Lorenzo Conti²; Dario Callegaro²; Stefano Radaelli²; Marco Fiore²; Deanna Ng³; Carol J. Swallow³; Alessandro Gronchi²; Chan Raut¹

¹Surgery, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA; ²Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ³Surgery, University of Toronto, Toronto, ON, Canada

Poster Presentations Listing

3220630

IMPACT OF SMOKING ON LUNG METASTASIS-FREE SURVIVAL IN SOFT TISSUE SARCOMA PATIENTS

Masatake Matsuoka²; Tamotsu Soma²; Ryuta Arai²; Norimasa Iwasaki¹; Hiroaki Hiraga²

¹Department of Orthopaedic Surgery, Hokkaido University, Sapporo, Japan; ²Department of Musculoskeletal Oncology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan

3225003

EFFICACY AND SAFETY OF TRABECTEDIN FOR PATIENTS WITH UNRESECTABLE AND RELAPSED SOFT TISSUE SARCOMA IN JAPAN: A JAPANESE MUSCULOSKELETAL ONCOLOGY GROUP (JMOG) STUDY

Hiroshi Kobayashi¹; Shintaro Iwata²; Toru Wakamatsu³; Keiko Hayakawa⁴; Junji Wasa⁵; Shigeki Kakunaka⁶; Michiyuki Hakozaki⁷; Takashi Yanagawa⁸; Satoshi Tsukushi⁹; Tsukasa Yonemoto¹⁰; Sakae Tanaka¹; Takafumi Ueda⁶

¹Orthopaedic department, The University of Tokyo Hospital, Tokyo, Japan; ²National Cancer Center Hospital, Tokyo, Japan; ³Osaka International Cancer Institute, Osaka, Japan; ⁴Cancer Institute Hospital of JFCR, Tokyo, Japan; ⁵Shizuoka Cancer Center, Shizuoka, Japan; ⁶National Hospital Organization Osaka National Hospital, Osaka, Japan; ⁷Fukushima Medical University, Fukushima, Japan; ⁸Gunma University Hospital, Gunma, Japan; ⁹Aichi Cancer Center Hospital, Nagoya, Japan; ¹⁰Chiba Cancer Center, Chiba, Japan

3229371

DETECTION OF CSF1 REARRANGEMENTS DELETING THE 3' UTR IN TENOSYNOVIAL GIANT CELL TUMOURS

Julie Ho¹; Brendan Dickson²; Thomas Peters³; David Swanson²; Anita Fernandez³; Marie-Anne Valentin³; Ursula Schramm³; Marc Sultan³; Torsten O. Nielsen¹; **Elizabeth Demicco**²

¹Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC, Canada;

²Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada;

³Novartis Institute for Biomedical Research, Basel, Switzerland

3230868

COMPETING RISKS ANALYSIS OF THE INFERIORITY OF PATIENTS AGED 80 YEARS OR OLDER WITH SOFT TISSUE SARCOMAS

Jungo Imanishi²; Lester Chan²; Peter Choong¹

¹Surgery, University of Melbourne, Melbourne, Victoria, Australia;

²Orthopaedics, St. Vincent's Hospital (Melbourne), Fitzroy, Victoria, Australia

3232627

ABDOMINAL METASTASES OF SOFT TISSUE SARCOMA. INCIDENCE AND OUTCOME IN 769 PATIENTS

Joanna Szkandera²; Maria A. Smolle¹; Angelika J. Schaffler³; Andreas Leithner¹; Veroniek van Praag⁴; Marko Bergovec¹; Bernadette Liegl-Atzwanger⁵; Maya Niethard⁶; Per-Ulf Tunn⁶; Michiel van de Sande⁴; Dimosthenis Andreou⁷

¹Department of Orthopaedics and Trauma, Medical University of Graz, Graz, Austria; ²Division of Clinical Oncology, Medical University of Graz, Graz, Austria; ³Zurich University Hospital, Zurich, Switzerland;

⁴Department of Orthopaedic Surgery, Leiden University Medical Centre, Leiden, Netherlands;

⁵Department of Pathology, Medical University of Graz, Graz, Austria; ⁶HELIOS Klinikum Berlin-Buch, Berlin, Germany;

⁷Department of Orthopaedic Surgery, University Hospital Muenster, Muenster, Germany

Poster Presentations Listing

3236442

PRIMARY RETROPERITONEAL ILIOCAVAL LEIOMYOSARCOMAS: OUTCOME FOLLOWING SURGICAL RESECTION AND THE CALL FOR NOVEL THERAPEUTICS

Chin-Ann J. Ong, MBBS (Singapore), FRCS (Edin), PhD (Cambridge)¹; Nicholas Shannon²; Myles Smith¹; Hayden Snow¹; Andrew Hayes¹; Dirk Strauss¹

¹Sarcoma and Melanoma Unit, Royal Marsden Hospital, London, United Kingdom; ²Division of Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore

3239268

SOFT TISSUE SARCOMAS OF THE TRUNK: CLINICAL OUTCOME AND FACTORS AFFECTING LOCAL RECURRENCE

Hiroshi Hatano¹; Tetsuro Yamagishi¹; Naoki Oike²; Takashi Ariizumi²; Hiroyuki Kawashima²; Akira Ogose³

¹Orthopedic Surgery, Niigata Cancer Center Hospital, Niigata, Niigata, Japan; ²Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Niigata, Japan; ³Orthopedic Surgery, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minami-Uonuma, Niigata, Japan

3240025

OUTCOMES OF ELDERLY PATIENTS WITH SOFT TISSUE SARCOMA OF THE EXTREMITIES

Shane A. Lloyd, MD, PhD¹; Jessica Chew¹; Ross Okimoto²; Amit J. Sabnis³; Eric Nakakura²; Carlos Corvera⁴; Melissa Zimel⁵; Andrew Horvai⁶; Soo-Jin Cho⁶; Rosanna Wustrack⁵; Alex Gottschalk¹; Richard O'Donnell⁵; Thierry Jahan²; Steve Braunstein¹

¹Radiation Oncology, University of California San Francisco, San Francisco, CA, USA; ²Thoracic Oncology, University of California, San Francisco, San Francisco, CA, USA; ³Pediatric Hematology-Oncology, University of California, San Francisco, San Francisco, CA, USA; ⁴Surgical Oncology, University of California, San Francisco, San Francisco, CA, USA; ⁵Orthopaedic Oncology, University of California, San Francisco, San Francisco, CA, USA; ⁶Pathology, University of California, San Francisco, San Francisco, CA, USA

3240767

TYPES OF PNEUMOTHORAX DURING TREATMENT WITH PAZOPANIB FOR SOFT-TISSUE TUMOR

Hisaki Aiba¹; Hiroaki Kimura²; Satoshi Yamada¹; Hideki Murakami¹

¹Orthopaedics, Nagoya City University, Nagoya, Aichi, Japan; ²Orthopaedics, Kanazawa University, Kanazawa, Ishikawa, Japan

3241937

SOFT TISSUE LEIOMYOSARCOMA: RECURRENCE RATE BASED ON TUMOR DEPTH

Elizabeth Wellings; Meagan Tibbo; Peter S. Rose; **Matthew T. Houdek, MD**
Orthopedic Surgery, Mayo Clinic, Rochester, MN, USA

3245414

ERIBULIN SUPPRESSES CLEAR CELL SARCOMA GROWTH BY INHIBITING CELL PROLIFERATION AND INDUCING MELANOCYTIC DIFFERENTIATION BOTH DIRECTLY AND VIA TUMOR VASCULAR REMODELING

Sho Nakai, Medical Doctor¹; Hironari Tamiya²; Yoshinori Imura²; Takaaki Nakai³; Naohiro Yasuda¹; Toru Wakamatsu²; Takaaki Tanaka²; Hidetatsu Outani¹; Satoshi Takenaka¹; Kenichiro Hamada¹; Akira Myouji¹; Nobuhito Araki⁴; Takafumi Ueda⁵; Hideki Yoshikawa¹; Norifumi Naka²

¹Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan; ²Orthopaedic Surgery, Osaka International Cancer Institute, Osaka, Osaka, Japan; ³Orthopaedic Surgery, Kawachi General Hospital, Higashiosaka, Japan; ⁴Orthopaedic Surgery, Ashiya Municipal Hospital, Ashiya, Hyogo, Japan; ⁵Orthopaedic Surgery, Osaka National Hospital, Osaka, Osaka, Japan

Poster Presentations Listing

3250619

RADIOGUIDED CORE NEEDLE BIOPSIES ARE ACCURATE FOR THE DIAGNOSIS OF DEEP ATYPICAL LIPOMATOUS TUMORS OF THE LIMBS: A RETROSPECTIVE STUDY OF 110 CASES FROM A CENTER OF THE FRENCH SARCOMA NETWORK NETSARC

Corinne Bouvier¹; **Alexandra Assolen**¹; Nicolas Macagno¹; Christophe Chagnaud²;

Alexandre Rochwerger³; Xavier Muracciole⁵; Florence Duffaud⁴; Sébastien Salas⁴

¹Pathology, Timone Hospital, Marseille, France; ²Service d'imagerie Médicale, Hôpital de la Conception, Marseille, France; ³Chirurgie Orthopédique, Hôpital Nord, Marseille, France; ⁴Service d'Oncologie Médicale, Hôpital de la Timone, Marseille, France; ⁵Service de Radiothérapie, Hôpital de la Timone, Marseille, France

3252202

SAFETY AND EFFICACY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH ANGIOSARCOMA

Vaia Florou, MD¹; Andrea Espejo¹; Neha Goel²; Andrew Rosenberg³; Breeelyn Wilky¹; Jonathan Trent¹

¹Medicine, University of Miami, Miami, FL, USA; ²Surgery, University of Miami, Miami, FL, USA; ³Pathology, University of Miami, Miami, FL, USA

3252942

OUTCOMES OF ELDERLY PATIENTS WITH SOFT TISSUE SARCOMA IN AN ASIAN TERTIARY CANCER CENTRE

Jiancheng Hong¹; Wei Lin Goh¹; Grace Fangmin Tan⁵; Timothy Kwang Yong Tay²;

Sathiyamoorthy Selvarajan²; Kesavan Sittampalam²; Chin-Ann J. Ong³; Grace Hwei Ching Tan³;

Claramae Shulyn Chia³; Melissa Ching Ching Teo³; Richard Quek⁴; Eileen Yi Ling Poon¹;

Nagavalli Somasundaram¹; Jason Yong Sheng Chan¹; Mohamad Farid¹

¹Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore;

²Department of Anatomical Pathology, Singapore General Hospital, Singapore, Singapore;

³Division of Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore;

⁴Parkway Cancer Centre Singapore, Singapore, Singapore; ⁵Internal Medicine, Singhealth, Singapore, Singapore

3253088

OVERALL SURVIVAL OF PATIENTS WITH SOFT TISSUE SARCOMAS NOT INFLUENCED BY SOCIO-ECONOMIC FACTORS WHEN PATIENTS TREATED AT A LARGE RESEARCH INSTITUTION

Boryana Eastman, MD, PhD¹; Daniel Hippe²; Landon S. Wootton¹; Matthew J. Nyffloat¹;

Matthew Thompson³; Seth Pollack⁴; Edward Kim¹; Matthew Spraker⁵

¹Radiation Oncology, University of Washington, Seattle, WA, USA; ²Radiology, University of Washington, Seattle, WA, USA; ³Orthopaedics and Sports Medicine, University of Washington, Seattle, WA, USA;

⁴Hematology and Oncology, University of Washington, Seattle, WA, USA; ⁵Radiation Oncology,

Washington University, St. Louis, St. Louis, MO, USA

3253172

IMMUNOTHERAPY AND HYPERPROGRESSION IN SOFT TISSUE SARCOMA: A TWO INSTITUTION EXPERIENCE

Anna Chalmers; Shelly Hummert; Vaia Florou

Huntsman Cancer Institute, Salt Lake City, UT, USA

Poster Presentations Listing

3253322

DEMOGRAPHICS, DISEASE CHARACTERISTICS, TREATMENT PATTERNS, RESOURCE UTILIZATION, AND SURVIVAL OF PATIENTS WITH ADVANCED SOFT-TISSUE SARCOMA IN TAIWAN USING THE NATIONAL HEALTH INSURANCE DATABASE

Narayan Rajan¹; Diego Novick²; Wesley Furnback³; Jenny Chang⁴; Rebecca Cheng⁴; Chou Tse-Chih⁵; Chee-Jen Chang⁵; Chueh-Chuan Yen⁶; Bruce Wang³

¹Eli Lilly Australia, West Ryde, New South Wales, Australia; ²Global Health Outcomes Research, Lilly Research Centre, Eli Lilly and Company, Windlesham, United Kingdom; ³Elysia Group Ltd., Taipei, Taiwan; ⁴Eli Lilly & Co. (Taiwan), Taipei, Taiwan; ⁵Clinical Informatics and Medical Statistics Research Center and Graduate Institute of Clinical Medicine, Chang Gung University, Tao-Yuan, Taiwan; ⁶Taipei Veterans General Hospital, Taipei, Taiwan

3253673

THE OUTCOMES OF INTENSIVE COMBINED THERAPY OF ADULT PATIENTS WITH HIGH RISK STAGE III PRIMARY LOCALIZED SYNOVIAL SARCOMA

Katarzyna Kozak; Pawel Teterycz; Hanna Kosela-Paterczyk; Tomasz Switaj; Iwona Lugowska; Tomasz Goryn; Wirginusz Dziewirski; Tadeusz Morysinski; Slawomir Falkowski; **Piotr Rutkowski, MD** Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland

3253904

REAL-WORLD OUTCOMES OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC EPITHELIOID SARCOMA

Mrinal M. Gounder¹; Priscilla Merriam²; Ravin Ratan³; Shreyaskumar Patel³; Rashmi Chugh⁴; Victor Villalobos⁵; Mark Thornton⁶; Brian A. Van Tine⁷; Amr Abdelhamid²; Preeti Joshi⁸; Jennifer Whalen⁸; Jay Yang⁸; Anand Rajarethinam⁸; Mei Sheng Duh⁹; Priyanka J. Bobbili⁹; Cristi L. Cavanaugh⁹; Lynn Huynh⁹; Todor Totev⁹; George D. Demetri¹⁰

¹Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; ³The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA; ⁴University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA; ⁵University of Colorado Cancer Center, University of Colorado, Aurora, CO, USA; ⁶Sarcoma Foundation of America, Damascus, MD, USA; ⁷Washington University School of Medicine, St. Louis, MO, USA; ⁸Epizyme, Cambridge, MA, USA; ⁹Analysis Group, Inc, Cambridge, MA, USA; ¹⁰Dana Farber Cancer Institute and Harvard Medical School and Ludwig Center at Harvard, Boston, MA, USA

3254053

PALLIATIVE RESECTION FOR RETROPERITONEAL SARCOMA: EVALUATION OF POSTOPERATIVE SYMPTOMS AND SURVIVAL

Jason T. Wiseman, MD, MSPH; Stephen Politano; Raphael Pollock; Valerie Grignol Surgical Oncology, The Ohio State University, Columbus, OH, USA

3254467

CLINICAL PRESENTATION, NATURAL HISTORY, THERAPEUTIC APPROACH AND TREATMENT OUTCOME IN PATIENTS WITH SOLITARY FIBROUS TUMOR

Patrick Schöffski⁶; Iris Timmermans⁶; Daphne Hompes²; Marguerite Stas²; Veerle Boecxstaens²; Paul De Leyn⁴; Willy Coosemans⁷; Dirk Van Raemdonck⁷; Esther Hauben⁵; Raf Sciot³; Paul M. Clement¹; Oliver Bechter⁶; Benoit Beuselinck⁶; Feng J. Woei-A-Jin⁶; Herlinde Dumez⁶; Tim Wessels⁶

¹Department of Oncology, KU Leuven, Leuven Cancer Institute, Leuven, Belgium; ²Surgical Oncology Department, University Hospitals Leuven, KU Leuven, Leuven, Belgium; ³University Hospitals Leuven, KU Leuven, Leuven Cancer Institute, Leuven, Belgium; ⁴Department of Thoracic Surgery and CHROMETA, University Hospitals Leuven, KU Leuven, Leuven, Belgium; ⁵Department of Imaging and Pathology, University Hospitals Leuven, KU Leuven, Leuven, Belgium; ⁶Department of General Medical Oncology, University Hospitals Leuven, KU Leuven, Leuven Cancer Institute, Leuven, Belgium; ⁷Department of Thoracic Surgery, University Hospitals Leuven, KU Leuven, Leuven, Belgium

Poster Presentations Listing

3251890

NEOADJUVANT RADIATION AND DUAL CHECK POINT BLOCKADE IN RESECTABLE SOFT TISSUE SARCOMA: INITIAL OUTCOMES IN FIRST 5 PATIENTS ON STUDY

Adrienne Victor, MD¹; Louis Constine³; Susan McDowell²; Peter Prieto⁴; Deepak Sahasrabudhe¹

¹Medical Oncology, University of Rochester, Rochester, NY, USA; ²Orthopedic Oncology, University of Rochester, Rochester, NY, USA; ³Radiation Oncology, University of Rochester, Rochester, NY, USA;

⁴Surgical Oncology, University of Rochester, Rochester, NY, USA

3254560

CLINICAL OUTCOMES OF SOLITARY FIBROUS TUMOR: A SINGLE INSTITUTION EXPERIENCE OF 54 CASES

Yongjune Lee; Jeong Eun Kim; Jin-hee Ahn

Department of Oncology, Asan Medical Center, Seoul, Seoul, Korea (the Republic of)

3254837

POTENTIAL PREDICTORS OF TUMOR RESPONSE TO NEOADJUVANT SYSTEMIC THERAPY IN PATIENTS WITH RETROPERITONEAL SARCOMA – A MULTI-INSTITUTIONAL TARPSWG STUDY

William W. Tseng, MD¹; Francesco Barretta²; Lorenzo Conti³; Markus Albertsmeier⁴; Martin Angele⁴;

Chan Raut⁵; Mark Fairweather⁵; Antonino De Paoli⁶; Frederico Navarria⁶; Piotr Rutkowski⁷;

Jacek Skoczylas⁷; Alessandro Gronchi³

¹Surgery, University of Southern California, Keck School of Medicine, Los Angeles, CA, USA;

²Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ³Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ⁴General, Visceral and

Transplantation Surgery, Ludwig-Maximilians-Universität München, Munich, Germany; ⁵Surgery, Surgical Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School,

Boston, MA, USA; ⁶Radiation Oncology, CRO-IRCCS, National Cancer Institute, Aviano, Italy;

⁷Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska Curie Institute Oncology Center, Warsaw, Poland

3254980

AN EVALUATION OF A MULTI-DISCIPLINARY PRECEPTORSHIP (MDTP) FOR ONCOLOGY TRAINEES IN NATIONAL CANCER CENTRE SINGAPORE (NCCS)

Wei Lin Goh¹; Jiancheng Hong¹; Nagavalli Somasundaram¹; Jason Yong Sheng Chan¹; Mohamad Farid¹;

Tom Wei-Wu Chen⁴; Herbert H. Loong⁵; Richard Quek²; Eileen Yi Ling Poon¹; **Gracieux Y. Fernando³**

¹National Cancer Centre Singapore, Singapore, Singapore; ²Parkway Cancer Centre, Singapore,

Singapore; ³University of the Philippines - Philippine General Hospital and University of the East - Ramon Magsaysay Memorial Medical Center, Manila, Philippines; ⁴National Taiwan University Hospital, Taipei,

Taiwan; ⁵The Chinese University of Hong Kong, Hong Kong, Hong Kong

3254984

COMORBIDITIES IN CASES WITH SOFT TISSUE SARCOMA-IMPACT ON THE COMPLETION OF STANDARD THERAPY AND ONCOLOGICAL OUTCOME

Takeshi Morii

Orthopaedics, Kyorin University, Tokyo, Japan

3255122

LONG-TERM OUTCOMES EFFICACY OF MULTIDISCIPLINARY TREATMENT OF EPITHELIOID SARCOMA

Piotr Rutkowski, MD¹; Pawel Teterycz¹; Jakub Sledz²; Marta Maksymiuk²; Tadeusz Morysinski¹;

Piotr Wisniewski³; Anna M. Czarnecka¹

¹Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland; ²Medical University of Warsaw, Warszawa, Poland;

³Pathology, Maria Sklodowska-Curie Institute - Oncology Center, Warszawa, Poland

Poster Presentations Listing

3255194

EVALUATION OF LATERAL EXTENT OF THE TUMOR INFILTRATION AREA AROUND SUBCUTANEOUS MYXOFIBROSARCOMA BY ULTRASONOGRAPHY

Munenori Watanuki¹; Masami Hosaka²; Kou Hayashi¹; Sinichirou Yoshida¹; Toshihisa Yano¹; Eiji Itoitoi¹
¹Orthopaedic, Tohoku University Hospital, Sendai, Japan; ²Orthopaedics, Miyagi Cancer Center, Natori, Japan

3255214

DERMATOFIBROSARCOMA PROTUBERANS - A UNICENTRIC RETROSPECTIVE ANALYSIS OF A 10-YEAR PERIOD AT A TERTIARY TEACHING HOSPITAL

Raquel L. Brás, Resident¹; Pedro Garrido²; Catarina Quadros³; Isabel Fernandes¹; Dolores Presa³; L M. Soares-Almeida²; Luís Costa¹; João Borges-Costa²
¹Medical Oncology, Hospital Santa Maria, CHULN, Lisbon, Portugal; ²Dermatology, Hospital Santa Maria, CHULN, Lisbon, Portugal; ³Pathology, Hospital Santa Maria, CHULN, Lisbon, Portugal

3255873

FIRST INTERIM RESULTS FROM A GERMAN RETROSPECTIVE STUDY OF SARCOMA PATIENTS TREATED WITH TRABECTEDIN (RETRASARC)

Bernd Kasper, MD, PhD²; Peter Reichardt³; Stephan Richter⁴; Anne Floercken⁵; Christoph K.W Deinzer⁶; Gerlinde Egerer⁷; Philipp Ivanyi⁸; Armin Tuchscherer⁹; Torsten Kessler¹⁰; Markus Schuler¹¹; Christian A. Schmidt¹²; Jeannette Bahr¹²; Till Ittermann¹³; Adrian Richter¹³; Daniel Pink¹
¹Hematology and Oncology, Helios Klinikum Bad Saarow, Bad Saarow, Germany; ²Sarcoma Unit, Interdisciplinary Tumor Center Mannheim,, Mannheim University Medical Center, Mannheim, Germany; ³Department of Oncology and Palliative Care, Helios Klinikum Berlin-Buch, Berlin, Germany; ⁴Department of Internal Medicine I, University Hospital and Medical Faculty Carl Gustav Carus, Dresden, Germany; ⁵Department of Hematology, Oncology, and Tumor Immunology, Charité University, Medicine Berlin, Berlin, Germany; ⁶Division of Hematology and Medical Oncology, Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany; ⁷Department of Hematology, Oncology, and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; ⁸Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany; ⁹Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; ¹⁰Department of Medicine A, University Hospital Münster, Münster, Germany; ¹¹Clinic for Oncology, Helios Hospital Emil von Behring Berlin, Berlin, Germany; ¹²Department of Internal Medicine C- Hematology and Oncology, Stem Cell Transplantation and Palliative Care, University Medicine Greifswald, Greifswald, Germany; ¹³Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany

3256569

DETECTION OF APO10 AND TKTL1 FOR FOLLOW AND POST TREATMENT SCREENING IN SARCOMA PATIENTS

Frank Traub, MD, PhD; Saskia Sachsenmaier; Sabine Schleicher; Evi Schmidt
Orthopaedic Surgery, University of Tuebingen, Tuebingen, Germany

Poster Presentations Listing

3258032

CHEMOTHERAPY IN ADVANCED MALIGNANT PHYLLODES TUMOR (PT) OF THE BREAST: A MULTI-INSTITUTIONAL EUROPEAN RETROSPECTIVE CASE-SERIES ANALYSIS

Elena Palassini¹; Olivier Mir²; Giovanni Grignani⁶; Bruno Vincenzi³; Hans Gelderblom⁴; Ana Sebio Garcia⁵; Giacomo G. Baldi¹; Antonella Brunello⁷; Giovanni Cardellino⁸; Andrea Marrari⁹; Gaetano Apice¹⁰; Giuseppe Badalamenti¹¹; Javier Martin-Broto¹²; Virginia Ferraresi¹³; Paola Poletti¹⁴; Anita Rimanti¹⁵; Salvatore Turano¹⁶; Ithar Gataa²; Paola Collini¹⁷; Angelo Paolo Dei Tos¹⁸; Massimiliano Gennaro¹⁹; Salvatore Provenzano¹; Axel Le Cesne²; Paolo Casali¹

¹Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;

²Department of Cancer Medicine, Gustave Roussy Cancer Campus, Paris, France; ³Department of Medical Oncology, Campus Biomedico University, Rome, Italy; ⁴Department of Medical Oncology, LUMC - Leids Universitair Medisch Centrum, Leiden, Netherlands; ⁵Hospital Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; ⁶Department of Medical Oncology, Sarcoma Unit, Candiolo Institute IRCCS, Candiolo Turin, Italy; ⁷Department of Medical Oncology, Istituto Oncologico Venete IRCCS, Padua, Italy; ⁸Department of Medical Oncology, Azienda Ospedaliera Universitaria Santa Maria della Misericordia, Udine, Italy; ⁹Department of Oncology and Hematology, Humanitas Cancer Center Rozzano, Rozzano Milan, Italy; ¹⁰Dipartimento Melanoma, Tessuti molli, Muscolo-Scheletrico e Testa-Collo, Istituto Nazionale Tumori Pascale, Napoli, Italy; ¹¹Department of Medical Oncology, Azienda Ospedaliera Universitaria Policlinico Carlo Giaccone, Palermo, Italy; ¹²Institute of Biomedicine Research (IBIS)/CSIC/Universidad de Sevilla, Seville, Spain; ¹³Regina Elena National Cancer Institute, Rome, Italy; ¹⁴Department of Medical Oncology, Papa Giovanni XXIII Hospital, Bergamo, Italy; ¹⁵IOM Istituto Oncologico Mantovano, Mantova, Italy; ¹⁶Azienda Ospedaliera Cosenza, Cosenza, Italy; ¹⁷Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ¹⁸Department of Pathology, Treviso Civil Hospital, Treviso, Italy; ¹⁹Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

3231289

GENERATING SOFT TISSUE SARCOMA PATIENT-DERIVED XENOGRAFT (PDX) MODELS FROM CORE-NEEDLE BIOPSY: A PROSPECTIVE CLINICAL TRIAL

Danielle S. Graham¹; **Mark A. Eckardt**²; Bianca Carapia⁹; Jonathan Nakashima³; Benjamin D. Levine⁴; Scott Nelson⁵; Arun Singh⁶; Nicholas M. Bernthal⁷; Fritz C. Eilber⁸

¹Surgery, University of California, Los Angeles, Los Angeles, CA, USA; ²Surgery, Yale School of Medicine, New Haven, CT, USA; ³Certis Oncology, San Diego, CA, USA; ⁴Radiology, University of California, Los Angeles, Los Angeles, CA, USA; ⁵Pathology, University of California, Los Angeles, Los Angeles, CA, USA; ⁶Medicine, Division of Medical Oncology, University of California, Los Angeles, Los Angeles, CA, USA; ⁷Orthopedic Surgery, University of California, Los Angeles, Los Angeles, CA, USA; ⁸Surgery, Division of Surgical Oncology, University of California, Los Angeles, Los Angeles, CA, USA; ⁹Certis Oncology Solutions, San Diego, CA, USA

3240354

ESTABLISHMENT OF A NOVEL HUMAN CIC-DUX4 SARCOMA CELL LINE, KITRA-SRS, WITH AUTOCRINE IGF-1R ACTIVATION AND METASTATIC POTENTIAL TO THE LUNGS

Sho Nakai³; Shutaro Yamada¹; Hidetatsu Outani³; Takaaki Nakai²; Naohiro Yasuda³; Hirokazu Mae³; **Yoshinori Imura**⁴; Toru Wakamatsu⁴; Hironari Tamiya⁴; Takaaki Tanaka⁴; Kenichiro Hamada³; Akira Myoui³; Nobuhito Araki⁵; Takafumi Ueda⁶; Hideki Yoshikawa³; Satoshi Takenaka³; Norifumi Naka⁴

¹Orthopaedic Surgery, Yao Municipal Hospital, Yao, Osaka, Japan; ²Orthopaedic Surgery, Kawachi General Hospital, Higashiosaka, Osaka, Japan; ³Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan; ⁴Musculoskeletal Oncology Service, Osaka International Cancer Institute, Osaka, Japan; ⁵Orthopaedic Surgery, Ashiya Municipal Hospital, Ashiya, Japan; ⁶Orthopaedic Surgery, Osaka National Hospital, Osaka, Japan

Poster Presentations Listing

3241614

CONTINUOUS INFUSIONAL IFOSFAMIDE FOR MANAGEMENT OF SOFT-TISSUE AND BONE SARCOMA: A SINGLE CENTRE RETROSPECTIVE COHORT ANALYSIS

Thomas Carter, MBChB, PhD; Marina Milic; Joanna McDerra; Vasilios Karavasilis; Maria Michelagnoli; Rachael Windsor; Beatrice Seddon; Jeremy Whelan; Palma Dileo; Sandra J. Strauss
Department of Oncology, University College London Hospital, London, United Kingdom

3247644

INFLAMMATORY TYPE UNDIFFERENTIATED PLEOMORPHIC SARCOMA TREATED WITH DOXORUBICIN, IFOSFAMIDE AND PREDNISOLONE. REPORT OF TWO CASES

Shigeki Kakunaga, MD, PhD; Ikuo Kudawara; Takafumi Ueda
Department of Orthopaedic Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan

3248538

BCOR SARCOMAS: A CASE SERIES WITH A NEWBCOR/CCNB3 FUSION GENE VARIANT

Anastasios Kyriazoglou¹; Louisa Mahaira²; Alexandra Papakosta²; Flora Zagouri¹; Michalis Liontos¹; Dimitra Michali²; Natalia Tourkantonis³; Amalia Patereli⁴; Kaliopi Stefanaki⁴; Efthymios Dimitriadis²; Meletios Athanasios Dimopoulos¹; Antonis Kattamis³

¹Department of Clinical Therapeutics, Alexandra General Hospital, Athens, Greece, Athens, Greece;

²Genetics, Aghios Savvas Hospital, Athens, Greece; ³Pediatrics Oncology, Aghia Sofia Children's Hospital, Athens, Greece; ⁴Pathology Department, Aghia Sofia Children's Hospital, Athens, Greece

3252967

HEPATIC METASTASES FROM SOFT TISSUE SARCOMA

Masanori Okamoto, MD, PhD; Masatake Matsuoka; Tamotsu Soma; Ryuta Arai; Hiroaki Hiraga
Sarcoma Service, National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan

3253032

RETROSPECTIVE ANALYSIS OF ADJUVANT TREATMENT FOR LOCALIZED, OPERABLE UTERINE LEIOMYOSARCOMA

Jomjit Chantharasamee, MD¹; Karlton Wong¹; Pasathorn Potivongsajarn²; Joshua Cohen³; Bartosz Chmielowski¹; Sandra Brackert¹; Anusha Kalbas⁴; Neda Motamed²; Jianyu Rao²; Scott Nelson²; Arun Singh¹

¹Hematology/Oncology, University of California, Los Angeles, Los Angeles, CA, USA; ²Department of Pathology, University of California, Los Angeles, Los Angeles, CA, USA; ³Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Los Angeles, Los Angeles, CA, USA; ⁴Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA

3253257

ASSOCIATIONS BETWEEN TREATMENT PATTERNS AND DISTANCE TO TREATING FACILITY AMONG PATIENTS WITH SOFT TISSUE SARCOMA OF THE EXTREMITY

Ambria S. Moten¹; Margaret von Mehren²; Sanjay Reddy²; Krisha Howell²; Elizabeth Handorf²;
Jeffrey Farma²

¹Surgery, Temple University Hospital, Philadelphia, PA, USA;

²Fox Chase Cancer Center, Philadelphia, PA, USA

3253345

BRAIN METASTASIS FROM SARCOMA

Toshiyuki Takemori¹; Teruya Kawamoto²; Masayuki Morishita³; Ikuo Fujita³; Hitomi Hara²; Yohei Kawakami²; Shuichi Fujiwara²; Kazumichi Kitayama²; Shunsuke Yahiro²; Takuya Fujimoto³; Ryosuke Kuroda²; Toshihiro Akisue²

¹Shinsuma Hospital, Kobe, Japan; ²Kobe University Graduate School of Medicine, Kobe, Japan;

³Hyogo Cancer Center, Akashi, Japan

Poster Presentations Listing

3253682

IDENTIFYING TUMOR SPECIFIC ANTIGENS IN SARCOMA PATIENTS WITH TUMOR REACTIVE T-CELLS: AN ANALYSIS OF MUTATIONS, NEOANTIGEN PEPTIDES AND EFFECTOR FUNCTIONS

Morten Nielsen²; Panagiotis Mantas³; Lars Rønn Olsen⁴; Inge Marie Svane²; **Niels Junker, MD, PhD**¹
¹Oncology, Herlev Hospital, Copenhagen, Denmark; ²Department of Haematology and Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital Herlev, Herlev, Copenhagen, Denmark; ³DTU Health Technology, Technical University of Denmark, Copenhagen, Denmark; ⁴Section for Bioinformatics, DTU Health Technology & Center for Genomic Medicine, Technical University of Denmark & Copenhagen University Hospital, Copenhagen, Denmark

3253949

POPULATION PHARMACOKINETIC ANALYSIS FOR COMPARISON OF PEXIDARTINIB EXPOSURE IN ASIAN AND NON-ASIAN PATIENTS

Chia-Chi Lin¹; Jun Guo²; William D. Tap³; Andrew Wagner⁴; Silvia Stacchiotti⁵; Jih-Hsiang Lee¹; Xiaoning Wang⁶; Jia Kang⁶; Hamim Zahir⁷; Shun-ichi Sasaki⁸; Ophelia Yin⁷
¹National Taiwan University Hospital, Taipei, Taiwan; ²Beijing Cancer Hospital, Beijing, China; ³Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA; ⁴Dana-Farber Cancer Institute, Boston, MA, USA; ⁵Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ⁶Metrum Research Group, Tariffville, CT, USA; ⁷Quantitative Clinical Pharmacology and Translational Sciences, Daiichi Sankyo, Inc., Basking Ridge, NJ, USA; ⁸Asia Development Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan

3254451

REAL WORLD CLINICAL PROGNOSTIC FACTORS AND EFFICACY OF UPFRONT WEEKLY PACLITAXEL FOR ADVANCED ANGIOSARCOMA PATIENTS

Changhee Park, MD; Miso Kim; Chan-Young Ock; Bhumsuk Keam; Tae Min Kim; Dong-Wan Kim; Dae Seog Heo
Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea (the Republic of)

3242595

VALUE OF A COMMUNITY-BASED MULTIDISCIPLINARY SARCOMA CASE CONFERENCE IN AN INTEGRATED HEALTHCARE SYSTEM

Tiffany Seto, MD⁴; Jeanette Yu²; Manpreet Sidhu³; Danny Sam⁴; Minggui Pan¹
¹Hematology-Oncology, Kaiser Permanente Santa Clara, Santa Clara, CA, USA; ²Hematology-Oncology, Kaiser Permanente, Oakland, CA, USA; ³Hematology-Oncology, Kaiser Permanente, Roseville, CA, USA; ⁴Internal Medicine, Kaiser Permanente, Santa Clara, CA, USA

3245232

PROGNOSIS IN RECURRENT/METASTATIC SOFT TISSUE SARCOMA PATIENTS WITH RETROPERITONEAL/INTRA-ABDOMINAL ORIGIN RECEIVING SYSTEMIC CHEMOTHERAPIES COMPARED TO THOSE WITH EXTREMITIES/TRUNK ORIGIN

Kenji Nakano¹; Yuki Funauchi²; Keiko Hayakawa²; Taisuke Tanizawa²; Keisuke Ae²; Seiichi Matsumoto²; Shunji Takahashi¹
¹Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; ²Orthopedic Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

Poster Presentations Listing

3253268

ESTABLISHMENT OF AN ACADEMIC TISSUE MICROARRAY PLATFORM AS AN EFFICIENT TOOL FOR SOFT TISSUE SARCOMA RESEARCH

Che-Jui Lee¹; Tom Van Cann²; Agnieszka Wozniak¹; Jasmien Wellens¹; Inti Zlobec³; Judith Bovee⁴; Christian Britschgi⁵; Raf Sciot⁶; Patrick Schöffski⁷

¹Department of Oncology, KU Leuven, Leuven, Belgium; ²Department of Medical Oncology, AZ Nikolaas and GZA hospitals, Sint Niklaas and Antwerp, Belgium; ³Institute of Pathology, University of Bern, Bern, Switzerland; ⁴Department of Pathology, Leiden University Medical Center, Leiden, Netherlands; ⁵Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland; ⁶Department of Pathology, UZ Leuven and KU Leuven, Leuven, Belgium; ⁷Department of General Medical Oncology and Department of Oncology, UZ Leuven and KU Leuven, Leuven, Belgium

3253417

SURGICAL OUTCOMES IN ELDERLY PATIENTS OVER 80 YEARS OF AGE WITH SOFT TISSUE SARCOMAS

Kunihiro Ikuta, MD¹; Yoshihiro Nishida²; Eiji Kozawa³; Satoshi Tsukushi⁴; Hiroshi Urakawa¹; Eisuke Arai¹; Tomohisa Sakai¹; Hiroshi Koike¹; Naoki Ishiguro¹

¹Orthopaedic Surgery, Nagoya University, Nagoya, Aichi, Japan; ²Rehabilitation, Nagoya University Hospital, Nagoya, Aichi, Japan; ³Orthopaedic Surgery, Nagoya Memorial Hospital, Nagoya, Japan; ⁴Orthopaedic Surgery, Aichi Cancer Center, Nagoya, Japan

3254145

RAPID AND COMPLETE REMISSION OF CHEMOTHERAPY/TYROSINE KINASE INHIBITOR RESISTANT RELAPSED SPONTANEOUS AND RADIATION INDUCED ANGIOSARCOMA FOLLOWING TREATMENT WITH COMBINED ANTI-CTLA-4 AND ANTI-PD-1 THERAPY

Andrew L. Pecora¹; Melinda Weber¹; Danielle Blair¹; Eileen Beysel¹; Themba Nyirenda²; Elli Gourna Paleoudis²

¹John Theurer Cancer Center at Hackensack Meridian Health, Hackensack, NJ, USA; ²Hackensack Meridian Health, Hackensack, NJ, USA

3254295

ADULT GENITOURINARY SARCOMA: CANCER INSTITUTE HOSPITAL OF JAPANESE FOUNDATION FOR CANCER RESEARCH EXPERIENCE

Tetsuya Urasaki¹; Kenji Nakano¹; Junichi Tomomatsu¹; Kyoko Yamashita³; Yutaka Takazawa³; Yoshinobu Komai²; Shinya Yamamoto²; Takeshi Yuasa²; Junji Yonese²; Shunji Takahashi¹

¹Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; ²Urology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; ³Pathology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

3252932

ANALYSIS OF DEDIFFERENTIATED LIPOSARCOMA ARISING FROM THE EXTREMITIES AND SURFACE OF THE TRUNK

Tetsuro Yamagishi¹; Hiroshi Hatano¹; Hiroyuki Kawashima²; Akira Ogose³; Takashi Ariizumi²; Naoki Oike²

¹Department of Orthopedic Surgery, Niigata Cancer center Hospital, Niigata, Niigata, Japan; ²Division of Orthopedic Surgery, Niigata Graduate School of Medical and Dental Sciences, Niigata, Niigata, Japan; ³Department of Orthopedic Surgery, Uonuma Kikan Hospital, Minamiuonuma, Niigata, Japan

3255188

SITES OF DISTANT METASTASES AND FACTORS AFFECTING OVERALL SURVIVAL: A STUDY OF 159 PATIENTS WITH METASTATIC LIPOSARCOMA

Nicholas Shannon; Deanna Ng

<http://www.nccs.com.sg/>, Singapore, Singapore

Poster Presentations Listing

3212091

MOLECULAR PROFILE IN SOFT TISSUE SARCOMAS (STS): USEFULNESS FOR SPECIFIC DIAGNOSIS OF PLEOMORPHIC SARCOMA?

Tomás J. Soulé; Andres Rodriguez; **Martin Angel**; Matias Chacon

Oncology, Instituto Alexander Fleming, Ciudad Autonoma de Buenos Aires, Argentina

3230196

EARLY BRAIN-ONLY METASTASES AFTER COMPLETE RESPONSE TO NEOADJUVANT THERAPY FOR HIGH-RISK LOCALIZED PLEOMORPHIC SARCOMA

Benjamin Powers, MD¹; Vickie Massey²; Howard Rosenthal³; Elizabeth Friedman⁴; Darren Lovick⁵

¹Medical Oncology, U of Kansas Cancer Center, Overland Park, KS, USA; ²Radiation Oncology, U of Kansas Cancer Center, Overland Park, KS, USA; ³Orthopedic Surgery, U of Kansas Health System, Overland Park, KS, USA; ⁴Pathology and Laboratory Medicine, U of Kansas Health System, Kansas City, KS, USA; ⁵Neurosurgery, AdventHealth Shawnee Mission, Shawnee Mission, KS, USA

3240092

CLINICAL STUDY OF SOFT TISSUE SARCOMA WITH ANTECEDENT PRIMARY MALIGNANCIES

Tomoaki Torigoe, MD, PhD; Jungo Imanishi; Yasuo Yazawa

Orthopaedic Oncology and Surgery, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan

3230600

PHASE II STUDY OF NEOADJUVANT CHECKPOINT BLOCKADE IN PATIENTS WITH SURGICALLY RESECTED UNDIFFERENTIATED PLEOMORPHIC SARCOMA AND DEDIFFERENTIATED LIPOSARCOMA-PRELIMINARY SAFETY DATA

Christina L. Roland, MD, MS¹; Emily Z. Keung¹; Alexander Lazar²; Wei-Lien Wang³; Janice Cormier¹; Ashleigh Guadagnolo³; Andrew J. Bishop⁴; Bilal Mujtaba⁹; Heather Lin⁵; Keila Torres¹; Kelly Hunt¹; Barry Feig¹; Justin Bird²; Valerae Lewis⁶; Shreyaskumar Patel⁷; Jennifer Wargo¹; Neeta Somaiah⁷

¹Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

²The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ³Radiation Oncology Department, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

⁴Diag Rad - Musculoskeletal Img, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ⁶Orthopedic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

⁷Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

⁸Pathology, Anatomical, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

3256138

BONE CEMENT IMPLANTATION SYNDROME IN BONE TUMOR SURGERIES: INCIDENCE, RISK FACTOR, AND CLINICAL EXPERIENCE

Tsung-Han Yang¹; Tzu-Hao Tseng²; Chih-Peng Lin²; Rong-Sen Yang²

¹National Taiwan University Hospital Hsin-Chu Branch, Hsinchu city, Taiwan; ²National Taiwan University Hospital, Taipei City, Taiwan

3256521

LONG TERM OUTCOMES AFTER SURGICAL MANAGEMENT OF DERMATOFIBROSARCOMA PROTUBERANS: A SINGLE INSTITUTION EXPERIENCE

Erin Strong¹; Justin Fazio⁴; Austin Livingston¹; Julia Kasprzak⁴; Melanie Clark⁴; William Dzwierzynski⁵; John LoGiudice⁵; Meena Bedi³; John Charlson⁶; Kara Walton⁴; David King²; Donald Hakbath²;

Michael Stadler⁷; Monica Shukla³; John C. Neilson²; **Callisia N. Clarke, MD, MS**¹

¹Surgery, The Medical College of Wisconsin, Milwaukee, WI, USA; ²Orthopedic Surgery, Medical College of Wisconsin, Milwaukee, WI, USA; ³Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; ⁴Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA; ⁵Plastic and Reconstructive Surgery, Medical College of Wisconsin, Milwaukee, WI, USA; ⁶Medical Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; ⁷Otolaryngology, Medical College of Wisconsin, Milwaukee, WI, USA

Poster Presentations Listing

3256560

REVISION RATES FOR MEGAPROSTHESES: REVIEW OF LITERATURE AND META-ANALYSIS

Jean-Camille Mattei, MD, PhD; Arnaud Felden; Philippe Anract; David Biau
AP-HM, Aix-Marseille University, Marseille, France

3256707

DISTRACTION OSTEOGENESIS SPECIFIC SURGICAL COMPLICATIONS IN RECONSTRUCTION OF OSSEOUS TUMORS

Daniel E. Prince, MD, MPH; Eugenia Schwarzkopf; Molly Klima
Orthopedic Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

3223323

THE IMPACT OF SURVEILLANCE INTERVAL FOLLOWING RESECTION OF PRIMARY WEL DIFFERENTIATED LIPOSARCOMA OF THE RETROPERITONEUM

Emily Keung; Nikita Rajkot; Janice Cormier; Neeta Somaiah; Keila Torres; Kelly Hunt; Barry Feig; Naruhiko Ikoma; Christina L. Roland
MD Anderson, Houston, TX, USA

3224146

CAN THE KATAGIRI SCORING SYSTEM PREDICT SURVIVAL FOR PATIENTS WITH METASTATIC BONE DISEASE TREATED SURGICALLY?

Hiten A. Doshi¹; Elif Ugur¹; Nicole L. Levine¹; Janet Tingling²; Bang Hoang²; **David Geller²**; Rui Yang²
¹Albert Einstein College of Medicine, Bronx, NY, USA; ²Orthopedic Surgery, Montefiore Medical Center, Bronx, NY, USA

3250165

CAN WE PREDICT RECONSTRUCTIVE SURGERY FAILURE IN SARCOMA PATIENTS?

Christie G. Mellor²; Daniel Saleh¹; Kenneth Rankin¹; T. Beckingsale; M. Ghosh; D. Lee; M. Ragbir
¹Plastic and Reconstructive Surgery, The Newcastle Upon Tyne Hospitals, Newcastle upon Tyne, United Kingdom; ²Medical School, Newcastle University Medical School, Newcastle upon Tyne, United Kingdom

3253295

INTRAOPERATIVE ANGIOGRAPHY FOR PREDICTING WOUND COMPLICATION IN SOFT TISSUE SARCOMA OF THE EXTREMITIES: A PILOT STUDY

Alexander L. Lazarides, MD; Eliana Saltzman; Julia Visgauss; Suhail Mithani; William Eward; Brian Brigman
Department of Orthopaedic Surgery, Duke University Medical Center, Durham, NC, USA

3255025

RECONSTRUCTION AFTER SOFT TISSUE SARCOMA OF THE LIMB USING MUSCLE SPARIN LATISSIMUS DORSI

Audrey Michot; Raphaël Blaquièrre; Eberhard Stoeckle
Oncological Surgery, Institut Bergonie, Bordeaux, France

3255197

ULTRASONOGRAPHY-GUIDED TUMOR EXCISION FOR IMPALPABLE AND ILL-DEFINED MALIGNANT SOFT TISSUE TUMOR

Akihiko Takeuchi, MD, PhD; Norio Yamamoto; Katsuhiro Hayashi; Shinji Miwa; Kentaro Igarashi; Yuta Taniguchi; Sei Morinaga; Yoshihiro Araki; Hiroyuki Tsuchiya
Orthopaedic Surgery, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan

Poster Presentations Listing

3255858

IMMEDIATE, ALL INTERNAL DISTRACTION OSTEOGENESIS AND BONE TRANSPORT AFTER TUMOR RESECTION

Nadine L. Williams; Alex Mierke; Omar Ramos; Brendon Bauer; Stephen Morris; Lee M. Zuckerman
Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, CA, USA

3255974

MID- TO LONG-TERM CLINICAL OUTCOMES OF HEMICORTICAL RESECTION AND RECONSTRUCTION USING FROZEN AUTOGRAFTS IN OSTEOSARCOMA PATIENTS

Norio Yamamoto, MD, PhD; Katsuhiko Hayashi; Akihiko Takeuchi; Shinji Miwa; Kentaro Igarashi; Yuta Taniguchi; Hirotaka Yonezawa; Yoshihiro Araki; Sei Morinaga; Hiroyuki Tsuchiya
Orthopaedics, Kanazawa University, Kanazawa, Japan

3256384

HYPERTHERMIC ISOLATED LIMB PERFUSION (HILP) IN EXTREMITY SOFT-TISSUE SARCOMA (ESTS): SHIFTING FROM PALLIATION TO THE NEO-ADJUVANT SETTING – BUT NOW OUTDATED? A MONOCENTRIC 18 YEAR EXPERIENCE

Eberhard Stoeckle; Audrey Michot; Maud Toulmonde; Raoul Perret; Paul Sargos; Antoine Italiano
Institut Bergonié, Bordeaux, France

3256704

DOUBLE LEVEL BONE TRANSPORT FOR SARCOMA RECONSTRUCTION

Daniel E. Prince, MD, MPH; Eugenia Schwarzkopf; Molly Klima
Orthopedic Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

3229449

DID THE PROPORTION OF SOFT TISSUE SARCOMAS PRESENTING AS UNPLANNED EXCISIONS INCREASE DURING THE GREAT RECESSION?

Duncan Ramsey; **Kenneth R. Gundle, MD**; James Hayden; Yee-Cheen Doung
Orthopaedics & Rehabilitation, Oregon Health & Science University, Portland, OR, USA

3244000

HARLEQUIN SYNDROME FOLLOWING MICROWAVE ABLATION THERAPY IN A 20-MONTH-OLD WITH PARASPINAL MASS

Caleb Oh; Anna L. Tamulonis; Paul Kent
Hematology/Oncology, Rush Hospital, Chicago, IL, USA

3253130

OUTCOME OF SURGICALLY TREATED BONE METASTASES OF EXTREMITIES FROM RENAL CELL CARCINOMA

Hitomi Hara¹; Yoshitada Sakai²; Teruya Kawamoto¹; Yohei Kawakami¹; Shuichi Fujiwara¹; Kazumichi Kitayama¹; Shunsuke Yahiro¹; Ryosuke Kuroda¹; Toshihiro Akisue³
¹Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan; ²Rehabilitation Medicine, Kobe University Graduate School of Medicine, Kobe, Japan; ³Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan

3253972

IS NEOADJUVANT CHEMOTHERAPY BENEFICIAL IN CARDIAC SARCOMA

Robert J. Cusimano, MD
Surgery, University Health Network, Toronto General Hospital, University of Toronto, Toronto, ON, Canada

Poster Presentations Listing

3255327

REAMED VERSUS UNREAMED INTRAMEDULLARY NAILING FOR THE TREATMENT OF IMPENDING AND PATHOLOGICAL HUMERAL SHAFT FRACTURES: A RETROSPECTIVE COMPARATIVE STUDY

Manaf H. Younis, MD, MPH; Spencer Barnhill; Sheila Conway; Juan Pretell-Mazzini
Orthopedic Oncology, University of Miami, Miami, FL, USA

3255777

OUTCOME AFTER BIOLOGICAL RECONSTRUCTION FOLLOWING INTERCALARY RESECTION OF MALIGNANT BONE TUMORS

Manish Pruthi, MS, DNB¹; Jagandeep Singh Virk¹; Gauri Kapoor²; Rajan Arora³
¹Orthopaedics, Rajiv Gandhi Cancer Institute & Research Center, Delhi, Delhi, India;
²Pediatric Oncology, Rajiv Gandhi Cancer Institute & Research Center, Delhi, Delhi, India;
³Plastic Surgery, Rajiv Gandhi Cancer Institute & Research Center, Delhi, India

3256553

POST-RADIATION PATHOLOGIC FEMUR FRACTURES FOLLOWING RESECTION OF SOFT TISSUE SARCOMAS: IS ENDOPROTHETIC RECONSTRUCTION A GOOD OPTION?

Ibrahim S. Alshaygy; Georges Basile; Jean-Camille Mattei; Anthony Griffin; Peter Ferguson; Jay Wunder
Orthopaedic Department, Mount Sinai Hospital, Toronto, ON, Canada

3256555

LONG TERM OUTCOMES OF VASCULAR RECONSTRUCTIONS IN SARCOMA SURGERY. WHAT TO EXPECT FROM VEIN RECONSTRUCTION?

Jean-Camille Mattei, MD, PhD; Julia Visgauss; Curtis Woodford; Thomas Lindsay; Georges Basile; Anthony Griffin; Jay Wunder; Peter Ferguson
AP-HM, Aix-Marseille University, Marseille, France

3214469

SANDWICH ISOLATION SURGERY PREVENTS LOCAL RECURRENCE IN PROGRESSIVE DESMOID TUMORS: A PILOT OBSERVATIONAL STUDY

Junqiang Yin; Yiwei Fu; Changye Zou; Gang Huang; Jingnan Shen
The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China

3255865

WHEN SHOULD LIMB SALVAGE SURGERY BE CONSIDERED DURING A MEDICAL MISSION?

Stephen Morris; Scott Nelson; **Nadine L. Williams**; Omar Ramos; Brendon Bauer; Alex Mierke; Lee M. Zuckerman
Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, CA, USA

Poster Presentations Listing

3256401

CLINICAL STUDY TO EVALUATE SAFETY AND ACTIVITY OF AUTOLOGOUS T CELLS WITH ENHANCED NY-ESO-1-SPECIFIC T-CELL RECEPTOR (GSK3377794) IN HLA-A*02+ PREVIOUSLY-TREATED AND PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED METASTATIC OR UNRESECTABLE SYNOVIAL SARCOMA AS PART OF A MASTER PROTOCOL DESIGN

Sandra P. D'Angelo, MD¹; Jean-Yves Blay²; Warren Chow³; George D. Demetri⁴; Fiona Thistlethwaite⁵; Michael J. Wagner⁶; David Loeb⁷; Steven Attia⁸; Albiruni Razak¹²; John Haanen⁹; Aisha N. Hasan¹³; Julia Billiard¹³; Laura Pearce¹³; Yuehui Wu¹³; Ran Ji¹³; Laura A. Johnson¹³; Chandra Srianth¹³; Aiman Shalabi¹³; Sandra J. Strauss¹⁰; Katherine Thornton⁴; Crystal Mackall¹⁴; William D. Tap¹; Brian A. Van Tine¹¹

¹Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Département de Cancérologie Médicale, Centre Léon Bérard, Lyon, France; ³City of Hope Comprehensive Cancer Center, Duarte, CA, USA; ⁴Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA, USA; ⁵The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom; ⁶Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA; ⁷Montefiore Medical Center, New York, NY, USA; ⁸Mayo Clinic in Florida, Jacksonville, FL, USA; ⁹Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands; ¹⁰University College London Hospitals NHS Foundation Trust, London, United Kingdom; ¹¹Washington University in St. Louis, St. Louis, MO, USA; ¹²Princess Margaret Cancer Centre and Mount Sinai Hospital, Toronto, ON, Canada; ¹³GlaxoSmithKline, Philadelphia, PA, USA; ¹⁴Stanford University, Palo Alto, CA, USA

3256432

EPIDEMIOLOGICAL STUDY IN A REFERENCE CENTER IN MEXICO FOR THE TREATMENT OF SARCOMA

Jorge L. Martínez Tlahuel, MsC¹; Jorge Alegria²; Alejandro Mohar²; Jaime de la Garza²

¹Medical Oncology Department, Instituto Nacional de Cancerología, Mexico City, Mexico; ²Research direction, Instituto Nacional de Cancerología, Mexico, Mexico

3224571

THE CLINICAL FEATURES OF GANGLIONEUROBLASTOMA IN ADULTS

Shinsuke Sugihara; Masahiro Kiyono

Department of Orthopaedic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan

3241689

APPLICATIONS OF CARBON FIBER INTRAMEDULLARY NAILS IN ORTHOPAEDIC ONCOLOGY

Caleb Yeung, MD; Nelson Merchan; Erik Newman; Joseph Schwab; Kevin Raskin;

Santiago Lozano-Calderon

Department of Orthopedic Surgery, Massachusetts General Hospital, Boston, MA, USA

3253423

A CASE OF HUGE, ABC-LIKE RIB TUMOR DIAGNOSED AS GCT OF BONE BY H3.3 G34W-IMMUNOSTAINING

Masayuki Morishita²; Toshiko Sakuma¹; Ikuo Fujita²; Takuya Fujimoto²; Takanori Hirose¹

¹Diagnostic Pathology, Hyogo Cancer Center, Akashi, Japan; ²Orthopaedic Surgery, Hyogo Cancer Center, Akashi, Japan

3255755

COMPLETE PATHOLOGIC RESPONSE WITH DOXORUBICIN AND DACARBAZINE IN METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS) TO THE LIVER IN AN ELDERLY PATIENT

Mark Gimbel, MD; Fade Mahmoud

Banner MD Anderson Cancer Center, Phoenix, AZ, USA

3255245

EFFICACY OF PAZOPANIB AS SECOND-LINE TREATMENT IN ASIAN PATIENTS WITH METASTATIC SOFT TISSUE SARCOMA: A REAL-WORLD RETROSPECTIVE STUDY

Kwonoh Park¹; Yun-Jung Hong²; Changhwan Kim³

¹Medical Oncology and Hematology, Pusan National University Yangsan Hospital, Yangsan-si, Korea (the Republic of); ²Neurology, Uijeongbu St. Mary's Hospital, Uijeongbu, Korea (the Republic of); ³Internal Medicine, Jeju National University School of Medicine, Jeju, Korea (the Republic of)

3253590

A CASE OF RESOLVED VINCRISTINE INDUCED CONSTIPATION FOLLOWING OSTEOPATHIC MEDICINE IN A PATIENT WITH INFANTILE FIBROSARCOMA

Jennifer A. Belsky, DO, MS¹; Kimberly Wolf²; Bhuvana Setty¹

¹Hematology/Oncology, Nationwide Children's Hospital, Columbus, OH, USA; ²Touro College of Osteopathic Medicine, Vallejo, CA, USA

3257776

ERIBULIN DOES NOT HAVE RELEVANT ANTI-TUMOR EFFICACY IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS OF GASTRO-INTESTINAL STROMAL TUMORS (GIST)

Yannick Wang¹; Agnieszka Wozniak¹; Bruce A. Littlefield²; Patrick Schöffski³

¹Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Leuven, Belgium; ²Global Oncology, Eisai Inc., Cambridge, MA, USA; ³Laboratory of Experimental Oncology, Department of Oncology, KU Leuven and Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium

3256514

METASTATIC EWING SARCOMA IN A 76M WITH DEMENTIA AND EXCELLENT RESPONSE TO CHEMOTHERAPY: CASE REPORT AND REVIEW OF THE LITERATURE

Adrienne Victor, MD

Medical Oncology, University of Rochester, Rochester, NY, USA

3254381

REPLACEMENT OF EXOGENOUS L-THYROXINE [L-T4] WITH L-TRIIODOTYRONINE [L-T3] IN HYPOTHYROID WOMEN WITH METASTATIC HIGH GRADE UTERINE SARCOMA IS ASSOCIATED WITH TUMOR RESPONSE AND IMPROVED SURVIVAL

Rony Weitzen, MD¹; Eytan Ben Ami¹; Aleck Hercbergs²

¹Oncology, Sheba medical center, Ramat Gan, Israel; ²Oncology, Cleveland Clinic, Cleveland, OH, USA

3225063

USE OF A TRK-INHIBITOR AS NEOADJUVANT THERAPY FOR PEDIATRIC NTRK-MUTATED SARCOMAS: A CASE REPORT

Nicole L. Levine¹; Elif Ugur¹; Bang Hoang²; Rui Yang²; David M. Loeb³; Daniel Weiser³; Alissa C. Baker³; Alexander J. Chou³; Simon Yaguare²; Amit Singla²; Jennifer Oliver-Krasinski⁴; Beverly A. Thornhill⁵; **David Geller**²

¹Albert Einstein College of Medicine, Bronx, NY, USA; ²Orthopaedic Surgery, Montefiore Medical Center, Bronx, NY, USA; ³Pediatrics, Montefiore Medical Center, Bronx, NY, USA; ⁴Pathology, Montefiore Medical Center, Bronx, NY, USA; ⁵Radiology, Montefiore Medical Center, Bronx, NY, USA

3256410

PLOCABULIN, A NOVEL TUBULIN INHIBITOR, HAS ANTITUMOR ACTIVITY IN A PATIENT-DERIVED XENOGRAFT (PDX) MODEL OF DEDIFFERENTIATED LIPOSARCOMA

Yannick Wang¹; Agnieszka Wozniak¹; María José Guillén²; Pablo M. Avilés²; Maria Debiec-Rychter³; Raf Sciort⁴; Patrick Schöffski⁵

¹Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Leuven, Belgium; ²PharmaMar, Madrid, Spain; ³Department of Human Genetics, KU Leuven and University Hospitals Leuven, Leuven, Belgium; ⁴Department of Pathology, KU Leuven and University Hospitals Leuven, Leuven, Belgium; ⁵Laboratory of Experimental Oncology, Department of Oncology, KU Leuven and Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium

3256452

GSK3377794 – TWO CASE STUDIES – ACUTE INFLAMMATORY DEMYELINATING NEUROPATHY

Michael J. Nathenson¹; Jocelyn Joseph²; George D. Demetri³; Jenna Tress⁴; Adeline Verticelli⁴; Sophia Goodison⁴; Miriam Marotti⁴; Soraya Shaikh⁴; Aisha N. Hasan⁴; Dejka Araujo⁵

¹Dana-Farber Cancer Institute, Boston, MA, USA; ²Department of Clinical Pharmacy Services, University of Texas MD Anderson Cancer Center, Houston, TX, USA; ³Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA, USA; ⁴GSK, Philadelphia, PA, USA; ⁵University of Texas MD Anderson Cancer Center, Houston, TX, USA

3256541

RADIATION THERAPY COMBINED WITH CHECKPOINT INHIBITOR IN PATIENTS WITH UNDIFFERENTIATED PLEOMORPHIC SARCOMA: A PROMISING TREATMENT APPROACH

Maya Khalil; **Anne GrandMaison, MD**

Medicine - Sarcoma Medical Oncology, Roswell Park Cancer Center, Buffalo, NY, USA

3257996

RECONSTRUCTIVE MANAGEMENT OF PATIENTS WITH SARCOMA OF THE FOOT

Tiphaine Menez¹; Camille Mocquard¹; Frederic Basselot²; Audrey Michot³

¹Plastic Surgery, CHU Rennes, Rennes, France; ²CHU Rennes, Rennes, France; ³Institut Bergonie, Bordeaux, France

3255332

A PROSPECTIVE CORRELATIVE TRIAL OF PERSONALIZED PATIENT-DERIVED XENOGRAFT (PDX) AS AVATARS FOR DRUG THERAPY IN PATIENTS (PTS) WITH METASTATIC OR RECURRENT SOFT TISSUE SARCOMAS (STS)

Kanan M. Alshammari, MBChB¹; Esmail Al-Ezzie¹; Jeremy Lewin¹; Samer Salah¹; Zachary Veitch¹; Eoghan Malone¹; Gina Paris²; Maria Mancini²; Alona Zer¹; Mohammad Ahmad³; Robert Beecroft⁴; Albiruni Razak¹

¹Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada; ²Champions Oncology, Hackensack, NJ, USA; ³Toronto Sarcoma Program, Mount Sinai Hospital, Toronto, ON, Canada; ⁴Department of Radiology, Mount Sinai Hospital, Toronto, ON, Canada

3255808

EPITHELIOD AND SYNOVIAL SARCOMA MIMICKING A PERIPHERAL NERVE SHEATH TUMOR

Alexander Chien²; **Nadine L. Williams**¹; Craig W. Zuppan³; Alex Mierke¹; Brendon Bauer¹; Stephen Morris¹; Omar Ramos¹; Lee M. Zuckerman¹

¹Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, CA, USA; ²Radiology, Loma Linda University Medical Center, Loma Linda, CA, USA; ³Pathology, Loma Linda University Medical Center, Loma Linda, CA, USA

3255908

THE CT AXIAL IMAGING CAN DETECT FEMORAL METASTATIC BONE TUMORS AT EARLY STAGE

Hirota Yonezawa; Norio Yamamoto; Katsuhiko Hayashi; Akihiko Takeuchi; Shinji Miwa;

Kentaro Igarashi; Yuta Taniguchi; Yoshihiro Araki; Sei Morinaga; Hiroyuki Tsuchiya

Department of Orthopaedic Surgery, Kanazawa University Graduate School of Medical Sciences, Ishikawa, Japan

3255058

SURGICAL MANAGEMENT OF BREAST DERMATOFIBROSARCOMA PROTUBERANS:

A FIVE CASES SERIES

Raphaël Blaquièrè¹; Audrey Michot¹; Tiphaine Menez²

¹Surgery, Institut Bergonié, Bordeaux, France; ²Surgery, Centre Eugène Marquis, Rennes, France

3253292

ROLE OF SURGICAL RESCUE OF RETROPERITONEAL LIPOSARCOMA RECURRENCE

José Manuel Asencio, PhD¹; Maria Luz Fernandez Vazquez¹; Javier Serrano²; Pablo Lozano¹;

María Fernandez¹; Ana Alvarez²; Mar Galera³

¹Surgery, Hospital General Universitario Gregorio Marañón, Madrid, Spain; ²Radiation Oncologist, Hospital General Universitario Gregorio Marañón, Madrid, Spain; ³Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

3254847

DO WE NEED ROUTINELY PLACE URETERAL CATHETERS PRIOR TO SURGRIES IN PATIENTS WITH PRIMARY RETROPERITONEAL LIPOSARCOMA?

Jun Chen, MD¹; Xiao Bing Chen¹; Shahbaz Hanif²; Meng Meng Xiao¹; Wen Jie Li¹; Cheng Li Miao¹; Cheng Hua Luo¹

¹Dept. of Retroperitoneal Tumor Surgery, Peking University International Hospital, Beijing, China;

²Beijing Spanal Medical Scientific Co. Ltd., Beijing, China

3255227

THE CLINICAL RESULTS OF TRABECTEDIN OR ERIBULIN CHEMOTHERAPY IN ADVANCED SOFT TISSUE SARCOMA

Masanobu Takeyama; Yusuke Kawabata; Kenta Hayashida; Shintaro Fujita; Yutaka Inaba
orthopaedic, Yokohama city University, Yokohama, Japan

3255273

ANLOTINIB FOR ADVANCED PROGRESSIVE SARCOMA: A RETROSPECTIVE STUDY

Zuoyao Long, Doctor¹; Yajie Lu¹; Minghui Li¹; Xin Xiao¹; Guojing Chen¹; Hongmei Zhang²; Zhen Wang¹

¹Orthopaedics, Air Force Medical University, Xi'An, Shan Xi, China; ²Department of Oncology,

Xijing Hospital, Air Force Medical University, Xi'an, China

3248434

MALIGNANT TUMOR WITH OVERLAPPING FEATURES OF MYOEPITHELIAL CARCINOMA AND EWING SARCOMA WITH EWSR1-ETV1 FUSION: A MOLECULAR CASE STUDY

Yen-Lin Liu, MD¹; Yu-Chien Kao³; Tsung-Han Hsieh⁶; Chikako Kiyotani⁴; Keita Terashima⁴; Hsi Chang¹; Wei-Tang Lee⁷; Hsin-Lun Lee⁸; Kevin L. Hsieh¹⁰; Tai-Tong Wong⁹; Sung-Hui Tseng⁵; James S. Miser²

¹Pediatrics, Taipei Medical University & Taipei Medical University Hospital, Taipei, Taiwan;

²Pediatrics, City of Hope National Medical Center, Duarte, CA, USA; ³Pathology, Taipei Medical University–Shuang Ho Hospital, New Taipei, Taiwan; ⁴Children’s Cancer Center, National Center for Child Health and Development, Tokyo, Japan; ⁵Physical Medicine & Rehabilitation, Taipei Medical University & Taipei Medical University Hospital, Taipei, Taiwan; ⁶Joint BioBank, Taipei Medical University, Taipei, Taiwan; ⁷Plastic Surgery, Taipei Medical University Hospital, Taipei, Taiwan; ⁸Radiation Oncology, Taipei Medical University Hospital, Taipei, Taiwan; ⁹Pediatric Neurosurgery, Taipei Medical University Hospital, Taipei, Taiwan; ¹⁰Radiology, Taipei Medical University & Taipei Medical University Hospital, Taipei, Taiwan

3255829

SECONDARY CHONDROSARCOMA ARISING FROM THE PROXIMAL FIBULA PRESENTING AS SCIATICA

Robert Vercio; **Nadine L. Williams**; Joseph Elsissy; Troy Shields; Lee M. Zuckerman
Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, CA, USA

3256396

PARASPINAL MASS SUCCESSFULLY TREATED WITH MINIMALLY INVASIVE PROCEDURE IN 20-MONTH-OLD CHILD

Caleb Oh; Anna Tamulonis; Madeline Link; Nathaniel Rice; Paul Kent
Hematology/Oncology, Rush Hospital, Chicago, IL, USA

3255987

ADAMANTINOMA OF PELVIS: A RARE ENTITY AT AN UNUSUAL LOCATION

Manish Pruthi, MS, DNB¹; Jagandeep Singh Virk¹; Sunil Pasricha²

¹Orthopaedics, Rajiv Gandhi Cancer Institute & Research Center, Delhi, Delhi, India;

²Pathology, Rajiv Gandhi Cancer Institute & Research Center, Delhi, India